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Abstract 
During the developmental programme, post-meiotic cells, gametes, fuse to form a zygote, 
which divides and forms embryo stem cells. In complex metazoans, such as humans, these 
cells proliferate and ultimately differentiate to form the distinct organs of a functioning adult. 
Genomic instabilities in stem cells, germ line cells and somatic cells can result in cells 
becoming cancerous and one of the primary oncogenic factors is DNA replication stress. In 
cancer tissues developmental programmes become deregulated with cells loosing cellular 
identity and potentially disconnecting from their micro environment and undergoing 
metastasis to other regions of the body, causing extensive organ failure. Within tumours, 
there are so called cancer stem cells, cells which may have been the original progenitor cells 
for the tumour formation, but which are also proposed to be capable of tumour self renewal 
and may be responsible for therapeutic resistance. The relationship between cancer stem 
cells, embryo stem cells and how their developmental programmes are regulated and linked 
to genomic instabilities is very poorly understood. 
  This current study explores the links between genome instability pathways and 
developmental programmes. Firstly, it is known that some meiosis-specific genes which 
function to drive meiotic chromosomal rearrangements become aberrantly activated in 
somatic, cancerous tissues. This resulted in the hypothesis that activation of meiotic 
recombination hotspots might generate regions which become refractory to somatic DNA 
replication and result in genomic loci with the potential to drive oncogenic rearrangements. 
Due to the technical difficulties of using mammalian cells, we addressed this hypothesis in a 
widely used experimental model eukaryote, the fission yeast. From this work no evidence for 
the activation of eukaryotic meiotic recombination hotspots under replicative stress 
conditions could be found.  
  Prior to this work a preliminary study had found that mouse embryo stem cells exhibited a 
significant sensitivity to the topoisomerase poison camptothesin, relative to full differentiated 
mouse embryonic fibroblasts.  This difference in sensitivity was not observed using other 
DNA damaging agents tested. Given that camptothecin generates DNA double-strand breaks 
in a replication-dependent fashion this current study set out to determine whether cells with 
stem cell characteristic have distinct responses to oncogenic insult which perturbs DNA 
replication. To explore this in humans the teratocarcinoma cell line NTERA2 was employed 
as it expresses many of the markers of stem cells / cancer stem cells and can be differentiated 
in vitro to provide isogenic differentiated and undifferentiated human cells. Studies of 
sensitivities of human NTERA2 (differentiated vs. undifferentiated) and preliminary analyses 
of mouse stem cells provides evidence that there are  inter-species distinctions and possible 
subtle mechanistic changes to cancer-suppressing genome stability mechanisms upon cellular 
differentiation in human cells away from the stem cell state.  
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Chapter 1  
 
1.1 Introduction 
For more than 100 years, human cancers have been identified as a morphologically 
heterogeneous population of cells (Hope, Jin & Dick 2004a). In the past ten years, however, 
it has become clear that functional heterogeneity exists within the cells that constitute various 
human cancers of the blood, breast, brain, skin, bone, and prostate (Bonnet, Dick 1997a, 
Gibbs et al. 2005). Cancer defines a group of disorders that involve uncontrolled cellular 
growth, cellular invasion of tissues and the probability of metastasis if not treated at a timely 
stage. These cellular abnormalities arise from collected genetic modifications, either through 
changes in primary genetic sequence or through epigenetic changes (Feinberg, Ohlsson & 
Henikoff 2006, Jones, Baylin 2007). 
Cancer is a genetic disease that modifies three kinds of genes, affecting tumour progression, 
termed stability genes, oncogenes and tumour suppressor genes (Vogelstein, Kinzler 2004). 
In the multi-step carcinogenesis model, cancer develops through several stages during the 
accumulation of molecular alterations, progressing from a pre-invasive to an invasive disease 
(Hong, Sporn 1997).  
 
1.2 Cancer stem cells 
It has been recently proven that just a small subpopulation of cancer cells can form new 
tumours in haematological malignancies (Pardal, Clarke & Morrison 2003a). In spite of the 
clonal source of many cancers, research into leukaemia and, more recently, solid cancers 
proposes that tumour cell populations are heterogeneous with regard to proliferation and 
differentiation. This characteristic is described by the cancer stem cell hypothesis. Supposed 
‗cancer stem cells‘ have been identified and characterized in myeloid leukaemia, breast, brain 
and lung cancers (Jordan 2004).  
The theory of a cancer stem cell originated based on the observation of correspondences 
between the self-renewal mechanisms of normal organs and successive proliferation in 
cancers (Reya et al. 2001a). The cancer stem cell hypothesis suggests that not all the cells in a 
tumour have the capability to proliferate and maintain the growth of the tumour, and that only 
a small subpopulation of cells in the tumour, named cancer stem cells, are primed to 
proliferate and self-renew. These unusual cells form tumours and maintain their growth, and 
have been separated in haematological cancers such as leukaemia (Bonnet, Dick 1997b) and 
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multiple myeloma, and in solid tumours such as breast tumours (Al-Hajj et al. 2003a) and 
brain tumours (Singh et al. 2003a).  
 
Stem cells are undifferentiated and unspecialized cells (Sell 2004). There are three classes of 
stem cells: embryonal, germinal and somatic (or adult) stem cells (Blagosklonny 2005). 
Embryonal stem cells are created during the ﬁrst divisions of a fertilised egg. These stem 
cells have the ability to develop into all of the cells in adult organs. Through the embryogenic 
system, the progeny of embryonal stem cells lose this potential and develop differentiated 
properties through a practice named determination. Germinal stem cells in adults make eggs 
and sperm. Somatic stem cells have ―limited‖ differentiation potential, and are responsible for 
cells that differentiate inside mature tissue. Different kinds of stem cells have different types 
of potential and reproduce differently. By deﬁnition, an adult stem cell is a cell that advances 
from a given organ, and which has long-term replicative potential and the capability to both 
self-renew and differentiate inside the environment of the organ. Stem cells in adult tissues 
are primarily quiescent, and have the ability for self-renewal and differentiation in all tissue 
types. Through unbalanced division, each stem cell generates one daughter cell that then 
continues as a stem cell and a daughter cell ―more differentiated‖, and so on. This initiates the 
process of determination and generates quickly proliferating progenitor cells, which are 
devoted to differentiation. Progenitor cells go through a limited number of cell divisions and 
then differentiate or die (Al-Hajj, Clarke 2004a). Thus, in normal tissue, three differing types 
of subdivision can be described: self-renewal subdivision involving quiescent stem cells, 
proliferating subdivision involving proliferating progenitors with the express potential for 
self-renewal and terminal subdivision involving differentiated cells or apoptotic cells. 
 
As mentioned above, the idea of the cancer stem cell originated when correspondences were 
observed between the self-renewal mechanisms of stem cells and those of cancer cells (Reya 
et al. 2001b). Both kinds of cells self-renew and differentiate into other cells. Tumours are 
heterogeneous in terms of cell phenotype and proliferative potential, and the concept of 
progressing mutations only partially describes this heterogeneity. Cancer stem cells are a 
minute population of tumour cells that are able to self-renew and develop into all the 
constituents of a heterogeneous tumour. 
 
Previous models of cancer attributed the unregulated growth of tumours to additional genetic 
changes that resulted in the activation of genes promoting proliferation, the silencing of genes 
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implicated in inhibiting proliferation and the circumvention of genes involved in programmed 
cell death (Al-Hajj, Clarke 2004b). In the cancer stem cell hypothesis, another crucial 
occurrence in tumour progression is the change of genes implicated in the regulation of stem 
cell renewal. It is thus not surprising that various genes originally identiﬁed as playing a role 
in tumour progression were subsequently implicated in normal stem cell self-renewal 
(Bjerkvig et al. 2005). Cancer stem cells and normal stem cells may participate in the same 
self-renewal and proliferation mechanisms. Alterations that deregulate the pathways 
regulating normal stem cell self-renewal have also been noticed in various cancers, 
suggesting that the deregulation of self-renewal pathways could be necessary for cancers to 
develop. 
 
1.3 Genomic instability 
It is widely accepted that cancer cells may be genetically unstable (Lengauer, Kinzler & 
Vogelstein 1998), and that the genomic instability is a mechanism of both tumour progression 
and heterogeneity. The tumour instability is explained by a more enhanced accumulation of 
genetic changes in tumours contrasted with normal cells, and is sorted into four various types, 
(1) subtle sequence alterations; (2) changes of chromosome numbers; (3) chromosome 
translocations; and (4) gene amplifications (Lengauer, Kinzler & Vogelstein 1998). 
 
1.4 Alterations in chromosome number 
Chromosome number instability (CIN), occurs in the majority of human malignancies 
(Mitelman et. al., 1994; 1997). As inspected by Lengauer et. al., (1998) in more detail, genes 
that, when mutated, can lead to CIN contain those concerned in chromosome condensation, 
sister-chromatid cohesion, kinetochore structure and function and centrosome-microtube 
formation, as well as checkpoint genes that observe the proper progression of the cell cycle 
(Hartwell, Smith 1985a, Hartwell 1992, Murray 1995, Fukasawa et al. 1996, Elledge 1996, 
Nasmyth 1996, Paulovich, Toczyski & Hartwell 1997, Taylor, McKeon 1997, Doxsey 1998, 
Jin, Spencer & Jeang 1998, Lane 1998, Rotman, Shiloh 1998). The fact that genetic defects 
of so many genes can lead to CIN proposes a heterogeneous basis for CIN in cancers, with 
many genes each playing a role in a distinc part of the tumour progression (Lengauer, Kinzler 
& Vogelstein 1998). In DNA-damage checkpoint deficiency, chromosomes comprising 
damaged DNA could separate inappropriately, resulting in CIN because sister chromatids 
remain linked by DNA or DNA-protein links, chromosomes which and are also susceptible to 
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gross structural changes due to single-stranded gaps or double-stranded breaks. Genomic 
deletion produced by double-stranded breaks can generate loss-of-heterozygosity (LOH), a 
major oncogene factor (Shen et al. 2000). Chromosome instability appearing from missed 
DNA damage checkpoints is often related to enhanced mitotic recombination as well as with 
irregular chromosome segregation (Hartwell, Smith 1985b), thus, tumourogenesis is 
eventually associated with the accumulation of gross chromosomal rearrangements (GCRs), 
such as translocations, deletions of chromosome arms, interstitial deletions or inversions 
(Gauwerky, Croce 1993, Shikano et al. 1993, Mitelman, Mertens & Johansson 1997, Chen, 
Kolodner 1999). In many instances, GCRs inactivate tumor-suppressor genes or give rise to 
novel fusion protein that initiates carcinogenesis. 
 
1.5 Chromosome translocations 
Translocations are rearrangements of chromosomes in which a chromosome portion is 
transplaced from one chromosome to another. Faults in chromosome replication can result in 
translocations (Mirkin and Mirkin, 2007). The system of chromosomal translocation brings 
two formerly unlinked parts of the genome the juxtaposition of elements that can interrupt the 
normal expression of the gene next to the breakpoint. These events are especially important 
when the breakpoint of the translocation cause in unacceptable expression of an oncogene or 
synthesis of an unknown oncogenic fusion protein (Agarwal et. al., 2006). Such chromosome 
alterations and mutations can activate cellular oncogenes in a dominant pattern. 
Chromosomal translocations are frequently associated with several cancers especially 
haematologic malignancies and childhood sarcomas (Aplan, 2006). In fact, the initial 
translocation identified in a human neoplasia was t (9;22) (q34;q11), causing the Philadelphia 
Chromosome (Novell and Hungerford, 1960). The symbols t (9;22) (q34;q11) indicate a 
translocation between chromosomes 9 and 22 with breakpoints in bands 9q34 and 22q11, 
respectively (Mitelman et. al., 2007).  Chromosomal translocations are increasingly being 
used in the clinic to guide therapeutic outcomes (Agarwal, Tafel & Kanaar 2006, Felix, 
Kolaris & Osheroff 2006, Aplan 2006). Even so, the processes that cause these translocations 
are still poorly understood (Aplan, 2006). These modifications can be discovered 
cytogenetically as fusions of various chromosomes or of normally non-contiguous parts of 
single chromosomes. Large parts of chromosomal arms are frequently removed through 
recombination that leads to translocations, and these deletions are viewed as the defeats of 
heterozygosity. Translocations can arise in cells that enter mitosis before recombination-
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promoting double-stranded DNA breaks are repaired. Alterations of genes implicated in 
double-stranded break repair or DNA damage checkpoints therefore, can cause the 
translocation instability in human cancers (Lengauer, Kinzler & Vogelstein 1998). 
 
1.6 Gene amplification 
Gene amplification is a well defined origin of oncogene activation throughout tumour 
development, and some genomic areas are more frequently amplified than others (Luo et al. 
2006). For example, amplification of chromosome locus 11q13 happens at high frequencies 
in defined human cancers, involving lung, bladder, breast and ovarian carcinomas, in addition 
in head and neck squamous cell carcinomas (HNSCCs) (Hui et al. 1997, Zaharieva et al. 
2003). 
 
Gene amplification, the addition in the copy number of a part of the genome, is a overall 
concept of genome instability in tumour cells and a key mechanism of oncogene activation in 
addition to drug resistance, because it leads to over-expression of related genes. 
Amplification of DNA sequences including cancer genes has been observed in various types 
of solid tumours and lymphomas (Futreal et al. 2004, Santarius et al. 2010). The fact that 
gene amplification has never been discovered in cells of normal origin (Wright et al. 1990, 
Tlsty 1990) suggests that either control mechanisms that preventing of gene amplification are 
active (such as the p53-mediated damage-sensing pathway), or cells carrying gene 
amplifications do not survive. Cytogenetic displays of amplified DNA include self-
replicating extrachromosomal elements termed ―double minutes‖ (DMs), amplified areas on a 
single chromosome (homogeneously staining regions, HSRs) or amplified areas distributed 
during the genome (Albertson 2006). The existence of specific regions of the genome that are 
hotspots for amplification in cancers with similar cell of origin suggests that they contain 
genes relevant for tumour formation and progression (Lockwood et al. 2008, Myllykangas et 
al. 2006). In addition, the genomic context where the amplified DNA is embedded 
(Gajduskova et al. 2007) and its proneness to breakage (Ciullo et al. 2002) seem to contribute 
to the propensity to amplify of specific genomic territories. Moreover, the instability of 
amplified DNA further increases the extent of amplification. A large body of evidence 
indicates that DNA double-strand breaks (DSBs) can promote gene amplification through 
different processes such as successive breakage-fusion-bridge (BFB) cycles, unequal sister 
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chromatid exchange, rolling circle replication or fold-back priming (Mondello, Smirnova & 
Giulotto 2010). 
 
1.7 Gross chromosomal Rearrangements  
Genetic instability is a transient or a persistent stage that resulted from a sequence of 
mutational events causing gross genetic changes (Jefford and Irminger-Finger, 2006; 
Venkatesan et. al., 2006). High fidelity DNA replication is intrinsic to avoid eukaryotic 
genomes acquiring mutations. DNA replication is continuously challenged by inherent 
conditions in cells such as damaged DNA templates, protein complexes bound to DNA and 
insufficient supplies of deoxyribonucleotide triphosphates (dNTPs) (Noguchi et al. 2004). In 
addition to intra cellular events causing DNA damage, it can also be generated by external or 
environmental factors, for instance, UV light, and gamma radiation (Venkatesan et. al., 
2006). Cells have processes to detect and repair DNA damage. However, incorrect repair can 
result in gross chromosomal rearrangements (GCRs) (Banerjee et. al., 2007).  GCRs include 
the structural alterations that may happen either at the chromosome level, leading to a 
decrease or increase of great portions of chromosomes such as, translocations, deletions, 
inversions, amplifications, chromosome termination to end fusions and ploidy changes or at 
the nucleotide level affecting gene structures or expression; for instance, mutations, deletions, 
gene amplifications, microsattellite amplification and gene silencing by epigenetic effects 
(Kolodner et. al., 2002; Aplan, 2006; Banerjee et. al., 2007) 
GCRs can be caused by primary mutations affecting DNA replication (Venkatesan et. al., 
2006; Mirkin and Mirkin, 2007). Throughout DNA replication, DNA replication forks can 
stall at broken DNA, at naturally occurring sequences such as replication fork barriers or 
when the collision happens with different proteins accompanying with DNA metabolism such 
as RNA polymerase II (Prado and Aguilera, 2005). In vertebrates, cancer is frequently linked 
to large genome rearrangements appearing from incorrect repair of DSBs (Hasty et. al., 2003; 
Aplan, 2006).  
 
1.8 Loss of heterozygosity (LOH) 
Human cells generally contain two distinct alleles for a given gene. This provides an 
additional functional gene, should one become inactive. Loss of heterozygosity (LOH) can 
result in the loss of the active gene and, if this is a tumor suppressor gene, this can result in 
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carcinogenesis. LOH can arise as a result of several processes, including chromosome 
breakage, translocation, deletion, gene conversion, mitotic recombination and loss, 
chromosomal fusion or entire chromosomal loss (Thiagalingam et al. 2002). A high 
frequency of chromosomal breakage can cause LOH and is a hallmark of genetic instability 
associated with oncogenesis (Thiagalingam et al. 2002). 
 
1.9 Repair of chromosomal breaks 
Non-homologous end joining (NHEJ) and homologous recombination (HR) are pathways for 
the repair of chromosome breaks, such as DSBs. DSBs are a type of DNA damage that can be 
generated by endogenous or exogenous agents. For instance, when the cell is exposed to 
ionising radiation (IR), this can cause complex, clustered kinds of DSB damages via the 
random deposition of energy. IR can also cause DBSs indirectly by the production of reactive 
oxygen species (O'Driscoll, Jackson & Jeggo 2006). Closely packed single strand-breaks can 
also cause DBSs. In certain recombination processes, like V(D)J recombination in the 
immunoglobulin genes of the immune mechanism (i.e. the generation of diversity in the 
development of T-Cells and B-Cells), DSBs are also produced by recombination activating  
proteins (RAG) (O'Driscoll, Jackson & Jeggo 2006). Meiosis division of a gamete-producing 
cell includes the programmed production of a location or site-specific of DSB (O'Driscoll, 
Jackson & Jeggo 2006). Telomere shortening can also activate DSB repair and the spread of 
apoptosis/senescence via p53 activation (Smith, de Lange 2000). However, there is 
significant variation in the events which cause DSBs and the activation of related repair 
pathways. For instance, the exogenous production of DSBs by IR during G1 of the cell cycle 
causes the activation of NHEJ and ATM signalling. Conversely, replication fork stalling 
activates initial HR and ATR signalling. The repair pathway choice is heavily influenced by 
the cell cycle period in which the damage occurs with NHEJ being more prevalent in G1and 
HR in S-phase and G2. The level of DSBs damage also influences the activation of the 
pertinent rejoining process (O'Driscoll, Jackson & Jeggo 2006). 
 
1.10 Non-homologous End Joining Pathway 
Most DSBs in eukaryotic cells are repaired by either NHEJ or HR. This is in spite of the fact 
that current works has established that a third of DBSs are repaired by lesser characterised 
repair mechanisms known as micro homology-mediated end joining (MMEJ) (McVey, Lee 
2008). NHEJ is the dominant pathway of DSB repair in mammalian cells , and even though 
8 
 
NHEJ-defective cell lines display marked defects in DSB repair and sensitivity to  IR,  cells 
defective  in ATM ,  a crucial protein kinase participating  in  NHEJ repair  and  cell  cycle  
arrest,  repair the majority DSBs usually  (Goodarzi, Noon & Jeggo 2009). Despite this, 10-
20% of visible IR-induced DSBs (repair foci) is repaired with slow kinetics and requires 
ATM and a target nuclease, Artemis, implicated in ends processing (Riballo et al. 2004). HR 
occurs in the late S-G2 phases, while NHEJ happens mostly in the G1 phase (O'Driscoll, 
Jeggo 2006, Lieber 2010). Central proteins involved in the NHEJ mechanism are Ku dimers 
(Ku70-Ku80), DNA-PKcs (the catalytic subunit of DNA-PK), XRCC4, Ligase IV, Artemis 
and cernunnos-XLF (Buck et al. 2006, Ahnesorg, Smith & Jackson 2006a). The Ku complex 
(Ku80/Ku70) is involved in the early recognition of DNA DSBs by its elevated attraction 
towards DNA ends. The addition the Ku heterodimer to the end of a DSB recruits DNA-
PKcs, a serine/threonine protein kinase. The regulatory Ku70/80/DNA-PKcs complex works 
as a DNA damage sensor. Purified Artemis protein has been shown to have single-stranded 5′ 
to 3′ exonuclease activity. However, when the Artemis protein creates a complex in the 
presence of DNA-PKcs, Artemis is phosphorylated and obtains endonucleotytic activity on 5′ 
and 3′ overhangs, and also hairpins (Ma et al. 2002). Artemis supplies a significant 
nucleolytic processing activity to organise DNA ends for re-ligation (Sekiguchi, Ferguson 
2006a). A member of the NHEJ protein family, Cernunnos-XLF, is believed to participate in 
DSB end joining alongside XRCC4 and Ligase IV, the precise function of this protein is not 
yet known. It has been proposed that Cernunnos-XLF might function as a link between 
XRCC4 and Ligase IV and the different NHEJ elements to assist in the enrolment of the other 
factors to the ends of DSBs (Ahnesorg, Smith & Jackson 2006b, Ahnesorg, Smith & Jackson 
2006b). Alternatively, it might be implicated in the regulation of XRCC4-Ligase IV activity 
through the variation of active and inactive multimeric stages of XRCC4 (Sekiguchi, 
Ferguson 2006b). DNA-PKcs and Ku70/80 have been shown to be required for telomere 
maintenance (d'Adda di Fagagna et al. 2001). Analogous mechanisms were observed in mice 
deficient in Ku86 which had raised chromosome end-to-end fusion with strong telomeric 
signals at a site of fusion. This, therefore, shows the significant function of Ku80/Ku86 in the 
telomere end capping process in mice (Samper et al. 2000, Espejel et al. 2002, Espejel, 
Blasco 2002). In the same way, DNA-PKcs  were shown to be necessary in conserving 
mammalian telomeres (Bailey et al. 2004) and that repression of DNA-PKcs caused raised 
levels of chromatid fusions (Bailey et al. 2001, Bailey, Goodwin 2004). Analogous research 
into DNA-PKcs defective mice showed increased levels of telomere fusions showing 
telomere dysfunction during the process of a telomere end capping (Samper et al. 2000, 
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Hande et al. 1999, Goytisolo et al. 2001). DNA - PK is characteristically participating in the 
repair of DSBs by assisting processing of damaged ends, however in the event of apoptotic 
conditions, it appears that the function of DNA-PK and Artemis changes to that of final 
executioners (Britton et al. 2009). 
 
1.11 Homologous Recombination (HR) 
Homologous recombination is another type of DSB repair engaging primarily in late S and 
G2 phases of a cell cycle. HR is often more precise than NHEJ because it uses a sister 
chromatid as a template when repairing DSBs. HR is mainly responsible for repairing DSBs 
that appear because of replication fork stalling (in late S phase). The HR pathway includes a 
nucleolytic mechanism, strand invasion, Holliday junction formation and branch migration 
(see figure 1.1). Many proteins are implicated in HR, including RAD51, RAD52, RPA, 
BRCA1, BRCA2, XRCC2, XRCC3, RAD54, DNA polymerases and DNA ligases. HR repair 
can be mediated two mechanisms, RAD51-dependent pathway, which is an error-free and 
RAD51-independent pathway, which can cause errors in the DNA sequence (Griffin, Thacker 
2004). The RAD51-dependent pathway includes a homology search and strand invasion to 
permit the recondition of the primary DNA sequence, dependent on the undamaged 
homologous sequence (Figure 1.1). Rad51 forms a filament on ssDNA and this structure 
mediates the invasion of the homologous duplex in an ATP-dependent reaction (Holthausen, 
Wyman & Kanaar 2010). Rad52 has an essential role in break-induced replication and single-
strand annealing (SSA) (McEachern, Haber 2006, Llorente, Smith & Symington 2008).The 
RAD52 protein identifies the broken DNA ends and binds to the DNA ends with a 3' single 
strand generated by the nucleolytic activity of the Mre11- Rad50- Nbs1 complex.  Rad52 
assist the loading of Rad51 onto ssDNA. Subsequently, the creation of a nucleoprotein 
filament across the 3' single-strand DNA is achieved via RAD51 polymerization and with the 
assistance of a single-strand DNA binding protein, RAD52 and replication protein A (RPA). 
The RAD51 nucleoprotein filament inspects for a homologous duplex, after which the DNA 
strand exchange gives rise to a linked molecule between the homologous damaged and 
undamaged duplexes. BRCA2 helps to load RAD51 onto the ssDNA molecule, while 
BRCA1 is needed as a regulatory protein. After branch migration and Holliday junction 
formation, DNA synthesis obtains the position where DNA polymerases and accessory 
elements fill the gap and DNA Ligase IV and XRCC4 relegate the remaining breaks. A 
BRCA1-defect leads to sensitivity to ionising radiation and sensitivity to DNA cross linking 
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agents like mitomycin C (Powell, Kachnic 2003). BRAC1 function has also been linked to 
heterochromatin formation (Zhu et al. 2011). In addition, a BRCA1-deficient human 
lymphoblastoid cell line has an elevated level of chromosome end-to-end fusion that proposes 
a function of BRCA1in telomere capping (Al-Wahiby, Slijepcevic 2005). 
 
1.12 DNA Replication  
Cells duplicate at cellular division, which requires the prior duplication of the genetic 
material via DNA replication (Karp , Branzei, Foiani 2007). Faults in chromosome 
replication can cause translocation that appears as a result of a recombination event next to 
stalled replication forks, and DNA replication pause locations can be hotspots for 
recombination (Labib, Hodgson 2007).  
 
DNA replication is semi-conservative because each daughter duplex includes one strand from 
the progenitor molecule. The occurrences included in the initiation of chromosomal 
replication are analogous in the eukaryotes Archae and Eubacteria. As a result of this, 
replication is initiated by association of specific initiator protein(s) to DNA sites, called 
replication origins, and this causes the localised unwinding of the DNA duplex followed by 
the formation of replication forks (Zakrzewska‐Czerwińska et al. 2007).  
 
1.13 Replication initiation 
Even though DNA replication is a necessary characteristic of cellular proliferation, the 
processes of its regulation in mammalian cells are poorly understood (Goldman 1988). There 
is significant uncertainty about the DNA sequences responsible for the initiation of 
replication along mammalian chromosomes (DePamphilis 1993, Dijkwel, Hamlin 1995, 
Huberman 1995).  
 
The molecular process controlling replication initiation in eukaryotes ensures that the 
numerous origins of replication fire just once per cell cycle (Kawasaki et al. 2006). The 
origin recognition complex (ORC) marks the location of replication origins in the genome 
and functions as the ‗landing pad‘ for the accumulation of a multiprotein, pre-replicative 
complex (pre-RC) at the origins. In the model organism Schizosaccharomyces pombe, the 
pre-RC contains Cdc18, ORC, mini-chromosome maintenance (MCM) and Cdc10-dependent  
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Figure1.1Graphic representation of NHEJ and HR. NHEJ A: DSB is discovered in a 
mammalian cell through sensor molecules MRN complex and ATM, which initiators 
Ku70/Ku80 heterodimmers that are bound to the ends of the broken DNA molecule. The 
doughnut shape of the Ku heterodimer is exactly matched to its DNA double helix shape and 
is inserted at the ends of the broken DNA molecule. B: The dimerization of Ku70/Ku80 
recruits DNA-PKcs to the ends of the broken DNA molecule, forming a Ku70/Ku80/DNA-
Pkcs complex. C: One of the functions of DNA-PKcs is to phosphorylate the Artemis 
molecule to activate its endonucleolytic properties to ―chew‖ any overhangs at the end of the 
DNA molecule, a process that is necessary for the proper re-ligation step. D: Ligation occurs 
in the presence of XRCC4 (known as the x-ray cross linking protein), Ligase IV protein and 
the newly discovered Cernunnos-XLF proteins. XLF protein may be used to bridge XRCC4 
and Ligase IV proteins (Yasaei 2009). 
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transcript protein (Cdt1). The MCM proteins function as crucial members in the process that 
limit eukaryotic DNA replication to once per cell cycle.  
DNA replication starts at multiple origins on eukaryotic chromosomes (Bell, Dutta 2002, 
Gilbert 2001) (Figure 1.2). Saccharomyces cerevisiae is noted to have about 400 origins of 
replication, located around every 40-150 kb. These are responsible for the replication of the 
14 Mb genome (Branzei, Foiani 2007).  
The origins of DNA replication in S. pombe contain a specific consensus sequence similar to 
the autonomously replicating sequence (ARS) consensus of S. cerevisiae (Clyne, Kelly 
1995). However, the origins of DNA replication in S. pombe are greater (> 500 bp), are AT 
rich and are mainly detected in intergenic regions (Dai, Chuang & Kelly 2005, Hayashi et al. 
2007). 
                                                                                                                                  
 
       
Figure1.2 Origin of replication and termination in eukaryotes. Linear eukaryotic 
chromosome replicates as many individual replicons moving bidirectionally Adapted from 
(Rothstein et al., 2000). 
1.14 Dynamics of the Replication Fork  
The replication fork is the point at which new DNA daughter strands are formed from the 
parental strands in a template-directed fashion. Because of its Y-shaped form, this reactive 
region is called a replication fork (Figure 1.3). Origin firing is accompanied by replication 
fork formation after the origins are permitted (Branzei, Foiani 2007). At a replication fork, 
the DNA of new daughter strands is created via a multi-enzyme complex that comprises 
DNA polymerases and numerous other proteins. The replication mechanism needs different 
activities and elements for each protein for the elongation, initiation and termination steps.  
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In eukaryotes, before the start of the S-phase of the cell cycle, protein kinases are activated, 
directing the initiation of replication. The unwinding of the DNA duplex and disconnecting of 
the strands requires the assistance of two kinds of proteins that join to the DNA. Firstly, a 
helicase is requiring unwind the duplex DNA and second, a ―primase‖ produces short RNA 
primers that are needed to start DNA synthesis. DNA helicases unwind the DNA duplex in a 
reaction that utilises energy from ATP hydrolysis to break the hydrogen bonds binding 
strands, exposing the single-stranded DNA templates. Associated with these are the multiple 
copies of the heterotrimeric single-stranded binding protein A (replication protein A; RPA), 
which preserve the DNA in a single-strand state. In one model of DNA polymerases ε and δ 
are involved in the replication of both leading and lagging strands, working with their 
accessory proteins, like replicating factor C (RFC) and proliferating cell nuclear antigen 
(PCNA). Together these proteins form a large complex termed the ‗replisome‘ (Figure 1.3) 
(Waga, Stillman 1998, Baker, Bell 1998, Johnson, O'Donnell 2005).  
 
The creation of a function of DNA replication requires many supplemental elements 
(Mcm10, Cdc45, Dpb11, Sld2, Sld3 and the GINS complex in S. cerevisiae) and activation of 
S-phase cyclin-depedent kinases (CDKs) and Cdc7- Dbf4 kinases (DDK), which both 
phosphorylate proteins of the repliosome (e.g. Mcm proteins, Sld2, Sld3) (Moldovan, Pfander 
& Jentsch 2007). These reactions function by assembling the replicative helicase, which is 
comprised of the Mcm2-7 complex with joined elements, and include the DNA polymerases 
and other elements essential for DNA synthesis (Figure 1.3). 
The two DNA strands are created via various processes. Leading strands can be replicated 
successively during the 5'- to - 3' polymerase activity of the DNA polymerase δ (Pol δ) 
(Figure 1.3). The lagging strand is simultaneously replicated in an ―interrupted‖ form, each 
Okazaki fragment is actually shorter than the stretch unwound in the replication fork. The 
RNA primer for DNA synthesis is constructed by the primase enzyme, followed by a small 
stretch of DNA synthesised by polymerase α (Pol α). Both enzymatic activities remain inside 
a single primase-Pol α protein complex. Pol δ or Pol ε (bound to the sliding clamp PCNA, 
loaded by RFC), and after that take over from Pol α. In lagging strand synthesis, when the 
replicative polymerase arrives at the completion of a preceding Okazaki fragment, it moves 
this fragment by continuing DNA synthesis, and a flap structure is produced. The flap 
structure-specific endonuclease-1 (FEN-1, Rad27 in S. cerevisiae) cuts out this structure and 
the cleaved site is sealed by DNA ligase1 (Cdc9 in S. cerevisiae). As the regularity between 
14 
 
the FEN1 and Pol δ is more efficient than regularity between the FEN1 and Pol ε, the Pol δ is 
thought to function on the lagging strand (Moldovan, Pfander & Jentsch 2007). 
In the replication fork, the catenation and positive super coiling ahead are negated by 
topoisomerases I and II. Cyclin-dependent kinase (Cdk) activity remains high following S 
phase and during mitosis and to avoid the regeneration of the pre-replicative complex 
(Lambert, Carr 2005). Termination of Cdk activity allows for the gathering of pre-RC for the 
following cell cycle (Johnson, O'Donnell 2005). 
         
Figure1.3 suggested structure illustrates the molecular activity at a eurokaryote 
replication fork. A, elements of S. cervisiae Pol ε holoenzyme, which consists of  Pol2, 
Dpb2, Dpb3, and Dpb4, reacts with a ring-shaped accessory element, GINS, and creates ― an 
open complex‖  that is then used at Pol ε, which has a potential of both dsDNA- and ssDNA 
binding (Maki et al. 1998, Tsubota et al. 2003), as a rope to the DNA template, even though 
Pol ε complex itself may provide direct intraction to primer template DNA  (Asturias et al. 
2005). The red line shows a primer strand. B, in this structure, hexameric Mcm2-7 
surrounded leading strand DNA and Pol ε is on the leading strand together with 
heterotetrameric GINS and Cdc45. Pol δ is on the leading strand with PCNA, RF-C, Fen1, 
and Dna2, along with Pol α-primase and RPA bound to the looping single-stranded DNA. 
Earlier researchs show that Dpb11 and Sld2 are detected at the replication origin, however 
dsDNA 
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they do not travel with the replication fork (Masumoto et al. 2002). The purple curvy line 
shows newly synthesized DNA, and the red line shows the RNA primer synthesized by Pol α-
primase. 
1.15 Replication fork progression and transcription  
Studies, both in vivo and in vitro, show that RNA polymerase complexes can actually hold 
back the process of replication forks and that cell viability is endangered as an outcome. The 
organisation of bacterial genomes showed that there is a bias to co-directional alignment of 
transcription units with replication, indicating selection against head-on collisions (Blattner et 
al. 1997). Studies in E. coli by (Mirkin, Mirkin 2007b) indicated that collisions in replication 
and transcription are preventable when both the processes continue in the co-directional 
orientation. By contrast, head on collisions cause critical inhibitions of the replication fork 
progression. This is basically collision between the DNA polymerase and RNA polymerase. 
 
Replication fork stalling that requires a new fork to restart and/or activation of checkpoint 
processes due to the lack of any extrinsic DNA damage is a shared event in both bacteria 
(Cox et al. 2000) and eukaryotes (Cha, Kleckner 2002a). Replication forks could 
recommence from endogenous DNA damage such as oxidation or replication barriers. 
Modification of damaged replication forks is an increasingly important factor for effective 
chromosomal duplication and the prevention of genetic instability (Calzada et al. 2005a).  
            
1.16 Regulation of the repliosome at a paused eukaryotic DNA replication fork. 
Replication barriers can cause the repliosome to pause or stall. The S-phase checkpoint 
responds to replication fork (RF) stalling and to intra-S-phase damage (mainly ssDNA gaps 
and DNA DSBs), preventing the firing of late replication origins and entry into mitosis. In 
this function, the checkpoint participates in the preservation of running forks by preventing 
their collapse. Various elements function at the RF to prevent stalling or fork collapse. In S. 
cerevisiae, these involve the Rrm3 helicase (Ivessa et al. 2003), which is needed for RF 
stability at natural obstructions. Mrc1, which creates a complex with Tof1 and Csm3 and 
works in RF preservation jointly with the Sgs1 helicase (Katou et al. 2003a, Calzada et al. 
2005b, Aguilera, Gómez-González 2008). The mammalian transducer kinases ataxia 
telangiectasia mutated (ATM) and ataxia telangiectasia and RAD3 related (ATR) are the 
central factors in starting the S-phase checkpoint response. ATR is stimulated in response to 
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stalled RFs and distinct kinds of damage that cause the generation of ssDNA, like 
UV-induced damage or resected DSBs, while ATM responds immediately to the DSBs to 
which it is enlisted during MRN complex processing (MRE11–RAD50–NBS1). ATR is 
enlisted by its cofactor ATRIP, which identifies RPA-coated ssDNA. However, it also needs 
activation at the RAD9–RAD1–HUS1 (9–1–1) replication processivity clamp (PCNA)-like 
complex, which is stopped by stalled forks by the RAD17 ‗RFC-like‘ complex. ATR and 
ATM kinases phosphorylate, the effector kinases CHK1 and CHK2 stimulating a checkpoint 
response. In this sequence of events, MCM is phosphorylated, which adds to its role in 
activating forks; in S. cerevisiae, the ATR orthologue Mec1 phosphorylates Sgs1 and Mrc1 
obstruct replisome dissociation and collapse (Katou et al. 2003b) (See Figure 1.4).  
                                     
  
Figure1.4 Replication fork progression and stalling. Apart from protein complexes/factors 
required for DNA replication additional factors are recruited in the RF complex encountering 
an obstacle. Encountering an obstacle can cause RF stalling, leading to ssDNA gaps and 
double-stranded breaks (DSBs). Several factors associate with the RF prevent its collapse, 
including the S. cerevisiae Rrm3 helicase, the Mrc1 checkpoint mediator in association with 
Tof1 and Csm3, or the nucleosome assembly factor Asf1. ssDNA gaps and DSBs are sensed 
by the S-phase checkpoint which is activated through Tel1 (ATM in humans) and Mec1 
(ATR in humans). In the case of a DSB, the checkpoint signaling spreads around the DSB 
site by histone H2AX phosphorylation (γH2AX) in humans (H2A in yeast). ATRIP/Ddc2, 
ATR/Mec1 interacting protein; CHK1/Chk1 and CHK2/Rad53, serine/threonine-protein 
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kinases; MCM, replicative helicase; MR(X)N, a nuclease complex; RPA, replication protein 
A; Sgs1, ATP-dependant helicase. (see text) Adapted from (Aguilera and Gomez-Gonzales, 
2008). 
Re-engaging of the RF is mediated by the S-phase checkpoint to avoid unscheduled 
recombination (Trenz et al. 2006). This was derived from the study of budding yeast S-phase 
checkpoint mutations (such to RAD53 and SGS1 respectively which result in a fork collapse 
in the entity of replication inhibitors, and the assembly of Holliday junctions (Cobb et al. 
2005, Sogo, Lopes & Foiani 2002, Lambert et al. 2005).  
 
If DSBs are produced at a fork, histone H2AX is phosphorylated (γH2AX) at its C-terminal 
tail as one of the earlier events at the break site. γH2AX spreads near the break, amplifying 
the primary damage signal and resulting in large, megabase-long chromatin domains that are 
suitable for the stable assembly of damage-response and cohesion elements that favour repair 
by sister-chromatid exchange (Strom et al. 2004). If this whole mechanism is interrupted by 
replication stress or S-phase checkpoint inactivation, breaks are created that could stimulate 
genomic instability.  
 
1.17 Replication fork pauses / barriers and recombination 
Replication arrests are related to genome rearrangements, which are thought to be caused by 
homologous or non-homologous recombination. Some proteins included in homologous 
recombination are also capable of changing an arrested replication fork into a recombination 
intermediate, which promotes replication restart and thus seemingly obstructs genome 
rearrangements (Michel 2000). Eukaryotic cells control the progression and integrity of DNA 
replication forks to preserve genomic stability and couple DNA synthesis to other 
mechanisms. 
In eukaryotes, sequence-specific termination appears to be the exception rather than the rule. 
However, replication fork barriers (RFBs) and replication fork pauses (RFPs) have been 
located at different genomic sites. RFP sites are described as transiently arresting replication 
fork movement and RFBs are explained as elements that result in irreversible ‗blocks‘ during 
replication of genomes (Hyrien 2000).  
Natural RFBs occur within the rDNA and centromeric areas of different organisms and at 
other genomic loci like tRNA genes (Deshpande, Newlon 1996) and the RTS1 (Replication 
18 
 
Termination Sequence 1) at the mat1 locus in S. pombe (Vengrova, Codlin & Dalgaard 
2002). An RFB has been detected in the 3' end of the rRNA genes in S. cerevisiae. This RFB 
needs the FOB1 gene (for fork blocking) for its activity. The biological roles of the RFB are 
believed to stop collisions at the replication and transcription machineries (Kobayashi 2003).  
 
1.18 Replication restarts from pauses. 
Chromosome replication is not a regular and constant process. The repliosome association 
with replication barriers in various stages relies on the nature of the block (McGlynn 2004, 
Michel et al. 2001). Initially, the repliosome might remain connected to the fork and simply 
pause, and then return to the start once the block has been removed (Figure 1.5a). 
Alternatively, the block might cause the collapse of the RF resulting in the fork being 
exposed to different processing molecules, like recombinases. The block might be dealt with 
following repliosome collapse and then the repliosome is re-recognised at the RF and 
replication proceeds (Figure 1.5i). It is possible that the fork might break, possibly because of 
a nick in one of the template strands, resulting in the creation of a DSB (Figure 1.5 b). This 
would need a recombination mechanism to re-establish the replication fork (Figure 1.5 c and 
d). Another option is that there is replication fork regression following detachment of the 
repliosome; this will give rise to a structure known as the ‗chicken foot‘ (fork reversal) which 
had a similar appearance to a Holliday junction (Figure 1.5 e). Such a structure could be dealt 
with in a number of directions, involving resolution to a DSB (Figure 1.5 g), which would 
need subsequent recombination to reconstruct the replication fork, or reversion immediately 
to a running replication fork once the obstruction is detached (Figure 1.5 f).  
 
Another possibility is that the replication structure can simply bypass the block, dependent on 
the nature of the block and the strand on which it is detected (Figure 1.6). Studies in S. 
cerevisiae showed that elimination of MEC1 (ATR orthologue) causes fork stalling and 
chromosome breakage by creating a genetically encoded replication slow zone (RSZ) (Cha, 
Kleckner 2002b), similar to that of mammalian fragile sites, which are precipitated by 
postponed progression during normally late-replicating areas (Laird et al. 1993, Letessier et 
al. 2011). These correspond with fragile sites in humans, which come to be more fragile in 
the absence of ATR. These areas in the chromosomes work to create secondary structures 
that could supply barriers for the replication fork, causing raised chromosomal 
rearrangements (Mirkin, Mirkin 2007a).  
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Figure 1.5 Possible Pathways for dealing with replication blockage (McGlynn 2004). 
 
 
 
 
 
 
 
Figure1.6 The way in which the replisome deals with a block can be dependent upon 
whether or not there is strand specificity to the block. (a & b) leading strand block: this 
mar result in fork regression and the generation of a recombinogenic structure. (c & d) 
leagging strand block: this might result in block or lesion by pass, resulting in a gap which is 
repaired post replication. 
1.19 Cancer stem cells 
1.19.1 A definition of cancer stem cells  
In 1937, Furth and Kahn provided the first determination of the frequency of malignant cells 
in leukaemia cell lines that could maintain hematopoietic tumours in mice, and the results 
Leading strand block 
Lagging strand block 
Current Opinion in Genetics & Development 
(a) (b) 
(c) (d) 
Current Opinion in Genetics & Development 
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suggested that not all of these cells might initiate a tumour. Hence, cancer stem cells (CSC) 
were first proposed. Many studies in the 1960s and 1970s showed the functional 
heterogeneity in tumours in that just a tiny subset of tumour cells can re-initiate tumour 
growth in vivo. These studies formally initiated the CSC concept (Bruce, Van Der Gaag 
1963, Becker, McCulloch & Till 1963, Buick, Till & McCulloch 1977, Goldberg 2005). 
Research into leukaemia has provided strong evidence for the existence of a supposed CSC 
subpopulation or a hierarchical model of cancer (Lapidot et al. 1994a). At the same time, 
CSCs have been found in various solid tumours including breast cancer, colon cancer, 
medulloblastoma, liver cancer, glioblastoma, pancreatic cancer, ovarian cancer and 
melanoma. The observation that leukemic stem cells (SCs) show a similar cell surface 
phenotype to that of normal hematopoietic SCs (HSCs) suggests that CSCs may initiate from 
their normal counterpart (Clarke et al. 2006a). In addition, an increasing amount of data 
indicate that CSCs may also derive from committed progenitors and even differentiated cells 
(Joseph et al. 2008, Zheng et al. 2008, Zheng et al. 2008). Jointly, CSCs may be obtained 
from stem cells that have acquired a tumourigenic capability, differentiated cells from 
committed progenitor cells that have the ability of self-renewal as well as tumourigenic 
properties. A CSC is a cell within a tumour that acquires the capability to self-renew to give 
rise to the heterogeneous lineages of cancer cells that constitute the tumour. After this, the 
reproduced tumours can be serially xenotransplanted (Clarke et al. 2006b, Clarke et al. 
2006b). 
1.19.2 Are stem cells implicated in cancer? 
The above definition of CSCs does not indicate the origin of these cells, and these tumour-
forming cells could assumedly result from stem, progenitor or differentiated cells (Rapp, 
Ceteci & Schreck 2008). The CSC hypothesis proposes that the malignancies accompanying 
the cancer result from a tiny population of stem-like, tumour-initiating cells. Even though 
cancer studies first isolated CSCs in 1994 (Lapidot et al. 1994b), this idea dates back to the 
mid-19th century. In 1855, German pathologist Rudolf Virchow suggested that cancers 
originate from the activation of dormant, embryonic-like cells that exist in mature tissue 
(Huntly, Gilliland 2005). Moreover, Virchow suggested that cancer does not develop 
naturally; rather, cancerous cells, like their non-cancerous counterparts, must result from 
different living cells. Solid support for the CSC hypothesis has come as a result of using cell-
surface protein markers to recognise a proportionately rare population of stem-like cells in 
acute myeloid leukaemia (AML) (Lapidot et al. 1994c).  Furthermore, other studies have 
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demonstrated that leukaemia-initiating cells from various AML subtypes were relatively 
immature in terms of differentiation (Bonnet, Dick 1997c). The cells were ―stem-like‖ – i.e. 
more closely linked to primitive blood-forming (hematopoietic) stem cells than to mature, 
committed blood cells. The identification of leukaemia-inducing cells has led to an attempt to 
isolate and distinguish CSCs in solid tumours and stem cell-like populations have since been 
identified by utilising cell-surface protein markers in tumours of the colon (O’Brien et al. 
2006a), brain (Singh et al. 2004, Li et al. 2007, Hermann et al. 2007), breast (Al-Hajj et al. 
2003b), pancreas and prostate (Collins et al. 2005, Patrawala et al. 2006). However, 
recognising markers that clearly characterise a population of CSCs remains challenging, even 
when there is proof that the assumed CSCs can be found in a given solid tumour type. For 
instance, in hepatocellular carcinoma, cellular analysis has revealed the existence of stem-like 
cells (Sell, Leffert 2008). Nethertheless, standard markers still need to be recognised to 
distinguish these assumed CSCs, even though many possible candidates have been suggested 
(Yang et al. 2008a, Yang et al. 2008b). In some cancers, the CSCs still need to be identified 
and work is ongoing to associate stem-cell markers with malignant cancer cells. For example, 
the proteins Nanog, Nucleostemin and Musashi1, which are highly expressed in embryonic 
stem cells and are necessary for the maintenance of the pluripotency of those cells, are also 
highly expressed in malignant cervical epithelial cells (Ye et al. 2008). While this result does 
not demonstrate the presence of cervical cancer CSCs, it does suggest that these proteins may 
have essential functions in cervical carcinogenesis and progression. 
 
1.19.3 Do CSCs originate from stem cells?  
Regarding the analogies between stem cells and tumour-initiating cells, researchers have 
attempted to determine if CSCs arise from progenitor cells, stem cells, or differentiated cells 
existing in adult human tissue. The issue is currently under discussion (Croker, Allan 2008, 
Clarke et al. 2006c) (see Fig. 1.7). 
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Figure 1.7 How cancer stem cells may arise. The processes that maintain ―stem-ness‖ in 
stem cells are also active in several cancers. This correspondence has guided scientists to 
suggest that cancers may originate when an event generates a mutation in a stem cell, 
plundering it of the potential to regulate cell division. This figure illustrates three theories of 
how a cancer stem cell may appear: (1) a stem cell acquires mutations, (2) a progenitor cell 
acquires mutations, or (3) a wholly differentiated cell acquires many mutations that transfer it 
back to a stem-like state. In all three, the nascent or consequent cancer stem cell has lost the 
ability to control its own cell division. 
1.19.3.1 Theory #1: Cancer cells originate from stem cells.  
Stem cells can be distinguished from other cells by two features: (1) they can divide to 
generate duplicates of themselves, or self-renew, under a suitable environment, and (2) they 
are pluripotent, or capable of differentiating into the majority, if not all, mature cell kinds. If 
the CSCs originate from normal stem cells existing in the adult tissue, de-differentiation 
would not be essential for tumour formation. In this way, cancer cells could simply use the 
existing stem-cell regulatory pathways to promote their self-renewal. The capability to self-
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renew provides stem cells with a long lifespan comparative to that of mature, differentiated 
cells (Allan et al. 2007). It has thus been theorised that the restricted lifespan of a mature cell 
reduces the likelihood that it will live long enough to undergo the many mutations required 
for tumour creation and metastasis. In support of this theory, research has revealed that CSCs 
associated with AML have been shown to contain distinct, hierarchically-arranged classes 
(like those observed in hematopoietic stem cells) that dictate obvious destinies (Hope, Jin & 
Dick 2004b). 
 
1.19.3.2 Theory #2: Cancer cells originate from progenitor cells.   
The differentiation process from a stem cell to a differentiated cell ordinarily includes one or 
more intermediate cell types. These intermediate cells, which are more plentiful in adult 
tissue than are stem cells, are called precursor or progenitor cells. They are slightly 
differentiated cells that exist in foetal and adult tissues and normally divide to generate 
mature cells. Nonetheless, they maintain a partial ability for self-renewal. This characteristic, 
when considered along with their plentifulness, in comparison to stem cells in adult tissue, 
has led some researchers to suppose that progenitor cells could be an origin of CSCs (Li et al. 
2006, Kucia, Ratajczak 2006). 
 
1.19.3.3 Theory #3: Cancer cells originate from differentiated cells.  
 Some studies have proposed that cancer cells could originate from mature, differentiated 
cells that by some means de-differentiate to become more like stem cells. In this way, the 
essential oncogenic (cancer causing) genetic or epigenetic changes would be required to lead 
to the de-differentiation pathway with the subsequent self-renewal of the proliferating cells. 
This opens up the probability that a relatively large population of cells in the tissue could 
have tumourigenic potential; however, only a tiny subset of these would really originate the 
tumour. Specific processes involved in which cells would de-differentiate have not been 
suggested. However, if a tissue includes an adequate population of differentiated cells, the 
rules of possibility show that a small proportion of them could, in principle, lead to the series 
of events necessary for de-differentiation. Furthermore, this series may involve several stages 
and recent studies have demonstrated that human adult somatic cells can be genetically ―re-
programmed‖ into pluripotent human stem cells by applying just four stem-cell factors (Yu et 
al. 2007a, Takahashi et al. 2007a).  
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1.19.4 Biological characteristics of CSCs 
 The characteristics of CSCs are: (1) sequent passage, (2) the potential for multilinage 
differentiation (such that they can recapitulate the multiple tumour cell types found in the 
parent tumour), (3) the tumourigenic capability or self-renewal, and (4) expression of a 
singular collection of surface markers that permit their recognition and purification (Clarke et 
al. 2006d). The CSC hypothesis postulates that in a given tumour, only an obvious 
phenotypic subset of cells has tumourigenic ability. At present, serial passages in 
xenotransplantation models offer the best standard assay to illustrate the CSC division 
(Frank, Schatton & Frank 2010). Normal tissue SCs firmly regulate the balance between self-
renewal, proliferation, differentiation and quiescence (Boman, Wicha 2008, Reya et al. 
2001c). Furthermore, the number of stem cells, in the context of the stem cell niche, is 
accurately maintained through the symmetric and asymmetric cell divisions and 
dysregulation of the self-renewal process occurs as an outcome in an excessive CSC 
population (Ricci-Vitiani et al. 2006, O’Brien et al. 2006b). This may result from an increase in 
symmetric divisions of the CSCs and may offer a possible drug target (Boman et al. 2007, 
Pece et al. 2010). As has been described in the hematopoietic process, the cells in solid 
organs develop to demonstrate a hierarchy in which stem cells lead to committed progenitor 
cells that result in rapidly proliferating cells. When ultimately become terminally 
differentiated cells. As SCs mature from self-renewaing stem cells to terminally differentiated 
cells, they gradually lose their ability for self-renewal and pluripotency; however, they show 
mitotic activity.  
 
1.19.5    OCT4 
OCT4 is a POU family transcription factor. It is known for its role in maintaining the 
pluripotency and self-renewal of embryonic stem cells (ESCs) and in producing induced 
pluripotent stem cells (iPSCs) as a fundamental reprogramming factor to date (Raymond, 
Ayala & Knuutila 2002). The expression and role of OCT4 in human tumours have been 
examined. OCT4 is putatively expressed in and correlated with germ cell tumours with 
pluripotent potential (Longhi et al. 2006a, Wittig et al. 2002a, Kubista et al. 2011, Mohseny 
et al. 2009). Many studies have also demonstrated OCT4 expression in adult stem cells and 
somatic cancers (Tang et al. 2008, Hogendoorn et al. 2003, Cleton-Jansen et al. 2009, Fuchs, 
Pritchard 2002, Sadikovic et al. 2010, Won, Kim & Park 2010, Ta et al. 2009, Ek, Dass & 
Choong 2006). OCT4-positive cells recognised in cancers may distinctly act as cancer stem 
cells (CSCs) (Clarke et al. 2006e, Ischenko et al. 2008, Koch, Krause & Baumann 2010), and 
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OCT4 expression is essential for maintaining the survival and self-renewal characteristic of 
cancer stem-like cells (Lapidot et al. 1994d, Bonnet, Dick 1997d). However, there is 
extensive evidence indicating that OCT4 is not expressed in tumour cell lines and somatic 
tumours (Longhi et al. 2006b, Wittig et al. 2002b, Tang, Ang & Pervaiz 2007, Iwasaki, Suda 
2009, Bae et al. 2010). Expression of Oct4 in embryonic stem cells (ES)cells has been found 
to be associated with a poor prognosis (Chen et al. 2008, Zhang et al. 2010b, Karoubi et al. 
2009). Further, deletion or knock down of Oct4 might cause apoptosis of a CSC-like 
population of lung cancer cells (Hu et al. 2008). Oct-4 has been identified to play an 
important role in cell viability, functioning as a stem cell survival factor, and causes induction 
of pluripotency in somatic cells (Ben-Porath et al. 2008). It also has a major function in 
maintaining self-renewal and the CSC-like, radio, and chemo-resistant characteristics of 
CD133+ NSCLC cells (Jeter et al. 2009). In squamous-cell carcinoma of the esophagus, Oct-
4 expression is high in side population (SP) in contrast to non-SP cells (Klarmann et al. 
2009). Oct4 is considered a hallmark of CSCs. A recent study has proven that cervical 
cancers comprise a sub-population of stem-like cancer cells containing Oct4 protein, 
indicating that Oct4 may be correlated with the initiation of cervical carcinogenesis (Feng et 
al. 2009). The expression of the Oct4 gene in different types of human cancer (Monk, 
Holding 2001a, Jin et al. 1999), a study illustrated function for Oct4 in adult stem cells (Tai et 
al. 2005), and the expansion of epithelial progenitor cells (Tai et al. 2005) sustain the 
hypothesis that cancer is a disease of stem cells. This hypothesis supposes that cancers appear 
in stem cells or early committed progenitors (Sell, Pierce 1994a) because of their incapability 
to differentiate in a controlled pattern. Oct4 clearly controls the transcription of genes, such 
as Trp53, Brca1, Parp1, and Bmi1, which serve a primary function in cells‘ tendency to 
sustain transformation, apoptosis, senescence, and differentiation.  
 
ESCs are characterised by two features: pluripotency and self-renewal capability. Lately, the 
ectopic expression of the of transcription factors Oct4, Nanog, Sox2,c-Myc, Esrrb, and Klf4 
has been induced to re-program human and mouse fibroblasts into a pluripotent stage. (Kaji 
et al. 2009, Okita, Ichisaka & Yamanaka 2007, Takahashi et al. 2007b, Takahashi, Yamanaka 
2006, Woltjen et al. 2009, Yu et al. 2007b). Induced pluripotent stem cells (iPSCs) are very 
analogous to ESCs, and they keep the capacity for self-renew and differentiate into all three 
germ layers. Therefore, iPscs have great therapeutic potential in regenerative medicine 
(Amabile, Meissner 2009, Maherali et al. 2007, Wernig et al. 2007). The Wnt pathway is 
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implicated in stem cell maintenance (Anton, Kestler & Kühl 2007, Sato et al. 2003), perhaps by 
regulating the levels of pluripotency factors Nanog, Oct4, and Sox2 (Kalmar et al. 2009). 
 
1.19.6 The role of niches in normal and cancer stem cells  
Recent studies have generated an obvious notion of the tumour progression scheme for 
cancer growth, which is established on the cancer stem cell postulate (Fig. 1.8, (Dick 
2008).Cancer tissues display the following characteristics: (1) self-sufficiency for growth 
signals, (2) insensitivity to anti-growth signals, (3) evasion of apoptosis, (4) tissue invasion 
and metastasis, (5) sustained angiogenesis, and (6) limitless capability to duplicate (Hanahan 
et al., 2000). Since the majority of these characteristics involve normal stem cell features, it is 
thought that tumour tissue, and some normal tissue, are constantly repopulated from pools of  
self-renewing stem-like cells, called CSCs in the case of tumours (Table 1). CSCs are 
proposed exit as a small population at the top of the hierarchy in tumours, and they retain 
stem-like properties such as the ability for self-renewal and expression of stem cell-related 
genes/markers. Moreover, they are involved in tumour initiation. 
                             
Figure1.8 Hypothesis for the progression of cancer stem cells. Stem cell and/or progenitor 
cells with the assembled genetic change indicate a sustained or resumed self-renewal ability, 
and at the definite stage, these cells, known as ‗cancer stem cells‘ lead to more 
differentiation. However, not fully developed cancer cells with aggressive proliferating 
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Table 1 Similarities and differences between cancers stem cell and normal somatic cells 
Cancer stem cell  Somatic stem cell 
Source of cellular lineage Source of cellular lineage 
Cancer initiation  
metastasis and relapse 
Organ generation  
tissue regeneration 
Self-renew  
(Pluripotency) 
Self-renew  
(Pluripotency) 
Tumour creation Tissue reconstruction 
 
 
In normal adult tissues, stem cells rely on the combination of both cell-intrinsic and cell-
extrinsic elements for appropriate, homeostatic tissue maintenance. It is likely that there is a 
functional microenvironment that assists cancer stem cells, a counterpart of normal stem cells 
and their niches. The participation of various elements has been demonstrated in the 
fundamental interaction between cancer stem cells and their microenvironment. Furthermore, 
studies have also shown that CD44 is essential for the homing and engraftment of the cancer 
stem cells to the niche in acute myeloid leukaemia and chronic myeloid leukaemia (Jin et al. 
2006, Krause et al. 2006). Surprisingly, the molecular processes of leukaemia cell homing to 
the niche are similar to those of the interaction between normal hematopoietic stem cells and 
their vascular niches.  CD133-positive brain tumour cells, that include CSCs, selectively 
attach to the endothelial cells that may form a vascular niche (Calabrese et al. 2007a). 
CD133-positive cells have been widely studied in pancreatic, colon and prostate cancers, and 
future research will show the fundamental molecular processes in the correlation between 
CD133-positve cancer stem cells and their niches. 
 
Several cellular components have also been indicated as the CSC niche and have specific 
signal transduction pathways. For instance, endothelial cells in the vasculature of the brain 
maintain neural stem cell properties, in part through Notch signalling (Shen et al. 2004), and 
this is the same for brain cancer stem cells and their vascular niche (Hovinga et al. 2010). 
Another extensively studied example is the mesenchymal stromal cells in the cancer stem cell 
niche in the intestine. In the normal intestine, stem cells reside in a stem cell niche composed 
of epithelial cells and mesenchymal cells of the myofibroblast lineage that line the crypt. 
Currently, the Wnt signalling cascade is considered to be a prominent force in controlling cell 
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proliferation, differentiation and apoptosis to maintain the stem cell fate at this region 
(Clevers 2006). As the counterpart of the normal intestinal stem cell niche, tumour-associated 
myofibroblasts and mesenchymal stem cells are indicated as the main factors in colon cancer 
stroma (Elliott, Blobe 2005). Colon cancer stem cells have exhibited high Wnt activity, which 
is orchestrated by myofibroblasts remaining in the tumour stroma during processes in the 
hepatocellular growth element (Vermeulen et al. 2010).   
 
These data suppose a strong connection between CSCs and their microenvironment and 
between normal stem cells and their niches, thus indicating the existence of a CSCs niche.  
Even so, a unlike normal stem cell niche, the conduct of CSCs might be regulated by the 
niche at various levels (Vermeulen et al. 2010). Under a normal environment, the stem cell 
niche usually represses stem cells from both differentiation and proliferation, and a transient 
proliferating signal is needed to activate tissue reproduction. On the contrary, in tumours, 
CSCs may be self-sufficient enough to undergo uncontrolled proliferation because of their 
internal mutations and/or alterations in the niche signals. This supports the hypothesis that the 
cancer stem cell niche is an environment that gives dominant signals in tumour cell 
proliferation and growth as well as more support compared to the normal stem cell niche. 
 
1.20 The origin of niches for cancer stem cells and cancer cells 
  In normal cells the microenvironment or niche where the cells remain is significant for 
maintaining the stemness, for differentiation and for the regulation of proliferation. The 
analogies between CSCs and normal stem cells (as indicated in Table I) could help develop 
the interesting theory of the stem cell niche to the presence of CSCs niche.  Various studies 
have demonstrated that specialised CSCs niches may be involved in tumour progression 
(Calabrese et al. 2007b, Gilbertson, Rich 2007), and they are to have a significant function in 
practically every aspect of the tumourigenic cascade, including the metastatic mechanism and 
drug resistance.  Generally, metastasis takes place in an organ-selective manner as illustrated 
by the ‗seed and soil‘ hypothesis, which shows that the localised microenvironment of 
particular organs appears to be more responsive to specific tumour cells than different organs. 
Thus, distributed tumour cells need to encounter an appropriate microenvironment in order to 
initiate and maintain a secondary tumour. The metastatic mechanism is very complex and 
inefficient and involves multi-steps such as circulation, intravasation, arrest, angiogenesis, 
extravasation and migration (Pawelek, Chakraborty 2008). Furthermore, tumour stromal cells 
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comprised of MSCs might be implicated in various phases of the metastatic process 
accompanied by the interaction of CSCs (Figure 1.9).  
          
 
Figure 1.9 Potential implications of tumour stromal cells involving MSCs/TAFs in a 
clustering metastatic model. Metastatic tumour cells may comprise cancer stem cells, 
completing a very complex metastatic mechanism that collaborates with tumour stromal cells. 
Soluble factors such as MMPs, CXCR4, CCL5, IL-6, SDF-1 and VEGF secreted from 
MSCs/TAFs may be involved in the metastatic mechanism (Honoki, Fujii & Tsujiuchi). 
Mesenchyaml stem cells have the ability to increase the growth and metastasis of particular 
tumours such as colon cancer (Shinagawa et al. 2010), and have been suggested to assist the 
progress of tumour-associated fibroblasts as well as promote tumour progression. The 
metastatic potential of osteosarcoma cells and breast cancer cells has also been indicated to 
be strongly increased when co-injected with MSCs during the paracrine signalling processes 
(Shinagawa et al. 2010). In this context, MSC-derived CCL5 seems to be a fundamental 
factor in increasing the growth and invasiveness of tumour cells. In addition, IL-6 from 
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MSCs is implicated in the growth promotion effect for osteosarcoma cells (Bian et al. 2010). 
MSCs also generate chemoattractant proteins such as MCP-1 and SDF-1 that attract 
spreading tumour cells such as B leukaemia cells and breast cancer cells (Burger, Kipps 
2002, Burger, Kipps 2002).   
 
The conversion of MSCs to tumor-associated-fibroblast (TAFs) (has been indicated to 
participate in tumour growth during fibrovascular network expansion and the generation of 
tumour-stimulating paracrine elements (Burger, Kipps 2002). Moreover, stimulated 
fibroblasts have also been found in liver metastasis, where they promote tumour outgrowth 
(Olaso et al. 1997). Fibroblast activation is apparently implicated in the priming of the 
premetastatic niche with fibronectin deposits (Kaplan et al. 2005), which pull tumour cells to 
sites for metastasis. Furthermore, the infiltration of activated fibroblasts or myofibroblasts 
precedes the recruitment of vascular endothelial cells in the hypoxic avascular metastatic 
environment, and they generate VEGF to promote transition and angiogenesis in a vascular 
step (Olaso et al. 2003). Furthermore, in paracrine signalling, MSCs preserve tumour cells 
against apoptosis and promote original tumour cell proliferation principally at direct cell – 
cell contact interactions (Roorda et al. 2010). All of this suggests that MSCs are implicated in 
the metastatic mechanism as the origin of the niche for metastatic tumour cells. In addition to 
the effect on tumour progression, tumour stromal cells may also contribute to drug resistance 
through complex mechanisms such as the direct cell contact, the interaction of extracellular 
matrices (ECM) and soluble factors (Nefedova, Landowski & Dalton 2003). Soluble factors 
that mediate drug resistance are produced by a dynamic interaction between tumour cells and 
stromal cells.  
 
 
1.21 Similarities between CSCs and embryonic stem cells  
Cancer cells share some features with embryonic stem cells (ESCs) such as self-renewal, 
uncertain proliferation, differentiation and migration (Pathak and Multani 2006). Together, 
CSCs and ESCs have capacity to ―undergo rapid clonal proliferation‖. Moreover, CSCs and 
ESCs contribute seven out of the nine signalling pathways associated with embryonic 
development and cancer. These are: the NOTCH signalling pathway, JAK/STAT pathway, 
the PI3K/AKT pathway, the MAP-Kinase/ERK pathway, the NFkB pathway, the TGFβ 
pathways and the Wnt pathway (Dreesen and Brivanlou 2007). 
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In addition, hESCs express a set of epitopes such as stage-specific embryonic antigens 
(SSEA-3 and SSEA-4 but not SSEA-1 unlike mESCs) and alkaline phosphatase (Adewumi et 
al. 2007; Stephenson et al. 2010; Takahashi et al. 2007). On inspection of 40 tumour forms 
with their normal tissue counterparts, Schoenhals and colleagues found that about half of the 
tumour types showed over expression of pluripotency factor(s) compared to the normal 
tissues. This elevated expression was linked to tumour progression and poor prognosis 
(Schoenhals et al. 2009). 
 
Understanding the processes behind self-renewal and resistance of CSCs to therapeutics 
would result in a better comprehension of tumours, thereby increasing the possibility of 
creating efficient anti-cancer medications by targeting these CSCs (Ebben et al. 2010; T. Lin 
et al. 2009). The pathways implicated in self-renewal contain: Wnt, Notch, Hedgehog (Hh), 
transforming growth factor β (TGF-β), bone morphogenetic protein (BMP), phosphatase and 
tensin homolog (PTEN) and BMI-1, a polycomb group member. Although these processes 
are used by both normal stem cells and CSCs, some compounds have been shown to target 
CSCs without affecting normal stem cells (e.g., parthenolide and rapamycin). This indicates 
that these processes may occur differently in CSCs and normal stem cells.  
 
1.21.1 Classes of stem cell type 
To date, four classes of stem cells have been identified: ESCs, induced pluripotent stem cells 
(iPSCs) (both pluripotent with the ability to produce all types of human cells), adult stem 
cells and chord blood/placental stem cells (both multipotent). (Dreesen and Brivanlou 2007; 
Takahashi and Yamanaka 2006; Takahashi et al. 2007). ESCs exhibit a distinct cellular 
morphology; that is, they are typically small cells with a high nuclear to cytoplasmic ratio and 
they grow in colonies (Thomson et al. 1998).  
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1.21.2 DNA repair in ESCs  
The DNA inside a cell is continuously susceptible to damage. The cell manages this situation 
by employing different processes to repair the damage. This is essential as unrepaired DNA 
will instigate cell cycle arrest or apoptosis, and in cells with abnormal repair mechanisms, 
mutations will appear, go unchecked and may finally lead to cancers.  
 
Figure 1.10 Signalling in double strand breaks. Organization of the DNA-damage 
response pathway. The presence of DSBs is recognised by a sensor, which transmits the 
signal to a series of downstream effector molecules through a transduction cascade, to 
activate signalling mechanisms for cell-cycle arrest and induction of repair, or cell death if 
the damage is irreparable‖(Khanna and Jackson 2001). 
The outcomes of mutations in ESCs could be destructive to the body; therefore, it is 
necessary to have an efficient repair system to guarantee the maintenance of genomic 
integrity. While mutations in differentiated cells can give rise to a number of somatic 
diseases, mutations in ESCs can be disastrous, affecting many cell types, also passing them to 
progeny. The mutation frequencies measured in embryonic stem cells are indicated to be 
considerably lower than that of somatic cells. Except for X linked genes, the majority of the 
mutations in ESCs cause loss of heterozygosity (LOH). However, ESCs can adopt some 
processes to maintain genomic integrity such as suppression of mutagenesis, apoptosis or 
differentiation. In addition, genes associated with DNA repair, such as Msh2 and Xrcc1, have 
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been found to be highexpressed in ESCs (Park and Gerson 2005; Tichy and Stambrook 
2008). 
 MESCs are found to have a p53-independent programme, i.e. they do not experience cell 
cycle arrest in response to DNA damage, in spite of the high expression of p53 (Savatier et al. 
2002). However, the levels of apoptosis frequency among mESCs are much higher than that 
of differentiated cells. This guarantees that no DNA-damaged cells are supplied to the 
developing organism (Aladjem et al. 1998; Cervantes et al. 2002; Frosina 2010; Hong et al. 
2007; Park and Gerson 2005; Serrano et al. 2010). 
The most harmful DNA lesion to the cell is a double strand-break (DSB) (Tichy and 
Stambrook 2008). DSBs can result from free radicals that appear during metabolism, ionizing 
radiation, stalled replication forks and also through meiosis (Park and Gerson 2005). In ESCs, 
replicating chromatin is especially susceptible to strand breaks (Banath et al. 2009). 
 
To date, the principal DNA repair mechanism recognised in stem cells comprises nucleotide 
excision repair (NER), mismatch repair (MMR) (BER), base excision repair, homologous 
recombination (HRR) and non-homologous end joining (NHEJ). In nucleotide excision 
repair, oligonucleotide pieces following irregular bases are removed and inappropriate or 
damaged bases are removed by base excision repair. In addition, the mismatch repair system 
recognises particular single mismatches or misaligned nucleotides (Park and Gerson 2005). 
 
Homologous recombination mediated repair (HRR) and NHEJ are the chief mechanisms 
involved in DSB repair (Lieber et al. 2003). In HRR, the RAD52 protein family has a major 
role and this repair pathway is error free, taking place during the late S to G2 phases, when 
sister chromatids are present to function as a template.  Furthermore, NHEJ is active in the 
G1 and early S phases when sister chromatids are missing (Morrison et al. 2000; Takata et al. 
1998). Conflicting reports are available concerning the percentage of each pathway that is 
used by cells for DNA DSBs repair. However, most studies report a major role for the HRR 
pathway in ESCs ranging from 75-81%, and some studies have claimed that 92% of DNA 
DSBs were repaired by NEHJ in ESCs (Francis and Richardson 2007; Pierce et al. 1999). 
Since ESCs spend about 75% of their cell cycle in the S phase, this may indicate that these 
cells would favour HRR rather than NHEJ for DSB repair (Savatier et al. 2002). In addition, 
studies on the RAD51 protein, which plays a major role in HRR, have shown that its levels in 
ESCs is 20-fold higher than that in mouse embryonic fibroblasts (MEFs), where NHEJ is the 
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preferred mechanism for repair. Indeed, NHEJ deficiency in mice causes an increased 
susceptibility to IR exposure. However, ESCs are capable of repairing DSBs, caused by IR 
exposure, much faster than MEFs (Tichy and Stambrook 2008). 
 
HESCs are more efficient in repairing DNA than human primary fibroblasts (Maynard et al. 
2008), and through a series of  hESC differentiation, the frequencies of DNA damage have 
been shown to increase and expression of DNA repair proteins to decline (Saretzki et al. 
2008). Although homologous recombination is used to repair DSBs, it can also generate 
deletions and rearrangements of chromosomes. Furthermore, defects in proteins implicated in 
HRR may cause acute radiation sensitivity and cancer (Park and Gerson 2005).  
 
1.22 Differentiation Therapy 
The enhanced understanding of the molecular, genetic, and cellular characteristics of 
carcinogenesis over the last few years has resulted in various recent targets for intervention. 
One novel suggestion or method is differentiation therapy. Differentiation requires planned 
changes in gene expression directed at limiting the expression of a different repertory of 
genes in pluripotential cells to those needed to achieve the specialised phenotype in unipotent 
cells in a precise tissue. Cellular differentiation often results in the formation of non-dividing 
cells (terminally differentiated cells). This is the outcome of the modulation of genes 
implicated in the regulation of senescence, cell proliferation, and programmed cell death 
(apoptosis). The treatment of cancers may be possible by inducing the differentiation of stem 
cells, that is, via differentiation therapy (Pierce 1983) if the malignant cells of cancers are 
CSCs (Sell, Pierce 1994b, Reya et al. 2001d, Pardal, Clarke & Morrison 2003b, Bonnet, Dick 
1997e, Singh et al. 2003b). The tumour stem cells of teratocarcinomas can be influenced by 
the environment of the maturing embryo to differentiate into normal adult tissues. If tumour 
cells can be compelled to differentiate and to stop proliferation, then their malignant potential 
will be regulated and controlled. Normal terminal differentiation always results in non-
proliferating cells that eventually undergo apoptosis as they complete their normal lifespan. 
Therefore, an improvement in planning to activate the normal mechanisms of differentiation 
in pre-malignant and malignant cells is reasonable by utilising physiological or 
pharmacological agents that can avoid the epigenetic and genetic abnormalities repealing 
differentiation. This method, called differentiation therapy, can be used to stop, suppress, or 
reverse the malignant phenotype by inducing differentiation with the connected growth arrest, 
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apoptosis, and senescence (Figures 1.11a, b and c). Differentiation therapy has limitations, 
but it can alter malignant tumours into benign tumours. Here, data on chosen differentiation-
inducing agents and their mechanisms of action are examined. A class of compounds, both 
natural and synthetic, is used to induce differentiation in vitro in different cell lines, including 
CSCs or stem cell-like termed NTERA2 cells, colorectal cells HCT116, and mouse 
embryonic cells. Some of these agents are illustrated as follows: (see page 38). 
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Figure 1.11 a. Targets for differentiation therapy. In a normal differentiation mechanism, 
a supposed stem cell indicated as A is needed to sustain the steps of progressive alterations in 
gene expression and the consequent phenotypic changes, symbolised by letters B, C, and D, 
before proceeding to the terminally differentiated cell stage, indicated as E. Cancer 
maturation is correlated with aberrant differentiation. This process is represented by a barrier 
in differentiation that can be formed before the development of premalignant cells. The 
design displays three possible blockages in late steps of the differentiation mechanisms (e.g., 
in stage D) and in early steps of the mechanism (e.g., at step B) (Lotan et al. 1990). 
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Figure 1.11 b. Features of agents used to induce differentiation in malignant cells. In 
Scheme 1, an agent can induce partial differentiation of cells obstructed in Step B by 
inducing them to sustain alterations to Step D. In Scheme 2, the agent can induce the cells 
obstructed in Step B to sustain full differentiation to the developed cell E. In Scheme 3, agent 
a can induce partial differentiation (from B to C), but at the same time, it makes the resultant 
cell C capable of responding to agent b which can complete the differentiation of cell C to the 
developed cell E. The latter example can serve as one of the rationales for the combination of 
agents for differentiation therapy. The designation of letters A–E is the same as in Figure 1 
(Lotan et al. 1990). 
                           
Figure 1.11 c. Inter-relations between differentiation and apoptosis. Several cell types 
sustain apoptosis as a normal result of terminal differentiation, so the treatment of cancer 
cells in Step B with agent b induces the cells in Step B to sustain differentiation to the 
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developed cell E and finally, to apoptosis. This scheme is contrary to that for an agent like a, 
which can induce apoptosis without inducing differentiation (Lotan et al. 1990). 
1.23 N, N-Hexamethylenebisacetamide (HMBA)  
HMBA is a hybrid polar compound that can induce the differentiation of both murine 
erythroleukaemia cells and several cell lines in vitro and in patients (Marks et al. 1995). 
Detailed studies using murine erythroleukaemia cells have described the early and late effects 
of HMBA (reviewed in Marks et al. 1995). The induction of differentiation by HMBA entails 
treatment at concentrations of 3–10 mmol L−1 for 3–15 days. Various studies have been 
performed with human cancer cells. HMBA induces the differentiation of human 
teratocarcinoma, glioma cells, and bladder carcinoma. Further, HMBA suppresses cell 
growth and reduces the tumourigenicity of the cells. The effects of HMBA were correlated 
with the expression and suppression of growth factors, such as transforming growth factor 
alpha, autocrine factor teratocarcinoma-derived growth factor-1, and a keratinocyte growth 
factor associated with the epidermal growth factor. HMBA induction, which results in a 
termination of proliferation, is partly mediated by the increased expression of cyclin-
dependent kinase inhibitor p27, enhanced association of p27 with cyclin E/cyclin-dependent 
kinase 2 (CDK2 complex), and suppression of kinase activity associated with cyclin 
E/CDK2. The formation of E2F complexes with pRB and the protein p130 has been 
associated with in growth inhibition. Other effects of HMBA include enhancement of gap-
junctional intercellular communication and induction of cell death, both of which can lead to 
the repression of growth. 
 
1.24 Retinoic Acid (RA)  
The all-trans RA (ATRA) is a metabolic compound derived from vitamin A and is 
extensively associated with neurogenesis (Lotan et al. 1990). Through embryogenesis, RA 
participates in the patterning of the neural plate and neural tube (del Corral, Storey 2004, 
Maden et al. 1996, Wilson et al. 2004). Retinoic acid plays a role in conservation of motor 
neurons (Novitch et al. 2003), and mammalian nerve regeneration (Zhelyaznik et al. 2003). 
RA is actually the most commonly used morphogen to generate in vitro neural progenitor 
cells and neurons from stem cells (Kim et al. 2009, Soprano, Teets & Soprano 2007, Martins 
et al. 2005, Hirami et al. 2009). It is one of the most important differentiation inducers. It can 
induce the differentiation and apoptosis of a number of tumour cells, including glioma cells 
(Haque, Banik & Ray 2007). ATRA represses growth and induces differentiation, so it has 
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therapeutic potential in cancer medication, particularly in combination with other therapeutic 
agents (Witcher et al. 2003). The combination of ATRA and paclitaxel-induced 
differentiation and apoptosis in human glioblastoma U87MG xenografts has been indicated 
(Karmakar, Banik & Ray 2008). However, the molecular processes of glioma cell 
differentiation induced by ATRA have not been completely elucidated. Retinoids, like RA, 
have been clinically used to treat many forms of cancer, but only a very small number of 
patients respond to them (for reviews, (Mongan, Gudas 2007, Freemantle, Spinella & 
Dmitrovsky 2003). This limitation is attributed to the effect of retinoid resistance, which 
refers to the deficiency in tumour cell response to the same pharmacological dosages of 
retinoids; normal cells respond by proliferation arrest or differentiation. Therefore, the 
problem of retinoid resistance remains to be overcome in cancer treatment. 
 
New and favourable results can be found in experimental animals (Zhang et al. 2010a) and in 
human clinical trials utilising retinoids in combination with other medicines. For instance, 
vitamin A and TRAIL jointly generate apoptosis just in intestinal polyps and not in the 
normal intestinal mucosa in the ApcMin mouse model of intestinal carcinogenesis (Zhang et 
al. 2010a). Therefore, the description of the molecular processes by which retinoids act 
provides a significant precedent. Further, there is a need to learn more about how 
transcriptional mechanisms in undifferentiated versus differentiated cells are regulated by 
bioactive retinoids like RA in order to understand complex mechanisms, such as pattern 
creation in progression, cell differentiation, progression of cells to malignancy, and the steps 
of CSCs in driving tumourigenesis. 
 
1.25 Mechanism of Activity of CPT: Poisoning of Topoisomesase I  
Topoisomerases are ubiquitous enzymes implicated in topological troubles generated by 
many nuclear activities, such as DNA replication, chromatin assembly, transcription, repair, 
recombination, and chromosome segregation (Lorence, Nessler 2004). These enzymes exist 
in all living cells, including yeast, viruses, archebacteria, plants, flies, and humans (Wang 
1996). Topoisomerases control DNA supercoiling and accomplish DNA decatenation using a 
complex exchange of DNA cleavage, rejoining, and manipulation reactions (Keck, Berger 
1999). There are two major classes of topoisomerases: topoisomerase I (Topo 1) and 
topoisomerase II (Topo 2). Each topoisomerase type can be further divided into two sub-
forms, A and B, which are unconnected in sequence and in construction (Keck, Berger 1999). 
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Topo 1 stimulates alterations in the linking number of DNA (i.e., the number of times one 
strand of DNA crosses the other) by one per cycle of the process through breakage, resealing 
of the phosphodiester bonds strands of DNA, and alteration in the linking number of DNA by 
two (Wang 1996). In all topoisomerase forms, a conserved tyrosine in the catalytic side acts 
to cleave DNA, forming a transient, covalent phosphotyrosyl intermediate (Keck, Berger 
1999). Topo 1-mediated reaction can be classified into four stages (Lorence, Nessler 2004, 
Rothenberg 1997a, Rasheed, Rubin 2003, Rasheed, Rubin 2003, Pommier 2006) as depicted 
in Figure 1.12. Camptothecin increases DNA damage by regulating a normally transient 
covalent complex between DNA and Topo 1 (Hsiang et al. 1985). Camptothecin links very 
feebly only to normal B-DNA under a physiological environment and it does not 
independently link to Topo 1 (Lorence, Nessler 2004). Cross-linking studies have proposed 
that CPT acts with the Topo 1-DNA complex, thereby creating a ternary complex that 
stabilises the trans-esterification intermediate (Hertzberg et al. 1990, Pommier et al. 1995). 
Therefore, by regulation of the cleavable complex, CPT converts the normally useful enzyme 
Topo 1 into an intracellular, cytotoxic poison. As a result, CPT has structural similarities with 
topoisomerase inhibitors or topoisomerase poisons (Lorence, Nessler 2004).  
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Figure 1.12 Pathway of activity of Topo 1 and pathway of CPT attack on the Topo 1-
DNA complex. (a) The cell cycle; all conditions illustrated in parts (b-i) occur in the S-phase. 
(b,f) Increase in tension and supercoiling of DNA. (c,g) Topo 1 links to one DNA strand and 
incises it (cleavage reaction). (d) The undamaged DNA passes in the nick, resulting in the 
relaxation of the torsional strain. (e) Topo 1 reseals the cleaved DNA strand (re-ligation step). 
(h) Interaction of CPT with the Topo 1-DNA complex, creating a ternary complex that 
regulates the trans-esterification intermediate. (i) Irreversible breakage of DNA (Kusari 
2010). 
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1.26 Aphidicolin 
Aphidicolin, a tetracyclic diterpenoid acquired from Cephalosporium aphidicola (Brundret et 
al. 1972), represses the growth of cultured human cells (Bucknall et al. 1973a, Pedrali-Noy, 
Spadari 1979) and also growth herpes vaccinia and simplex viruses (Bucknall et al. 1973b). 
DNA replication stress (stalled DNA replication forks) frequently causes DNA damage. 
Aphidicolin (Aph), is an inhibitor of a-like DNA polymerases, has also been shown to 
increase DNA damage (Brox, Hunting & Belch 1984), most likely via degenerating 
replication forks. Aph-induced DNA damage may result in the formation of DSBs (Liu, Kuo 
& Melendy 2003). Aph is commonly used to synchronise cells in the cell cycle (Tobey, Oishi 
& Crissman 1990, Gong, Traganos & Darzynkiewicz 1995). H2AX phosphorylation in cells 
subjected to replication stress by hydroxyurea or aphidicolin appears to be mediated not by 
ATM (Kurose et al. 2006a) but by ATR (Ward, Minn & Chen 2004). Aphidicolin induces 
further delay in the progress of replication, which leads to the unreplicated in DNA (Hellman 
et al. 2002, Wang et al. 1999, Hellman et al. 2000). AT-rich dinucleotide flexibility islands 
represent one of the presumed inherent features of common aphidicolin-inducible fragile 
sites. These sites might contribute to replication upset either because of their high DNA 
flexibility (Chen, Rau & Charney 1985) or of their possible capability to form DNA 
secondary structures that can disturb the progression of the replication fork (Zlotorynski et al. 
2003, LaDuca et al. 1983). 
 
1.27 Hydroxyurea 
Hydroxyurea leads to the exhaustion of deoxynucleotide triphosphates (dNTPs) in cells 
(Bianchi et al. 1986; Koc et al. 2004; Matsumoto et al. 1990). It is an inhibitor of 
ribonucleotide reductase, which is required for de-oxyribonucleotide synthesis, dNTPs are 
required by DNA polymereases as the building materials for DNA synthesis. With reduced 
levels of dNTPs, the DNA polymerase constituent of replication fork pauses which can result 
in fork collapse (Feng et al. 2006, Mirkin, Mirkin 2007c). 
 
To arrest replication fork stalling, the cell may adapt to or overcome HU inhibition. It may 
also be released from stalling when HU is removed from the environment, and the dNTP 
supply is replenished in the cell (Kurose et al. 2006b, Lopes et al. 2001, Mulder, Winkler & 
Timmers 2005). Regardless of how long the replication fork is captured to make the 
necessary repairs, RFs must be capable of resuming so that the cell cycle can terminate. As a 
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further complication, the cells through the stalled RFs have an increased danger for DNA 
damage, resulting in alteration or cell death (Bernstein et al. 2009, Bryant et al. 2009, Froget 
et al. 2008, Kai et al. 2005, Mao, Kojic & Holloman 2009, Noguchi et al. 2003, Petermann et 
al. 2010c). Significantly, a short-duration (2–4 h) use with HU has been shown to cause 
global replication stalling. However, once the drug is removed, the stalled forks are 
reactivated in an XRCC3/RAD51-dependent manner (Petermann, Helleday 2010). By 
contrast, a lengthy treatment with the same drug results in the collapse of the stalled 
replication forks. As a result, homologous recombination repair is required to restore the 
integrity of the genome, whereas de novo activations of fresh replication origins are 
implicated in the re-commencement of replication. Therefore, prolonged treatment with 
hyrdoxyurea leads to increased events of cell death (Petermann et al. 2010a). The lengthy HU 
treatment results in the collapse of the activated replication forks, and replication is re-started 
with the activation of new origins (Petermann et al. 2010b). 
 
1.28 Phleomycin 
Phleomycin is a copper-containing protein, acquired from the culture medium of 
Streptomyces verticillus (Maeda et al. 1956a). In bacteria, it is a specific inhibitor of DNA 
synthesis (Falaschi, Kornberg 1964) and plays the role of an anti-tumour agent (Bradner, 
Pindell 1962a). These mechanisms supposedly take place via a direct influence on DNA, 
although the exact pathway has not been confirmed. Phleomycin has been recognised to link 
to DNA and to lead to the in vitro repression of DNA polymerase I of Escherichia coli 
(Falaschi and Kornberg 1964). Further, chromosome breaks have been discovered in human 
lymphocytes cultured in the existing drug (Jacobs, Neu & Gardner 1969). The biological 
properties of phleomycin are common. Phleomycin inhibits the growth of bean rust (Smale, 
Montgillion & Pridham 1961) and a diverse number of animal tumours (Shooter 1963, 
Bradner, Pindell 1962b). It also causes phage growth in lysogenic bacteria (Lein, Heinemann 
& Gourevitch 1962)and in Gram-positive and Gram-negative bacteria ( Maeda et al. 1956b, 
Tanaka, Yamaguchi & Umezawa 1963). 
 
In T. brucei, RAD51 can be discovered in distinct foci in the parasite cell nucleus after 
phleomycin treatment (Proudfoot, McCulloch 2005, Hartley, McCulloch 2008) or is 
implicated in the production of a site-specific DSB by the I-SceI meganuclease (Glover, 
McCulloch & Horn 2008). The creation or stabilisation of RAD51 foci additionally relies on 
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a number of elements in the eukaryotes, of which BRCA2, RAD51-3, and RAD51-5 have 
been shown to play a role in T. brucei following phleomycin treatment (Proudfoot, 
McCulloch 2005, Hartley, McCulloch 2008). These finding suggest phleomycin generates 
chromosomal strand breaks which require HR for their repair. 
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Chapter 2 Materials and Methods  
 
2.1 S. pombe strains, media and plasmids 
S. pombe strains were grown and stored as described by Moreno et al. (1991). Media used is 
listed below. The S. pombe strains employed in this study are listed in Table 2.1.  Plasmids 
employed in this study are pSRS5 (Pryce et al., 2009) and pade6-469 (Szankasi et al.,1988). 
General molecular biology techniques used are as described by Maniatis et al. (1982). 
 
2.2 S. pombe Meiotic crosses protocol  
Cultures of appropritate S. pombe strains were grown in yeast extract liquid (YE; see 2.8) 
supplemented with adenine (200 mg/l) to a density of approximately 2x10
7
 cells/ml. Equal 
volumes of each culture were mixed in microfuge tubes, pulse centrifuged and aspirated. Cell 
pellets were washed with 1 ml of dH2O and finally resuspended in 20 µl dH2O. 
 
Suspensions were spotted onto fully supplemented synthetic sporulation medium (SPA; see 
2.8) and incubated at the required temperature for 3-4 days (4-5 days for room temperature 
crosses). After incubation, sporulating cells were scraped into a microfuge tube containing 1 
ml of a 0.6% β-glucuronidase® (Sigma) in dH2O and incubated for 16 hrs at 25°C. After 
incubation, spores were harvested and resuspended in 30% ethanol and incubated at room 
temperature for not longer than 5 minutes. Spore suspensions were then centrifuged, aspirated 
dry and spore pellets were resuspended in 1 ml dH2O.  
 
2.3 Fluctuation analysis for calculation of mitotic recombination frequency  
Cells were inoculated into appropriate liquid medium. The inoculated culture was incubated 
overnight at 30°C in a rotary incubator. A serial dilution of the culture was made and plated 
onto appropriate agar plates (selection was maintained for all cultures where strains contained 
plasmid). Plates were incubated for a period of no more than two days at 30°C until 
microcolonies could be observed. Single colonies were picked from the agar plate using a 
sterile Pasteur pipette and inoculated into 5 mls of appropriate liquid medium (selection was 
maintained when necessary) containing supplementary adenine (200 µg/ml) to avoid 
selection of recombinants. Cultures were incubated at 30°C in a rotary incubator until the 
culture was saturated (approximately 3 days). Serial dilutions were made and aliquots plated 
out onto selective NBA (no adenine) to quantify recombinants and NBA with supplementary 
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adenine (200 µg/ml; to count viable cells). For each strain a minimum of seven cultures per 
experiment were used and the median recombination frequency (adenine prototrophs / viable 
cell) was calculated and mean values of three independent median values were subjected to 
Student‘s t- test.  
 
2.4 Construction of plasmid pSRS5 for plasmid by chromosome recombination assay 
(fluctuation analysis) 
The plasmid based recombination assay, was carried out employing the plasmid pSRS5 
which contains a mutated ade6 gene. The ade6 gene was mutated by deletion of one 
nucleotide ‗G‘ at 1483 bp of the ade6 gene (taking the A of the ATG start codon as position 
1) (Pryce et al., 2009).   
 
2.5 Isolation of plasmid DNA from E. coli 
Plasmid DNA was acquired employing the method as described in the GenEludeTM HP 
Plasmid Miniprep Kit. E. coli DH5 from the -70°C freezer stock was streaked on Luria 
Bertani (LB) media (see 2.8) with the appropriate antibiotic and grown overnight at 37°C. A 
single colony from this culture was inoculated into a 5 ml LB broth with the appropriate 
antibiotic and was incubated overnight at 37°C in an orbital incubator.  The cells were 
collected by centrifugation at 3,000 g for 1 minute and resuspended in 200 μl of 
Resuspension Solution containing RNase A. Cells were then lysed with 200 μl of the lysis 
buffer. The cell remains were precipitated with 350 μl of Neutralization / Binding Buffer and 
parted by centrifugation at 3,000 g for 1 minute. The cleaning buffer was supplemented to the 
supernatant and centrifuged. Ultimately, the plasmid DNA was eluded out with 50 μl Elute 
solution utilizing the column supplied with the kit.  
 
2.6 Preparation of S. pombe chromosomal DNA   
5 ml cultures were grown to saturation in YEL+ adenine (200 µg/ml) then harvested by 
centrifugation at 5000 r.p.m. for 1 minute in a bench top Microfuge. Cell pellets were then 
transferred to screw-cap microcentrifuge tubes and washed with 1 ml of ddH2O, re-
centrifuged, and aspirated to an approximately 0.5 ml of ddH2O. To each  sample 0.2 ml of 
lysis buffere (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris-HCl [pH 8.0], 1 mM 
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EDTA) was added and followed 0.2 ml of phenol:chloroform:isoamyl alcohol (25 : 24 : 1) 
and 0.3 g of acid-washed glass beads. Tubes were then vortex for 3 - 4 minutes and then spun 
in a bench top Microfuge for 5 minutes at 15,000 r.p.m.. The aqueous layer was then 
transferred to fresh 1.5 ml microfuge tubes and 1 ml of 100% ethanol was added. Tubes were 
then mixed by inversion, and spun for 2 mins at 15,000 r.p.m.. Pellets were then aspirated and 
resuspended in 0.05 ml of TE (pH 7.6-8.0) and stored at 4°C until use. 
 
2.7 S. pombe transformation via electroporation   
200 ml cell cultures of S. pombe cells were grown to a density of 1 x 10
7
 ml
-1
 (OD595 = 0.5) in 
supplemented nitrogen base (NB) medium. 50 ml samples where then chilled on ice for 20 
mins before being harvested by centrifugation at 3000 r.p.m.. for 5 mins at room temperature. 
Each sample was then washed three times in ice-cold 1 M sorbitol before being resuspended 
in ice-cold 1 M sorbitol to a density of 1 x 10
9
 cells/ml. Samples were then mixed in pre-
chilled Eppendorf tubes containing 1 µg DNA in 3 µl of TE buffer (pH 7.6) then immediately 
electroporated in pre-chilled Equibio ECU-102
®
 cuvettes using settings of 2.25 kV, 201 
Ohm, 25 µF. Immediately after pulsing 1 ml of ice-cold 1 M sorbitol was added to the 
cuvette, and the sample transferred to a pre-chilled Eppendorf tube. Samples where then 
washed and resuspended in 1 ml of ice-cold 1M sorbitol and 50 µl aliquots were spread onto 
EMM2 plates with or without required supplements and incubated for 6 days at 30°C. 
 
2.8 Media, chemical, reagents 
Reagents for yeast and bacterial media and supplements were obtained from Difco (Becton 
Dickinson) and Sigma. All other shared laboratory reagents were acquired from Sigma or 
BDH unless determined otherwise stated. Enzymes and buffers were from New England 
Biolabs (NEB), unless otherwise stated. When minimal media was used appropriate amino 
acid supplements were added to a final concentration of 200 mg/l. For liquid media the agar 
was omitted. 
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SPA /500 ml 
Glucose 5 g 
KH2PO4 0.5 g 
Agar 15 g 
Vitamins (x1000) 0.5 ml 
 
 
 
NITROGEN BASE NB /1 litre   
NB 1.7 g 
(NH4)2SO4 5 g 
Glucose 5 g 
Agar 10 g 
 
YE /1 litre 
Yeast extract 5 g 
Glucose 30 g 
Agar 14 g 
 
EMM2 /1 litre 
potassium 
hydrogen phtalate 
3 g 
Na2HPO4 2.2 g 
NH4Cl 5 g 
Glucose 20 g 
Vitamins ( x1000) 1 ml 
Minerals (x10,000) 0.1 ml 
Salts (x50) 20 ml 
Agar 14 g 
 
 
 
 
1 ml 1000 x Vitamins in every 500 ml, Added after 
autoclaving media 
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SALTS x50 /500ml 
MgCl2.6H2O 26.25 g 
CaCl2.2H2O 0.3675 g 
KCl 25 g 
Na2SO4 1 g 
 
MINERALS x10,000 /500ml 
Boric acid 2.5 g 
MnSO4 2 g 
ZnSO4.7H2O 2 g 
FeCl2.6H2O 1 g 
KI 0.5 g 
Molybdic acid 0.2 g 
CuSO4 0.2 g 
Citric acid 5 g 
 
VITAMINS x1000 /1 litre   
NB 1.7 g 
(NH4)2SO4 5 g 
Glucose 5 g 
Agar 10 g 
 
 
 
 
 
 
 
 
After autoclaving add a few drops of  
1:1:2chlorobenzene/dichlorethane/chlorobutane 
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Table 2.1 The S. pombe strains used in this project 
Strain  
Number 
Genotype Source 
BP1 
 
h- 972 (Wild type) McFarlane 
collection 
BP8 
 
h+ 972 (Wild type) 
 
McFarlane 
collection 
 
BP88 
 
h- leu1-32 ura-D18 
McFarlane 
collection 
 
BP89 
 
h+ leu1-32 ura4-D18 
McFarlane 
collection 
 
BP90 
 
h- ade6-M26 ura4-D18 leu1-32 
McFarlane 
Collection 
 
BP1004 
 
ade6-210 ura4-D18 swi1∆::ura4+  
 
This study 
 
BP1518 
 
h- ade6-M26 ura4-D18 pade-6(469) 
 
This study 
 
BP1519 
 
h- ade6-M375 ura4- D18 pade-6(469) 
 
This study 
 
BP1757 
 
h- ura4-D18 leu1-32 swi1∆::ura4+ 
 
This study 
 
BP1758 
 
h+ ura-D18 leu1-32 swi1∆::ura4+ 
 
This study 
 
BP1836 
 
h+ swi1∆::ura4+ ade6-M26 leu1-32 ura4-D18 
 
This study 
 
BP1837 
 
h- swi1∆::ura4+ ade6-M26 leu1-3 ura4-D18 
 
This study 
BP1905 h- swi1∆ :: ura4+ ade6-M26 leu1-32 ura4 -D18 This study 
BP1906 h- ade6-M26 ura4-D18 leu1-32 (pSRS5) This study 
BP1956 h- ade6-M375 ura4-D18 leu1-32 swi1∆::ura4+ (pSRS5) This study 
BP58 h- ade6-M26 pat1-114 This study 
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2.9 Meiotic induction of  pat1-114 
Strain was streaked onto fresh YEA plate and incubated at 25C for 4-5 days. Single colonies 
were taken to inoculate 5 ml YEL, incubated shaking AT 25C to a concentration of 5-6 ×106 
cells/ml. The cultured was washed extensively in equal volume of MM-N (1% glucose; 40 
mg/l leucine), and then resuspended in MM-N (1% glucose; 40 mg/l leucine) to a density of 
4×10
6
 cells/ml. The cell density is expected to be approximately 8×10
6 
cells/ml after 6 hrs 
and 30 mins, with most cells expected to have arrested at G1. Equal volume of fresh MM-N 
(1% glucose; 40 mg/l leucine) pre-warmed to 34C, and culture was transferred to shake at 
34C to induce meiosis. This was recorded as time-point 0 hrs. 
2.10 Interpretation of 2D gel images 
The results from the prepared 2D gel image are read. The interpretation of the image is as 
illustrated in Figure 2.2. 
         
Figure 2.1 Interpretation of two dimensional agarose gel electrophoresis (2D gel) 
analysis. First dimension separation (arrow from left to right) of the replication intermediates 
is by size and second dimension separation (arrow from top to bottom on the left side of the 
image) by shape.  The pre-digested DNA with restriction endonuleases incisions the 
replication bubble, causing replication intermediates (RIs) of various forms. These look as 
simple ‗Y‘ (A), bubble (B), Double ‗Y‘ (C), bubble or ‗Y‘ (D) and ‗Y‘ to double ‗Y‘. 
 A spot would be caused on the Y arc when a similar size replication intermediate assembles 
at particular part of the replication fork; this shows a replication fork is being blocked from 
progression. 
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2.10.1 Two- dimensional gel electrophoretic analysis of DNA replication intermediates  
S. pombe cells were grown to a cell count of 1 x 10
7
 cells / ml in 400 ml of yeast extract liquid, then 
decanted into pre-chilled centrifuge tubes. Sodium azide was added to a final concentration of 0.1% to 
stop metabolic growth. Ice flakes were added and the culture was chilled on ice. The cells were 
harvested at 3,000 g for 10 minutes at 4ºC. The supernatant was removed and the cells were washed 
once with ice cold dH2O and finally harvested at 3,000 g for 10 minutes.  The cell pellet was 
resuspended in 2 ml NIB buffer [nuclear isolation buffer; 50 mM MOPS (pH 7.2), 150 mM KAc, 2 
mM MgCl2] and transferred to a cold Falcon tube containing 2-3 ml of acid washed glass beads. Cells 
were then vortexed for 30 seconds followed by incubation on ice for 30 seconds; this was repeated 15 
times. The lysate was removed and transferred to ice cold Oakridge tubes. The beads were washed 
with three volumes of ice cold NIB buffer and the wash was pooled with the lysate. The lysate was 
centrifuged at 13,000 r.p.m. for 30 minutes at 4ºC. The supernatant was removed and the pellet was 
resuspended in 4 ml TEN buffer (5 mM TRIS, 50 mM EDTA, 100 mM NaCL: pH 8.0) containing 
1.5% sodium sarksyl and 0.5 mg/ml proteinase K. Samples were then gently mixed and incubated at 
42ºC for a minimum of 2 hours. Following incubation the samples were centrifuged at 5,000 r.p.m. 
for 5 minutes at 4ºC and the supernatant was transferred to a 15 ml Falcon tube containing 4.2 g 
cesium chloride. Samples were then loaded into Quick-Seal centrifuge tubes (Beckman) and Hoescht 
dye (5 μl of a 5 mg/ml stock) was added. The sample was then centrifuged at 50,000 g for 18 hours at 
20ºC. DNA was visualized with a long wave ultra violet light trans illuminator and the middle band 
was collected using a syringe and washed five times with equal volumes 5:1 isopropanol:dH2O. DNA 
was precipitated using two volumes of ice cold 70% ethanol, spooled out and washed three times with 
3 ml 70% ice cold ethanol. The DNA was air dried and resuspended in 400 μl TE buffer (pH 8.0) at 
4ºC. DNA was digested over night with appropriate restriction enzymes followed by purification with 
phenol/chloroform and ethanol precipitation. The DNA was finally resuspended in 200 μl NET buffer 
(10 mM TRIS, 1 mM EDTA, 1 M NaCl, pH 8.0). To isolate replicative intermediates the DNA was 
enriched for structures containing single-stranded DNA using BND cellulose. 2 ml BND cellulose 
solution was added to a 3 ml syringe plugged with glass wool. The liquid was allowed to drip through 
and the column was washed with 2 ml NET buffer. The DNA solution was loaded and fractions were 
collected and the column was washed twice with 1 ml NET buffer. The DNA was eluted with two 750 
μl volumes of 1.8% caffeine in NET buffer, collected and centrifuged at 10,000 r.p.m. for 10 minutes 
to remove residual BND.  The supernatant was transferred to a fresh tube and precipitated with 
ethanol and finally resuspended in 15 μl TBE. Samples were run in the first dimension in a TBE gel 
of 0.5% agarose for 16 hours at 20 V. Slices of this gel containing the DNA were then run in the 
second dimension in a TBE gel of 1.2% agarose containing 0.5 μg/ml ethidium bromide at 200 V. 
DNA was blotted onto a Gene Screen™ membrane (NEN Life Science Products) as described in the 
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manufacturer’s guide. Membranes were probed with an appropriate probe labeled with P32-γATP 
using the Mega Prime Labeling System™ (Amersham Biosciences). 
2.11 Origin of cell lines 
Table 2.2 Origin of cell lines 
Name of cell line Type of cell line Source 
NTERA2 (NT2) Testicular germ cell tumor  
cancer 
P. W. Andrew (University 
of Sheffield) 
HCT116 Colon Cancer cells European Collection of Cell 
Cultures (ECACC) 
E14 Mouse Embryonic stem 
cells 
European Collection of Cell 
Cultures (ECACC) 
 
2.11.1 NTERA2 cell culture 
The NTERA2 cells were a kind gift from Dr. Peter W. Andrews (University of Sheffield, 
UK.). They were seeded (5 × 10
6
  cm
2
 flask) in high glucose Dulbecco‘s modified Eagle‘s 
medium 1X (DMEM + GlutaMAX™-I) (Invitrogen, GIBCO 61965) supplemented with 10% 
foetal bovine serum (FBS) (Invitrogen, GIBCO 10270-098) and maintained in a humidified 
atmosphere of 10% CO2/ 90% air at 37°C.  Cells were passaged on reaching confluency by 
means of mechanical separation every three days by splitting a confluent flask of cells at 
ratios 1:2, 1:3, 1:4. 
 
2.11.2 HCT116  
Cells were cultured in 1× McCoy‘s 5A medium + GlutaMAXTMI, (Invitrogen, GIBCO 
36600) supplemented with 10% FBS. 
 
2.12 Freezing cells 
Cells were cultured in T75 flasks, washed with PBS and trypsinized media was added after 
the cells started to detach, and after a centrifugation of 5 minutes at 2,000 r.p.m.. Cells   from 
each flask were resuspended in 1ml freezing media (1% DMSO, 90% FBS). Tubes were then 
moved to a ice box including isopropanol and incubated at -80°C for overnight. Next day the 
frozen vials of cells were transferred to a liquid nitrogen container for longer term storage.  
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2.13 Thawing cells 
The cell suspension was rapidly thawed in a water bath at 37°C then the cell suspension was 
diluted in 5 ml of growth media and centrifuge at 2,000 r.p.m., for 5 minutes. The cells were 
re-suspended in 14 ml growth media and transfer into T75 flasks. The cells were then 
incubated in 37°C incubator at 10% CO2. 
 
2.14 Cell counting by Haemocytometer 
Cells were cultured as desired, media aspirated, washed with PBS and trypsinized. The 
trypsin (Sigma, T3924) was deactivated by adding media to it. 10 μl of a trypain/ media 
mixture) was added to the two chambers of the coverslips on a Hemocytometer. Under a 
microscope, the number of cells was counted on both the grids of the Haemocytometer. For 
each grid, cells were counted on 25 squares. The mean number of cells per grid was taken for 
both the grids (two chambers), divided by 2 (since we counted 25 squares). The total number 
of the cells was multiplied by 10
4
 to get the number of cells per ml. The number of cells per 
flask can now be calculated dependent on the volume of media in the flask. 
 
2.15 Western blot 
Cells were grown as required, washed twice with 1X PBS and trypsinize to detach the cells 
from the flask surface by adding 0.5 ml in 6-well plate or 1 ml in T75 flask  to detach the 
cells from the flask surface/ 6 well plate surfaces. Cells were washed once with medium 
containing serum (to inactivate the trypsin), followed by two washes with ice cold 1x PBS. 
Cells were counted during one of these steps by using haemocytometer. cells were then 
centrifuged at 2,000g for 5 minutes and resuspended in lysis buffer 50 mM Tris-HCl 
pH7.4, 200mM sodium chloride, 0.5% Triton X-100, 1mM AEBSF (4-(2- aminoethyl)-
benzenesulfonyl fluoride) and one complete, mini, EDTA-free protease inhibitor cocktail 
tablet (Roche- cat#11836170001) per 10 ml of lysis buffer, each tablet contains 0.02 mg/ml 
Pancreas-extract, 0.0005 mg/ml Thermolysin, 0.002 mg/ml Chymotrypsin, 0.02 mg/ml 
Trypsin, 0.33  mg/ml Papain. An equal volume of 2X (loading) Laemmli buffer (20% (v/v) 
glycerol, 0.2% (w/v) bromophenol blue, 4% (w/v) SDS (sodium dodecyl sulphate), 200 mM 
DTT (Dithiothreitol), 100 mM Tris-HCl (pH6.8) was added and the lysates were boiled for 
5-10 minutes until the cells were disrupted. The lysates were then loaded on 1 mm thick 4-
12% TRis glycine precast gels (Invitrogencat# EC60352BOX) or 0.75 mm thick 7.5% SDS-
PAGE (sodium dodecyl sulphate –polyacrylamide gel electrophoresis). Precision Plus Protein 
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Dual colour standards (BioRad- cat#161-0374) were also run as markers to detect the protein 
sizes. Gels were run at 125 volts for 2-3 hours. Proteins were transferred to methanol wet 
Immobilon-P PVDF membrane (Millipore- cat#IPVH00010) at 500 mA for 15-18 hours in 2x 
Towbin buffer (380 mM Glycine, 50m M Tris). After transfer, the membrane was blocked in 
10% milk in PBS overnight at 4°C or 1 hour at room temperature. Immunodetection was 
performed in 10% non-fat dry milk + 0.1% Tween 20 (Sigma- cat#D-1379) for monoclonal 
primary antibodies and 0.5% Tween 20 for polyclonal primary antibodies. Primary antibody 
solutions were incubated  at room temperature for one hour or 4°C overnight, after which a 
15-minute cleaning is done in 10% non-fat dry milk + 0.1% Tween 20  at room temperature. 
A secondary antibody was incubated again at room temperature for one hour or 4°C 
overnight. The details of antibody can be seen in tables 2.3 and 2.4. Following incubation 
with secondary antibody membranes were washed for 10 minutes in 10% non-fat dry milk, 
followed by two washes for 10 minute in PBS/0.1% Tween 20 (for monoclonal primaries) or 
PBS/0.5% Tween 20 (for polyclonal primaries). Bands were visualised on Kodak X-OMAT 
AR film with Super signal west pico chemiluminesent ECL substrate (Pierce- cat#34080). 
 
Table 2.3 Primary Antibody.  
Antibody Clone no. 
/ 
Cat no. 
Lot no. Source Host Clonality Sto-ck 
conc. 
IF Western 
Anti-Ki-
67 
PP-67 - Abcam Rabbit polyclonal 2 µl/ml   
Anti-
Lamin 
A+C 
636/ sc- 
7292 
H2007 Santa-
Cruz 
mouse monoclonal 200 μg/ 
ml 
- 1/750 
Anti-Oct4 Ab19857 - abcam rabbit polyclonal 0.1 
mg/ml 
1 µg/ml 1 µg/ml 
 
Anti-
SSEA-1 
MAB4301 - Millipore mouse monoclonal 100 
µg/ml 
1µg/ml 
 
- 
Anti-
Tubulin 
T6074 - Sigma mouse monoclonal 2 mg/ml - 1: 5000 
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Table 2.4 Secondary Antibody. 
Antibody Conjugate Stock 
conc. 
Require of 
con. 
Source 
Goat anti-mouse AlexaFlour 488 2 mg/ml IF (ML) 1/400 Molecular Probes 
Goat anti-mouse AlexaFlour 568 2 mg/ml IF (ML) 1/400 Molecular Probes 
Goat anti-rabbit AlexaFlour 488 2 mg/ml IF (ML) 1/200 Molecular Probes 
Goat anti-rabbit AlexaFlour 568 2 mg/ml IF (ML) 1/200 Molecular Probes 
Donkey 
antirabbit 
HRP 0.8 mg/ml W 1/25000 Jackson Immunoresearch 
Donkey 
antimouse 
HRP 
 
0.8 mg/ml W 1/25000 Jackson Immunoresearch 
 
 
2.16 Immunostaning 
Cells were seeded in 24- well plates. Sterile coverslips were plated under the cells prior to 
cell loading, and the cells were incubated according to the condition of an experiment. Cells 
were then washed twice in 1X PBS (phosphate-buffered saline) then fixed by adding 4% 
paraformaldehyde and incubated for between 15-20 minutes at room temperature. The cells 
were then washed gently twice with 1X PBS then blocking by adding 1X PBS + 5% FBS for 
one hour at room temperature or leave them overnight at 4°C. Then the cells were incubated 
with primary antibodies (see Table 2.3) diluted in 5%FBS for 30 minutes at 37°C or 
overnight at 4°C. The cells were then washed three times with PBS for 10 minutes or five 
times for 5 minutes. The secondary antibody immunostaning suspention was incubated at 
37°C for 30 minutes or overnight at 4°C and then washed three times in 1X PBS for 10 
minutes or five times for five minutes . Cells were then washed with 1X PBS and on the 
second washing the propidium iodide staning (1 µg/ml) was added to PBS after secondary 
antibody incubation. The cells were then imaged by using a Zesis LSM 510 confocal 
microscope.  
 
2.17 Chemically induced differentiation 
Cells were differentiated by two inducer agents, hexamethylene bisaetamide (HMBA) and 
retinoic acid (RA). Cells were treated with four poisons camptothecin (CPT), aphidicolin 
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(APH), hydroxyurea (HU), phleomycin (PHL) see table and four types of poisons were 
added to all the cells (NTERA2, HCT116, E14) as follows: 
 
Table 2.5 Poisons and inducers. 
Type of agent Origin Cat. No Concentration 
hexamethylene bisaetamide 
(HMBA) 
Sigma  3 mM 
Retinoic acid (RA) Sigma R2625 10
-2
M (3 mg/ml) 
camptothecin (CPT) Sigma C9911 1 µM, 2 µM, 0.5 µM, 
0.05 µM, 0.1 µM, 0.25 
µM and 0.025 µM 
aphidicolin (APH) Sigma A0781 1 µM and 2 µM 
hydroxyurea (HU) Sigma H8627 1 µM 
phleomycin (PHL) Sigma P9564 100 mg/ml and          
200 mg/ml 
 
 
2.18 Mouse Embryonic stem cell method 
 
Table 2.6 Mouse Embryonic stems cell method 
Item Volume Company + Cat.No 
DMEM Glutamax, 4.5 g/l 
glucose 
410 ml (Store in Fridge) GIBCO (32430-027) 
15 % Serum (EmbryoMax 
FETAL CALF SERUM) 
75 ml (Store in Freezer – 20) MILLIPORE (ES-009-B) 
Amino acids non-essential 
1X 
5 ml (Fridge) GIBCO (11140-035) 
Pen/strep. 5 ml (Freezer – 20) GIBCO (15140-122) 
Sodium Pyrovate (NaPyr) 5 ml (Fridge) GIBCO (11360-039) 
Β- mercapto ethanol 1 ml (Fridge) GIBCO (31350-010) 
(ESGRO) LIF (10
7
)(1000 
u/ml) 
50 µl (Freezer -20) MILLIPORE (ESG1107) 
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Can store in 50 µl aliquots 
ready for use in 500 ml) 
UltraPure water with 0.1% 
Gelatin  
 Millipore (ES-006-B) 
Trypsin: EDTA (0.05% 
trypsin 0.53 mM EDTA in 
Hanks salt 
 Millipore (SM-2002-C) 
2x Freezing media w/DMSO 
for ES cells 
 Millipore (ES-002-F) 
 
2.18.1 Plating Mouse Embryonic Fibroblasts (MEFs)  
 The optimal MEF density per dish was determined by Millipore protocol. MEFs were 
thawed and plated at density of 1 x 10
6
 cells per dish. Mouse ES (mES) cells were passaged 
onto MEFs and maintained for 2 days.  
 
2.18.2 Plating MEFs 
A 10 cm tissue culture plate was coated with 0.1% gelatin and incubated for a minimum of 30 
minutes in the tissue culture hood at room temprature. One vial of MEFs was thawed by 
swirling in a 37°C water bath and 10 ml of warmed DMEM medium was mixed in gently. 
The cells were centrifuged at 1,500 r.p.m. for 3.5 minutes. Medium was aspirated and the 
pellet was resuspended in 2 ml of DMEM medium. Gelatin were aspirated and replaced with 
9 ml/dish of DMEM medium. 1 ml of resuspended MEFs was transferred to each plate and 
incubated for 24 hours at 37°C at 5% CO2.  
 
2.18.3 Thawing Mouse ES cells  
MEFs were plated on to a gelatin-coated plate at least one day prior to mES flating to permit 
adherence and flattening. Cells were taken from liquid nitrogen/dry ice and thawed quickly in 
a 37°C water bath. Cell suspensions were moved to sterile 15 ml tubes comprising 8 ml 
warmed growth medium, and cells were mixed. Conical tubes containing cells were 
centrifuged at 1,500 r.p.m. for 5 minutes at room temperature. The freezing medium was 
aspirated and cells were resuspended in 2 ml of the warmed ES growth medium. Cells were 
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plated in 10 cm dish (10
6
 cells per dish) containing MEF feeder cells. Cells were maintained 
by daily medium exchange. Cells were a passage at 75% - 90% confluence. 
 
2.18.4 Passaging of MouseES cells  
 Cells were passaged every 2-3 days depend upon the growth rate of the cells. The optimal 
condition was to maintain cells at roughly 80% confluent on day 2 to prevent spontaneous 
differentiation.  Fractions range was spilt in a range from 1:4 to 1:10. The optimal cell 
numbers for seeding in dishs were 10
5
 –106 cells per 10 cm dish. Used medium was taken off 
from cultures and culture tissue washed with PBS. 1 ml/dish of trypsin was added and set in 
an incubator for 5 minutes or up to the time where the cells start to visibly dissociate from the 
plate. Trypsin solution was used 2-3 times to separate cells from the plate. DMEM media was 
added to the plate; the volume of the media added was depended on the splitting ratio. A 
Suitable amount of cell suspension was transferred to new gelatine-coated plates. Plates were 
rocked slowly to achieve a uniform cell distribution.  
 
2.18.5 Cyropreservation of murine ES cells  
Medium was removed from cell cultures and cells were washed with PBS. 1 ml/dish was 
supplemented by trypsin and put in an incubator for 5 minutes or up to the time of cells start  
to separate from the plate. Trypsin solution was used for 2-3 times to separate cells from a 
plate. The detached cell aggregate was moved to a 15 ml conical tube including 5 ml mES 
growth medium. The dish was washed with an additional 1 ml of a growth medium to collect 
any remaining aggregates. The conical tube containing cells was centrifuged at 1,500 r.p.m.. 
for 5 minutes at room temperature. Supernatant was taken off and cells were resuspended in 
0.5 ml media then transferred to a cryovial containing 0.5 ml of freezing medium. The 
cryovial was placed in an isopropanol freezing vessel and stored at -80°C overnight. The vial 
was moved to liquid nitrogen vapour for storage. 
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Chapter 3 Analysis of a developmentally programmed recombination hotspot during 
mitotic proliferation 
 
3.1 Introduction 
In most organisms stem cells and the germ line are formed early during embryogenesis 
following the formation of the zygote by the fusion of two gamete cells. Gametes are 
generated during the sexual cycle when a specialist cell division, meiosis, reductionally 
segregates the chromosomes of a diploid cell into haploid gametes. In most organisms the 
homologous chromosomes of a diploid progenitor germ cell undergo programmed 
rearrangements during meiosis resulting in gametes with an unique genetic configuration. 
This process is mediated by meiotic recombination between homologous chromosomes and 
recombination intermediates serve to physically conjoin homologues during the first meiotic 
division to ensure homologues align and segregate correctly in a reductional configuration 
(Figure 3.1) (Phadnis, Hyppa & Smith 2011).  
 
During mitotic cell division recombination is used as a mechanism for repairing random 
DNA strand breakages and these pathways have an intimate association with the DNA 
replication machinery, enabling them to respond to damage incurred during S-phase 
(McFarlane, Al-Zeer & Dalgaard 2011). However, during meiosis DNA double-strand breaks 
(DSBs) are specifically generated to initiate recombination and complex chromatin associated 
mechanisms direct the repair partner choice to ensure an increased bias towards inter-
homologue events, which in mitotically dividing cells could be highly detrimental due to the 
potential to drive loss of heterozygocity events. Inter-homologue events in meiosis form 
physical recombination intermediates, either single (Cromie et al. 2006) or double Holliday 
junctions (Schwacha, Kleckner 1995) which ultimately result in chiasmata, the inter-
homologue connections required to enable homologues to resist the pulling forces of the 
meiosis I spindle apparatus.  
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Figure 3.1 Schematic representation of the basic overview of the meiotic cell division. A 
diploid progenitor cell (top) under goes meiotic DNA replication to generate four chromatids 
(two pairs of homologous chromosomes). Homologues align and become conjoined via 
genetic recombination intermediates to form a bivalent which is required for alignment of the 
chromosomes on the metaphase I plate. Recombination which results in chiasmata (the sites 
of conjoining) occur at specific chromosomal loci termed hotspots. Resolution of chiasmata 
results in separation of homologues at meiosis I and the crossing over of chromosomal arms 
between participating chromatids; this results in the formation of four genetically distinct 
chromatids. Meiosis II then ensues where centromerically conjoined recombined sister 
chromatids separate generating four genetically distinct haploid gametes (sex cells).   
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DSBs are formed by a meiosis-specific topoisomerase II–like protein, Spo11 (Rec12 in S. 
pombe), and they can be processed down distinct pathways, only some of which culminate in 
chiasmata, which are associated with the formation of cross over events between participating 
chromatids; others will be dissolved/resolved without the formation of an associated 
crossover event (Whitby 2005). DSBs and recombination do not occur with a random 
distribution throughout genomes during meiosis; rather, there are genomic sites known as 
hotspots which are the preferential targets for DSB formation and there are genomic regions 
which are refractory to Spo11, which are termed cold spots, for example centromeric 
heterochromatin (Petes 2001, Wahls, Davidson 2010). What features of the genome 
constitute a hotspot has been the subject of much research and debate, although an 
overarching feature of hotspots is that they are regions in which the chromatin takes on a 
more open configuration during meiosis, the so called meiotic hotspot chromatin transition 
(Petes 2001). Hotspots tend to be in non-coding regions of the genome and some hotspots in 
both humans and yeast have been found to have a sequence specificity to them which 
indicates that they bind specific trans acting factors to mediate hotspot activation. Recent 
work in humans has shown a 17 base pair motif, which is the binding site for the zinc finger 
histone methyl transferase PRDM9 serves as a human meiotic recombination hotspot (Berg et 
al. 2010, Hinch et al. 2011). Intriguingly, the binding sites for PRDM9 have been associated 
with human genetic disease breakpoints and this suggests that the unscheduled activation of 
these sites in somatic, mitotically dividing cells might result in disease-inducing genetic 
rearrangements (De Raedt et al. 2006, Myers et al. 2008).  
The study of sequence-specific meiotic recombination hotspots has largely been previously 
confined to the study of the S. pombe M26 and M26-like family of hotspots (Pryce & 
McFarlane, 2009), as prior to the discovery of the PRDM9 motif, this was the only 
characterised family of sequence-specific meiotic recombination hotspots, although these are 
not the only hotspot-determining elements within the S. pombe genome (Pryce & McFarlane, 
2009; Steiner et al., 2011). M26 is a heptameric DNA sequence (5'-ATGACGT-3') which 
binds to the heterodimeric stress response transcription factor Atf1-Pcr1 (Mayr & Montminy, 
2001). Other Atf1-Pcr1 binding sites, the so called cAMP response elements (CREs) also 
serve as meiotic recombination binding sites indicating that the binding of Atf1-Pcr1 is 
critical for hotspot activation. Indeed, this is the case and both Atf1-Pcr1 have been shown to 
be required for M26/CRE hotspot activity (Wahls & Smith, 1994; Kon et al., 1997). The 
binding of Atf1-Pcr1 to CREs is dependent upon the activation of these factors via a mitogen-
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activated protein kinase (MAPK) pathway which is required both for Atf1-Pcr1 
transcriptional activation in response to osmotic stress and meiotic hotspot activation (Kon et 
al., 1998; Gao et al., 2008). This activation is then linked to an array of poorly defined 
functions which mediate the chromatin transition at M26/CRE sites during meiotic entry 
although the mechanism by which Rec12 (Spo11) is then recruited to these sites remains 
unknown (Pryce & McFarlane, 2009).  
DNA binding proteins, including RNA polymerase II are known to have the potential to 
generate barriers to the progression of the DNA replication fork (for example, see Prado & 
Aguilera, 2005). These DNA replication fork barriers (RFBs) can have recombinogenic 
potential, but not all barriers serve as mitotic recombination hotspots under normal 
conditions. A recent study from the McFarlane group demonstrated that a RFB generated by 
tRNA genes bound to RNA polymerase III did not serve as a recombination hotspots (Pryce et 
al., 2009). However, when they mutated a component of the replisome progression complex 
(RPC), the Timeless orthologue Swi1, they found that the tRNA gene-mediated RFB became 
a mitotic recombination hotspot (Pryce et al., 2009), a finding later corroborated for tRNA 
genes throughout the genome (Rozenzhak et al., 2010). The function of Swi1 (Timeless) and 
the RPC is proposed to be to monitor replicative barriers and ensure that they do not result in 
a DNA replication fork collapse which might generate recombinogenic lesions (McFarlane et 
al., 2010).  
Previous work has demonstrated that the recombination hotspot activity of CRE sites is 
restricted to meiosis (Pryce & McFarlane, 2009). However, analysis of meiotic recombination 
potential has not been carried out under conditions which would trigger the MAPK pathways 
which activates Atf1-Pcr1 meiotic hotspot activation. Moreover, it is not known whether the 
binding of Atf1-Pcr1 to CRE sites within the genome under stress conditions generate a de 
novo barrier to the progression of the replisome which must be accommodated via the action 
of the RPC. It has been demonstrated that stresses which trigger failings in DNA replication 
are a major oncogenic factor (for example, see Bartkova et al., 2006) and this, in combination 
with the observation that a human meiotic recombination hotspot motif is associated with 
disease-related genomic rearrangements (Raedt et al., 2006; Myers et al., 2008; Berg et al., 
2009), led us to hypothesis that under stressed conditions meiotic recombination hotspots 
form barriers to DNA replication progression which require the RPC to prevent them from 
driving unscheduled and potentially genome damaging, recombinogenic lesions. Here we test 
the specific hypothesis that the M26-containing meiotic recombination hotspot ade6-M26 
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takes on mitotic recombinogenic potential in response to stresses which induce Atf1-Pcr1 
binding at M26, and that Swi1 is required to suppress this recombinogenic potential.  
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3.2 Results  
 
3.2.1. ade6-M26 does not serve as an inter-molecular mitotic recombination hotspot 
under non-stressed conditions 
During meiosis the ade6-M26 allele serves as an inter-homologue recombination hotspot, 
stimulating recombination by approximately one order of magnitude relative to a non-hotspot 
(no Atf1-Pcr1 binding site) control allele, ade6-M375, which carries a single point mutation 
adjacent to the M26 Atf1-Pcr1 DNA binding sequence (Pryce & McFarlane, 2009). Mutant 
alleles of ade6 can be used to measure recombination frequency as one can measure the 
frequency of the occurrence of prototroph (Ade
+
) recombinants within a defined population 
of cells or spores (for example, see Pryce et al., 2005). The McFarlane group has recently 
developed an inter-molecular recombination assay in which the frequency of mitotic 
recombination can be measured between a chromosomally bourn allele of ade6 and a plasmid 
bourn allele ade6 (Figure 3.2; Pryce et al., 2009). We set up this system so that the 
chromosomal allele of ade6 was either ade6-M26 (meiotic recombination hotspot) or the 
ade6-M375 (non-hotspot control allele); the plasmid bourne allele was a marker mutant 
allele, ade6-∆G1483, in cases where a LEU2+ plasmid marker was required (when using 
swi1::ura4
+
 strains) and pade6-469 when a ura4
+
 marked plasmid could be used. We then 
carried out fluctuation analyses to determine the median recombination frequency for both 
hotspot (ade6-M26) and non-hotspot (ade6-M375) chromosomally encoded alleles.  
Initially, we measured mitotic plasmid-by-chromosome recombination in strains carrying 
ade6-M26 and ade6-M375 chromosomally encoded alleles with no stress added to the media 
and a RPC proficient background (swi1
+
). We observed no statistically meaningful difference 
between the hotspot (ade6-M26) and non-hotspot (ade6-M375) alleles (Figure 3.3). This 
confirms previous studies which demonstrate that ade6-M26 has no measurable mitotic 
recombination hotspot activity (Pryce & McFarlane, 2009).  
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Figure 3.2. A schematic of the mitotic inter-molecular (plasmid-by-chromosome) 
recombination system employed in this study. S. pombe has three chromosomes, indicated 
here by the vertical lines [centromere (cen) positions are indicated by black circles]. The ade6 
gene is located on chromosome III (Chr III), the smallest chromosome. The alleles used in 
distinct strains in this study (ade6*) were ade6-M26 (hotspot encoding) and ade6-M375 (non-
hotspot). The large open circle represents the plasmids which bears the partner ade6 allele for 
the inter-molecular recombination assay (this is not to scale). The two plasmids employed in 
this study were pSRS5 and pade6-469 which carried distinct ade6 alleles (ade6**), which 
were ade6-∆G1483 or ade6-469 respectively. Mitotic recombination between the 
chromosomal and plasmid bourn alleles can result in an ade6
+
 wild-type recombinant which 
generates a prototroph (Ade+) and the frequency of prototrophs within a population can be 
measured to give Ade+ cells per 10
6
 viable cells.  
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Figure 3.3. Analysis of mitotic inter-molecular recombination for the ade6-M26 meiotic 
recombination hotspot.  The plot shows the mean values for three (or more) median values 
derived from fluctuation analyses for plasmid-by-chromosome recombination frequencies for 
ade6-M26 (left) and ade6-M375 (right) alleles. The plasmid employed in these analyses was 
pade6-469. Error bars represent one standard deviation and the P value is derived by 
Student’s t-test. N ≥ 3 in all cases.  
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3.2.2. ade6-M26 is not activated for mitotic inter-molecular recombination hotspot 
activity in the presence of stress.  
Whilst the mitotic recombination activity of ade6-M26 has previously been demonstrated to 
be no different from the non-hotspot control allele, an observation confirmed using our 
system (Figure 3.3), it has not been tested under stress conditions. Atf1-Pcr1 bind to the CRE 
consensus sequence and serve as a transcriptional activator under stress conditions as they 
represent part of a stress response pathway. We postulated that under stressed conditions 
Atf1-Pcr1 bind to the M26 site in the ade6-M26 allele and trigger mitotic hotspot 
recombinogenic potential. This postulate has not been previously tested, to our knowledge. 
To test this, we employed our plasmid-by-chromosome inter-molecular recombination system 
to determine whether ade6-M26 would serve as a mitotic recombination hotspot in stress 
conditions which would mediate Atf1-Pcr1 binding to the M26 heptamer; we used both 
osmotic stress (1.2 M sorbitol) and  salt (0.2 M KCl), both of which are known to trigger an 
Atf1-Pcr1-mediated transcriptional response. Fluctuation analyses were carried out as 
described above, but cells were cultured in the presence of osmotic (Figure 3.4) or salt 
(Figure 3.5) stress. As can be seen, neither stress condition activated the ade6-M26 hotspot 
for inter-molecular mitotic recombination.  
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Figure 3.4. Analysis of mitotic inter-molecular recombination for the ade6-M26 meiotic 
recombination hot spot under osmotic stress (1.2 M sorbitol).  The plot shows the mean 
values for three (or more) median values derived from fluctuation analyses for plasmid-by-
chromosome recombination frequencies for ade6-M26 (left) and ade6-M375 (right) alleles. 
The plasmid employed in these analyses was pade6-469. Error bars represent one standard 
deviation and the P value is derived by Student’s t-test. N ≥ 3 in all cases.  
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Figure 3.5. Analysis of mitotic inter-molecular recombination for the ade6-M26 meiotic 
recombination hot spot under salt stress (0.2 M KCl).  The plot shows the mean values for 
three (or more) median values derived from fluctuation analyses for plasmid-by-chromosome 
recombination frequencies for ade6-M26 (left) and ade6-M375 (right) alleles. The plasmid 
employed in these analyses was pade6-469. Error bars represent one standard deviation and 
the P value is derived by Student’s t-test. N ≥ 3 in all cases.  
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3.2.3. Loss of Swi1 function elevates recombination under stress conditions, but does not 
induce hotspot activity for ade6-M26 
Given the finding that stress conditions in which Atf1-Pcr1 should bind to the M26 heptamer 
within the ade6-M26 allele did not induce hotspot activity for ade6-M26 we concluded that 
any Atf1-Pcr1 binding to this site could be tolerated during DNA replication and did not 
result in the formation of replication fork collapse-mediated recombinogenic lesions. This 
was not entirely surprising as the replication machinery must encounter many such 
transcription factors bound to the replication template during each S-phase and the fork 
collapse avoidance mechanisms must cope well with such events (Labib & Hodgson, 2007). 
Indeed, the McFarlane group recently demonstrated that tRNA genes, where RNA polymerase 
III is associated with the DNA duplex and can mediate a RFB, are not recombinogenic when 
the RPC is fully functional. Given this, we set out to address whether loss of RPC function, in 
this case loss of Swi1 function, would make the ade6-M26 hotspot recombinogenic in our 
plasmid-by-chromosome inter-molecular mitotic recombination assay; the idea here is that in 
the absence of a function required to avoid replication fork collapse (Swi1) Atf1-Pcr1 bound 
to the replicative template will cause a recombinogenic lesion at the site of the M26 heptamer 
(where Atf1-Pcr1 bind).  
We firstly tested this theory in the absence of any stress (Figure 3.6). We compared the 
mitotic recombination frequencies of the hotspot (ade6-M26) and non-hotspot (ade6-M375) 
alleles in strains in which the swi1 gene had been deleted (Figure 3.6A). As can be seen in 
Figure 3.6A there was no statistically meaningful difference between the hotspot and non-
hotspot allele, indicating that in the absence of stress the loss of the Swi1 RPC component 
does not render ade6-M26 recombintionally active.   
In addition we compared ade6-M26 mitotic recombination activity with and without mutation 
of swi1 (Figure 3.6B). Again, no statistically meaningful difference was observed. This was 
slightly unexpected as previous studies have shown that the loss of Swi1 activity results in an 
elevation of all basal recombination during mitosis (Sommariva et al., 2005; Pryce et al., 
2009), which does not appear to be the case in this system in the absence of stress.  
Following this we explored the possibility that ade6-M26 would only become 
recombinationally active as a meiotic hotspot when RPC function was diminished (swi1 
mutation) and Atf1-Pcr1 was induced to bind to the M26 heptamer within the ade6-M26 
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allele by stress activation; both osmotic (Figure 3.7) and salt stress (Figure 3.8) conditions 
were tested. 
A comparison of hotspot (ade6-M26) and non-hotspot (ade6-M375) alleles under osmotic 
stress (1.2 M sorbitol) conditions in a swi1∆ strain showed there was no hotspot activation of 
ade6-M26 under these conditions (Figure 3.7A), although a comparison of ade6-M26 with 
and without an active RPC (swi1
+
 vs. swi1∆) demonstrated that loss of Swi1 function did 
elevate the recombinogenic potential at ade6 in a statistically meaningful fashion, although 
the meiotic hotspot allele (ade6-M26) was not activated further than the non-hotspot (ade6-
M375) control (Figure 3.7A). Likewise, salt stress conditions resulted in no enhancement of 
recombination potential of the ade6-M26 allele over the non-hotspot ade6-M375 allele 
(Figure 3.8A), but again loss of Swi1 function did give a statistically meaningful elevation in 
recombination frequency at ade6 (Figure 3.8B), but not one which is hotspot specific.  
One minor point of some note is that using the plasmid pSRS5 gave a relatively low 
recombination activity with the ade6-M26 chromosomal allele in the RPC competent cells 
(swi1
+
) under salt and osmotic stress conditions (Figure 3.7B and 3.8B) compared to these 
same conditions used with the pade6-469. The reason for this is not clear, but we believe that 
this might simply reflect the relative stability of these two distinct plasmids under the stressed 
conditions.  
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Figure 3.6. Analysis of the inter-molecular recombinogenic potential of the ade6-M26 
meiotic recombination hot spot in cell defective for Swi1 function.  A. A comparison of 
the mitotic recombination activity of the ade6-M26 meiotic recombination hot spot in a 
swi1∆ background compared to a non-hotspot control (ade6-M375). B. Comparison of ade6-
M26 hotspot activity in both wild-type and swi1∆ cells demonstrates that mutation of swi1 
does not increase the mitotic recombination potential of the hotspot alleles. The plasmid 
employed in these analyses is pSRS5. Error bars represent one standard deviation and the P 
value is derived by Student’s t-test. N = 3 in all cases.  
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Figure 3.7. Analysis of the inter-molecular recombinogenic potential of the ade6-M26 
meiotic recombination hot spot in cell defective for Swi1 function in the presence of 
osmotic stress (1.2 M sorbitol).  A. A comparison of the mitotic recombination activity of 
the ade6-M26 meiotic recombination hot spot in a swi1∆ background compared to a non-
hotspot control (ade6-M375). B. Comparison of ade6-M26 hotspot activity in both wild-type 
and swi1∆ cells demonstrates that mutation of swi1+ does not increase the mitotic 
recombination potential of the hotspot alleles. The plasmid employed in these analyses is 
pSRS5. Error bars represent one standard deviation and the P value is derived by Student’s t-
test. N = 3 in all cases.  
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Figure 3.8. Analysis of the inter-molecular recombinogenic potential of the ade6-M26 
meiotic recombination hot spot in cell defective for Swi1 function in the presence of salt 
stress (0.2 M KCl).  A. A comparison of the mitotic recombination activity of the ade6-M26 
meiotic recombination hot spot in a swi1∆ background compared to a non-hotspot control 
(ade6-M375). B. Comparison of ade6-M26 hotspot activity in both wild-type and swi1∆ cells 
demonstrates that mutation of swi1 does not increase the mitotic recombination potential of 
the hotspot alleles. The plasmid employed in these analyses is pSRS5. Error bars represent 
one standard deviation and the P value is derived by Student’s t-test. N = 3 in all cases.  
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3.2.4. Physical analysis of DNA replication fork progression through the ade6-M26 
allele.  
The genetic analysis of inter-molecular mitotic recombination of the meiotic recombination 
hotspot ade6-M26 (see above) reveals no evidence for the activation of the hotspot under the 
conditions we tested. To investigate this further we initiated a physical analysis of DNA 
replication intermediates at the ade6 locus in strains carrying the ade6-M26 allele.  For this 
two dimensional gel electrophoresis and Southern blotting was used. Two dimensional gels 
separate DNA molecules based on both mass (first dimension) and structure (second 
dimension); this enables Y structures generated by the progression of a DNA replication fork 
through a specific region to be resolved on an agarose gel, which can then be subjected to 
Southern blotting to identify the replicative structures associated with a specific genomic 
region (Brewer & Fangman, 1988). Y structures for a given region of the genome, as defined 
by restriction digest sites, will vary in the lengths of the replicated and un-replicated section 
of the Y structure (Figure 3.9), which results in a distinctive arch structure on the two 
dimensional gel (Figure 3.9). The ade6 locus is replicated in a unidirectional fashion (Ahn et 
al., 2005) which gives a replication Y arc of a uniform intensity, indicating that there are no 
normal significant impediments to DNA replication fork progression in this region. If DNA 
replication fork barriers are present in a specific region then Y structures will accumulate as 
the fork stalls at this particular position, resulting in a region of greater intensity on a 
replicative Y arc on a two dimensional gel.   
We firstly analysed the ade6 locus in a wild-type ade6-M26 mitotically dividing haploid 
grown without stress. This gave an arc of uniform intensity indicating no measurable pausing 
of the DNA replication fork as it passed through the ade6-M26 allele (Figure 3.9). We failed 
to obtain enough DNA for analysis from mitotically dividing cells under stress (salt or 
osmotic stress) and so we extracted DNA from haploid ade6-M26 cells which had been 
induced to traverse meiosis using a temperature sensitive mutant, pat1-114, which initiates 
meiosis at the restrictive temperature and activates the M26 hotspot in the ade6-M26 allele. 
Here we could see no significant pausing on the Y arc associated with the position of the M26 
heptamer (the site of Atf1-Pcr1 binding). We did observe a small increased intensity in one 
region of the arch, but this was not reproducible (work carried out by Dr. D. Pryce) and we 
believe this to be a signal emanating from the RNA polymerase II binding site within the 
ade6 promoter with no evidence for a direct causal link to M26. Analysis of swi1 mutants 
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was initiated by others within the group independently and no ade6-M26-specific replicative 
pauses were observed (D. Pryce, personal communication). 
 
Figure 3.9. Two dimensional gel analysis of the ade6-M26 allele in mitosis and meiosis. 
A. A schematic of a simple Y arc two dimensional gel. The arc represents the mobility path 
for a continuous DNA replication fork through a specific genomic region (as determined by a 
specific Southern blot probe). The inflection point of the arc represents the point at which 
sections of daughter duplexes are of an identical length to the remaining un-replicated section 
for a particular genome restriction fragment. A pause in DNA replication fork progression 
will be apparent by a build up of Y structures at a specific point on the arc (as illustrated). 
The 1
st
 and 2
nd
 dimensions are shown; the first dimension separates restriction digested 
fragments of the genome based on mass and the second dimension separates based on non-
linear structure. Following running all restriction digested genomic DNA on the gel, the 
replication structures for specific genomic regions can be detected using Southern blotting 
with a region-specific probe (in this case an ade6-specific probe). The lower part of A shows 
the ade6-M26 allele with schematic approximations of the positions of the restriction sites 
used (RE), the probe position, the ade6 promoter, the direction of DNA replication and the 
approximate position of the M26 heptamer. B. The two dimensional gel for the ade6-M26 
region in mitotically dividing wild-type cell grown in non-stress conditions. The uniform 
intensity of the Y arc demonstrates no discernable impediment to DNA replication 
progression. C. The two dimensional gel for the ade6-M26 region going through meiotic S-
phase from a haploid induced meiosis. The white arrow indicates the position of a possible 
weak DNA replication fork barrier which is believed to correspond to the approximate 
position of the ade6 promoter and not the M26 heptamer.  
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3.3. Discussion 
Unscheduled genomic rearrangements and mutations are essential for the process of 
evolution of living systems; however, when these occur in human somatic or germ line 
tissues they can cause serious genetic disease, including cancers (for example, see Moynahan 
& Jasin, 2010). Despite the potential dangers of lesions which can initiate genomic 
rearrangements, homologue alignment and bivalent formation during meiosis I is dependent 
upon the programmed formation of one of the most genotoxic lesions, DSBs. The formation 
of DSBs is elevated at hotspot regions and they are processed to drive recombination events 
with an elevated inter-homologue bias (Schwacha & Kleckner, 1997). To reduce the potential 
for these lesions to be generated in non-meiotic cells where they could he highly deleterious, 
the molecular mechanisms controlling DSB formation and inter-homologue partner choice 
must be regulated in such a way as to ensure a very tight meiosis-only restriction. To date, 
little work has been done to determine whether deregulation of the meiotic DSB and partner 
choice programme in somatic tissue has any role to play in oncogenic progression. However, 
evidence is starting to emerge which might indicate that such deregulation may indeed have 
oncogenic potential. For example, the meiosis-specific protein NUT, which has no known 
function, has been shown to form an oncogenic fusion protein which mediates the epigenetic 
down regulation of p53 gene expression causing aggressive tumours in juveniles known as 
NUT midline carcinomas (Reynoird et al., 2010).  
At the onset of this work it was becoming apparent that there was a link between the DNA 
sequences associated with meiotic recombination hotspots in humans and cancer-associated 
genomic rearrangement sites (Raedt et al., 2006; Myers et al., 2008; Berg et al., 2009). This 
led us to speculate that a primary oncogenic driver might be the activation of a meiotic 
recombination hotspot in somatic tissues. Indeed, the recent identification of the motif 
associated with the human meiotic hotspot regulator, PRDM9, provides further support to this 
argument as this motif has also been linked to genetic disease-associated break points (Raedt 
et al., 2006; Myers et al., 2008; Berg et al., 2009). 
At first viewing this hypothesis appears flawed in that there seems to be a high number of 
meiosis-specific genes which would be required to generate DSBs in the same way that they 
are generated in meiosis. This would suggest that the deregulation of the meiotic DSB 
inducing programme would need to be on a significantly large enough scale to ensure that all 
minimal component parts for DSB formation were present in the somatic tissue undergoing 
oncogenic change. However, there is existing evidence which suggests that when one meiotic 
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gene is aberrantly expressed in somatic cells, then many others are also de-repressed, which 
might be indicative of a dysfunction in a master regulator (Fratta et al., 2011).  
Not withstanding the possibility of a fully de-regulated and activated minimal DSB-inducing 
pathway we presented another hypothesis to provide a possible explanation for the activation 
of meiotic recombination hotspots in somatic tissues which is not dependent upon there being 
a need for the full activation of a minimal DSB pathway. We postulated that the activation of 
the primary step in hotspot activation, the binding of the primary trans activator, in this case 
the Atf1-Pcr1 heterodimer binding to M26 (but it could also be PRDM9 binding to the 13 bp 
human motif) generates a novel and unscheduled block to the progression of the DNA 
replication machinery. This blockage thus increases the likelihood of the replication fork 
collapsing at this site resulting in a recombinogenic lesion which might drive a genomic 
instability event, particularly if the partner choice is aberrant. This hypothesis is also 
consistent with the finding that one of the major factors leading to instability is DNA 
replication stress. Previous work has demonstrated that pauses in DNA replication can result 
in gross chromosomal rearrangements (Ahn et al., 2005; Lambert et al., 2005) and that 
protein complexes which are associated with DNA, such as RNA polymerase II, can drive 
recombination when a collision with the replisome occurs (Prado & Aguilera, 2005). 
However, this is not true for all protein complexes associated with the replicative template 
and indeed the more normal case might be that the replication machinery can prevent 
replicative pauses from becoming recombinogenic (Pryce et al., 2009).  
To test our hypothesis we took a stepwise approach in a simple genetically tractable model 
system, S. pombe, in which a well defined sequence-specific meiotic recombination hotspot 
had been characterised. Firstly, we explored whether or not the ade6-M26 meiotic 
recombination hotspot served as a mitotic hotspot in the plasmid-by-chromosome system we 
have developed. We find that this is not the case and this is consistent with earlier work and 
demonstrates that under normal conditions in a wild-type cell that the hotspot activity of M26 
is confined to meiosis. However, this does not dismiss the possibility that M26 does cause 
recombinogenic lesions during mitosis which are processed by inter-sister chromatid 
recombination which would not give a genetic readout in the inter-molecular plasmid-by-
chromosome system we employed, although we believe that this is unlikely as we could find 
no evidence of replication pauses by two dimensional gel analysis of M26 within ade6-M26 
in the wild-type (Figure 3.9).  
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Next, we asked whether stress, in this case salt and osmotic stress could activate M26 in 
mitosis. The idea being that these stresses are known to induce Aft1-Pcr1 transcriptional 
activation and so this should elevate the levels of Atf1-Pcr1 bound to M26 in mitotic cells, 
which, in turn would generate a replication pause inducing barrier at the position of M26 
which would drive the formation of recombinogenic lesions. Again, we found no evidence 
for stress-induced elevations in recombination. We did not directly test binding of Atf1-Pcr1, 
increased replication pausing at M26 or lesion formation at M26 under stressed conditions. 
Had we done this we could have established whether or not Atf1-Pcr1 binding was indeed 
generating replicative pause sites, and if so, were they forming recombinogenic lesions. 
Rather than executing these extensive physical assays we simply set out to now ask whether 
mutation of the machinery which is responsible for suppressing recombination at DNA 
replication fork barriers could induced mitotic hotspot activity at M26 under stressed or non-
stressed conditions. It is known that loss of Swi1 activity can convert a replicative barrier, 
which is normally encountered in the genome, to become a source of recombinogenic lesions 
and signals (Sommariva et al., 2005; Pryce et al., 2009; Rozenzhak et al., 2010) and so we 
believed that this genetic test was appropriate prior to embarking on extensive physical 
analyses. We found that whilst loss of Swi1 function gave an elevation of recombination 
under stressed conditions, it did not result in an M26-specific hotspot elevation, indicating 
that loss of Swi1 function does not result in the activation of M26 under any of the conditions 
we tested. The basal elevation in recombination is to be expected due to the loss of RPC 
activity (Sommariva et al., 2005; Pryce et al., 2009; Rozenzhak et al., 2010). 
These findings can be interpreted in a number of ways. Firstly, there may be no significant 
binding of Atf1-Pcr1 in our system, even under stress conditions. We believe this to be 
unlikely as ade6-M26 has previously been demonstrated to be a target for binding (Gao et al., 
2008). Secondly, Atf1-Pcr1 binding to M26 may not cause a significant pause to DNA 
replication progression. This is partly supported by the finding that we do not observe a 
meiosis-specific measurable pause at the M26 using two dimensional gels (Figure 3.9C). 
Moreover, it may be he case that the pausing generated by Atf1-Pcr1 binding, if any, is not of 
sufficient magnitude to require the function of Swi1 and the RPC to prevent recombinogenic 
lesions forming, or these lesions, if they are formed, are always driven down the inter-sister 
chromatid route and do not result in measurable inter-molecular recombination in the 
plasmid-by-chromosome assay we have established.  
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3.4. Final comment 
These studies have not generated any evidence for the hypothesis we set out with, which 
postulates that a defined meiotic recombination hotspot can be activated in mitotically 
proliferating cells by generating a recombinogenic DNA replication fork perturbation. Whilst 
this preliminary study has its limitations (for example, limited physical analyse) we feel that 
there is not enough of a platform to justify taking the work further in this system at this stage. 
This brings back into focus the question of how meiotic hotspot sequences might be linked to 
break points in human genetic diseases and it raises the other possibility that meiotic hotspots 
do become activated by a switching on of a minimal DSB-inducing programme which is 
normally tightly restricted to meiosis. This possibility has now taken on more favour within 
the McFarlane research group. A recent finding from the group has demonstrated that many 
of the factors which are thought to be meiosis-specific, including Spo11, are indeed switched 
on in normal, non-cancerous somatic cells (R. McFarlane, personal communication of 
unpublished data). This remarkable and unexpected finding might indicate that there is not 
the need for a significant and wide-spread de-regulation of key DSB mediators as they are 
already present. Rather, there may only be the need for some specific factors to be combined 
with these factors to mediate DSB formation which has mechanistic similarities to meiotic 
DSB formation. In yeast cells Spo11 (and Rec12) are tightly regulated and are highly 
meiosis-specific; the situation in humans appears to be different and this might mean we must 
re-think some long held pre-conceptions. Interestingly, the human hotspot activator, PRDM9, 
unlike Spo11, is not present in normal somatic cells and gene expression is limited to the 
testis, but it is switched on in approximately half of the cancer tissues / cell lines studied to 
date (33 analysed to date), indicating that regulation of the production of this key regulator 
may be the trigger for activating the DSB machinery to function in a meiotic hotspot 
activating fashion. In this regard genes such as PRDM9 may be proven to be significant 
genotoxic oncogenes. 
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Chapter 4 Effect of camptothecin on the embryonal cancer line NTERA2 
 
4.1 Introduction 
The NTERA-2 cL.D1 cell line is a pluripotent human testicular embryonal carcinoma cell 
line obtained by cloning the NTERA-2 cells isolated from a nude mouse xenograft of the 
TERA-2 which was initially obtained from a metastasis of a human testicular teratocarcinoma 
(Andrews et al. 1984a, Dewji, Singer 1997). NTERA2 xenografts include various cell forms, 
especially neural precursors. NTERA2 was isolated as single-cell clone, and NTERA2 clone 
D1 (NT2/D1) became the standard line that is at present used. NTERA2 cells express features 
shared with other human EC cells such as SSEA4 and SSEA3, also TRA-1-60 and a high 
ratio of the liver isozyme of alkaline phosphatase. Not only do NTERA2 EC cells form well-
differentiated teratomas when produced as xenografts in nude mice, they also respond to 
retinoic acid and other treatments in vitro (Andrews 1984a). After exposure to 10
-5
 or 10
-6 
M 
retinoic acid, NTERA2 cells rapidly lose their EC phenotype, obtaining a considerably 
different growth pattern and cellular morphology. Cultures exposed to retinoic acid 
characteristically lack expression of EC markers like SSEA4, SSEA3, or TRA-1-60 over a 
one-two week time period. Simultaneously, different antigens, especially ganglioseries 
glycolipids, appear on the surface of the cells (Fenderson et al. 1987). Mostly, a 2- to 3-day 
exposure to retinoic acid is enough to cause nearly all the cells to differentiate, and in less 
than 2–3 weeks, EC cells cannot be identifing in the cultures.  
 
Differentiation of NTERA2 EC cells is distinguished not just by variations in surface antigen 
expression, but as well as by variations in predisposition to infection with particular viruses, 
especially human immunodeficiency virus (HIV) and human cytomegalovirus (HCMV). For 
instance, NTERA2 EC cells are immune to infection with HCMV and HIV, while the 
differentiated cells are permissive for the replication of both viruses (Gonczol, Andrews & 
Plotkin 1984a, Hirka et al. 1991a). In the situation of HCMV, resistance effects from 
inactivity of the main immediate early promoter of the virus in the EC cells (Lafemina, 
Hayward 1988a, Nelson, Groudine 1986a).  
 
Several genes have a marked regulation through NTERA2 differentiation. Oct4 for example, 
which is characteristically expressed by EC cells and ES cells, is down-regulated after 
retinoic acid induction of NTERA2 cells (Przyborski et al. 2000). Simultaneously, other 
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genes are induced. One of these is the Wnt family member, Wnt13, which is not expressed by 
NTERA2 or other human EC cells, however is induced substantially by retinoic acid 
induction (Wakeman, Walsh & Andrews 1998a). No other expression of different members 
of the Wnt family through NTERA2 differentiation while, for instance, Wnt1 has been 
notable for be induced through differentiation of the murine EC line P19 (Papkoff 1994a).  
 
NTERA2 EC can be induced to differentiate with different agents, the most notably 
hexamethylene bisacetamide (HMBA) (Andrews et al. 1990) and proteins of the BMP family 
(Andrews et al. 1994). The differentiation potential of the NTERA-2 cL.D1 cell line has been 
compared to a recognized pluripotent human ES line, BG01 (Mitalipova et al. 2003). It is 
suggest that NTERA-2 cells can be a potential alternative to human ES cell source of help in 
the domain of embryonic stem cell biology perfecting alternative human ES cells. 
 
Although, EC stem cells can supply a simple and robust experimental model, their 
differentiation potential is frequently restricted, dissimilar to ES cell differentiation, which is 
unlimited (Przyborski et al. 2004). 
 
Undifferentiated NTERA2 EC cells, like human ES cells, express the connexin 43 protein 
and, consequently, possess functional gap junctions (Bani‐Yaghoub, Bechberger & Naus 
1997, Wong et al. 2004). The NT2/D1 cell line is a human EC which does not needs any 
feeder layer to prevent its undifferentiated potential, and it may produce embryoid body-like 
forms in vitro, a characteristic also noticed in other EC tumours (Parchment, Gramzinski & 
Pierce 1990, Soprano et al. 1988, Takeuchi, Watanabe & Uno 1983). The presence of some 
differentiating agents, such as as RA, in the culture medium, seems to activate the 
neuroectodermal differentiating program (Andrews 1984b), where the NT2/D1 cells cause 
neural cells but as well as nonneural cells.  
 
4.2 Cancer therapy 
Cancer or tumor cells at various stages of the cell cycle will deal with chemotherapy or 
radiotherapy very differently (Marx 1994).  It has been proposed that there might be a small 
population of resting period cells residing in the quickly proliferating tumor populations, and 
a different subpopulation of cancer stem cells (CSCs) and SP (side population). It is proposed 
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that dormant cells were closely connected with tumor progression, disease return or drug 
resistance (Pang et al. 2010, Dalerba et al. 2007, O’Brien et al. 2006c). 
 
Removal of tumor-initiating and tumor-maintaining cell populations is thus potential cancer 
treatment. To improve such treatments, the cellular processes of resistance leading to failure 
of demonstrated therapies must be avoided or removed. 
 
Here we postulate that cancer stem cells can become more sensitised to a cancer therapeutic 
agents when they are progressing through the differentiation process. We believe that this 
will also apply to embryo stem cells and this work has implications for how we 
therapeutically eliminate cancer stem cells and for understanding how neoplastic 
transformations can be avoided in regenerative medicine approaches using stem cells. 
The aim of this chapter was to investigate the different DNA damage responses in G0 phase 
and proliferating NTERA2 cells after camptothecin (CPT) exposure in different culture 
densities and treatment in different the periods. 
 
4.3  Camptothecin and mechanism of resistance 
4.3.1 Camptothecin inhibits topisomerase I 
Topoisomerase l is an enzyme which non-covalently binds to torsionally strained, 
supercoiled, double-stranded DNA and produces a transient single-strand break in the DNA 
molecule. This enables for the passage of an entire complementary DNA strand through the 
break. This mechanism is active throughout transcription, replication, recombination and 
other DNA functions (Maxwell, Gellert 1986). The enzyme-bridged DNA breaks, and is then 
resealed by the topoisomerase I enzyme. Disconnection of the enzyme returns an entire, 
freshly relaxed DNA double helix. Camptothecin inhibits the action of topoisomerase I and 
has been employed as chemotherapeutic.  
 
4.3.2 Camptothecin and mechanism of antitumor and resistance activity 
Camptothecin binds to the cleavable complex between the free 3′-phosphate of the DNA and 
topoisomerase I. The resulting enzyme-linked DNA breaks cannot be religated during the 
poison is existing (Hertzberg et al. 1989a). S-phase-specific cytotoxicity arises when the 
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progress replication fork and bound complex collide, causing irreversible fork breakage (Fig 
4) (Pommier et al. 1996).  
 
 
 
Figure 4. Mechanism of function of the camptothecin 
 
 
However, whilst single-strand DNA breaks are downgraded quickly upon deletion of the 
topoisomerase I inhibitor, double-strand breaks persist for long times after drug elimination 
(Hertzberg et al. 1989b). Camptothecins are not typical enzyme inhibitors; they alter the 
activity of a normal endogenous protein to create a cellular toxin (Takimoto et al. 1999). 
 
Resistance to camptothecin analogs in vitro is frequently connected with either lowered levels 
of cellular topoisomerase (McLeod, Keith 1996, Saleem 1997) or with gene alterations that 
downregulate or change the topoisomerase I enzyme (Gupta et al. 1988, Gupta, Gupta & 
Goldstein 1996, Benedetti et al. 1993, Fujimori et al. 1996). Decreased uptake of 
camptothecins because of overexpression of the multidrug resistance-associated protein 
(Jonsson et al. 1997, Chen et al. 1999, Chu et al. 1999) and to a smaller degree of P-
glycoprotein (Chu et al. 1999, Hendricks et al. 1992) has also been demonstrated. 
Nevertheless, the degree of multidrug resistance to camptothecin is clearly less than that 
noticed with different multidrug resistance substrates.  
 
We hypothesized that transiently exposing NTERA2 as cancer stem cell or stem cell-like to 
CPT would have damaging effects on DNA replication causing their death while 
simultaneously having little or no effect on replication after differentiation by two inducers 
such as HMBA and retinoic acid see (chapter 5 and 6). This hypothesis arises from work 
which demonstrated camptothecin was high toxic to undifferentiated mouse ES cells, but not 
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proliferating differentiated embryonic fibroblasts (MEF) (Wakeman & McFarlane, 
unpublished data). 
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4.4 Results 
Previous work had exposed mouse ES cells to CPT and found that they were sensitive to 
chronic exposure (24 hours) at a CPT concentration of 2 M. However, mouse embryonic 
fibroblasts (MEFs) which were subjected to the same treatment did not show any loss of 
viability following treatment (Wakeman & McFarlane, unpublished data). Unfortunately, the 
MEFs and the ES cells employed in that preliminary studies were not isogenic and were 
derived from distinct laboratory mouse strains. However, this work potentially indicates that 
ES cells have distinct sensitivity to CPT in comparison to proliferating differentiated cells in 
the mouse. Here we hypothesised that this would be true for human cells with stem-like 
characteristics and employed the well characterised EC cell line NETRA2, as these cells can 
be cultured and differentiated in vitro.  
 
Prior to using NTERA2 we set out to establish the experimental conditions to be employed 
for this cell line. The first aim was to establish the appropriate cell density of the starting 
culture which would permit cell proliferation for the required experimental time period 
(which in later chapters is up to 8 days). The second aim was to determine whether NTERA2 
at the chosen cell densities could continue to proliferate and show no loss of viability in 
response to DMSO, the solute required for CPT. Thirdly, the previous work had employed 
two CPT concentrations with both an acute (3 hour) treatment and a chronic (24 hour 
treatment); establishing which conditions, if any, gave significant loss of viability for 
NTERA2 was important. 
 
4.4.1 NTERA2 can tolerate chronic and acute exposure to the solute DMSO 
Because CPT is solubilised in DMSO we grew NTERA2 cells to different cell numbers in 2 
ml of medium in six well plates. Cell numbers tested were 25,000, 50,000, 75,000 and 
100,000. Cells were treated with 1 µl or 2 µls of DMSO for 3 hours (acute) and then the 
DMSO containing medium was washed off and replaced with fresh, pre-warmed medium. 
Cultures were followed for up to 5 days, with cell number being counted after 3 hours and 
every 24 hours thereafter. In all cases cells treated with DMSO exhibited no loss of viability 
relative to the untreated control; Figure 4.1 shows the data for 50,000 cells and a similar trend 
was observed for the other cell densities tested (data not shown). A similar study was carried 
out for cultures treated for 24 hours of exposure to 1 µl or 2 µl DMSO and again, no 
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significant loss of viability was observed when comparisons were made between treated and 
untreated cultures. Figure 4.2 shows the 100,000 cells as an example; a similar pattern was 
seen with other starting cell numbers (data not shown). These data confirm that DMSO is not 
cytotoxic to NTERA2 under the treatment regime to be used for treatment with CPT.  
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Figure 4.1. Total number of NTERA2 cells following exposure to DMSO as control. 
50000 of NTERA2 cells were exposed to 1 µl and 2 µl of DMSO in 6 well plates, 2 ml/ well 
for 3h, the total number of cells remaining at each time point determined by cell counting 
using haemocytometer. Error bars represent Standard Error of Mean and the p value is 
derived by one way ANOVA in all cases. 
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Figure 4.2.  100,000 NTERA2 cells were exposed to 1 µl and 2 µl of DMSO in 6 well 
plates, 2 ml/ well for 24h, the total number of cells remaining at each time point determined 
by cell counting using haemocytometer. Error bars represent Standard Error of Mean and the 
p value is derived by one way ANOVA in all cases. 
 
 
 
 
 
 
 
 
 
 
 
NA 
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Figure 4.3 Confocal image showing presence of Oct4 in NTERA2 undifferentiation cells 
(stem cell-like) which were treated with 1 µl and 2 µl DMSO to confirm that DMSO has 
no affect for on growing cells during 3h or 24h. Dapi staining (blue) stains the nucleus of 
the cells. DIC image shows the cells without any staining and merged image shows the 
expression of oct4 (green) and down-regulated SSEA-1 (red) in the cells. Last image, 
NTERA2 cells without treatment but the (red) indicate to Pi (nucleus stain). 
  
Control (NTERA2 without treatment) 
NTERA2 cells with 1 µl DMSO (3h) 
NTERA2 cells with 2 µl DMSO (3h) 
NTERA2 cells with 1 µl DMSO (24h) 
 
NTERA2 cells with 2 µl DMSO (24h) 
            Oct4                  SSEA-1               DIC                  Merge  
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4.4.2 Treatment with DMSO does not alter the levels of the stem cell marker Oct4 
Previous studies have demonstrated that prolonged exposure of NTERA2 cells to high 
concentrations of DMSO can result in cellular differentiation (Andrews 1984a). Whilst 
DMSO treatment does not result in loss of viability or reduced cell proliferation (see above), 
it is important to confirm that the NETRA2 cells retain their stem cell-like characteristics in 
response to the relatively low levels of DMSO employed here. To test this we carried out 
confocal microscopy to determine whether or not the stem cell marker Oct4 remains present 
in the cells after DMSO treatment. Moreover, as cells differentiate away from the 
pleuripotent state they turn on expression of the SSEA-1 marker. Figure 4.3 shows cells 
immunostained with antibodies against Oct4 and SSEA-1 following acute exposure to DMSO 
(3 hours; Figure 4.3. A) and chronic exposure (24 hours; 4.3. B). in both cases Oct4 is clearly 
present in the majority of the cells within the population and SSEA-1 is almost undetectable; 
this pattern is identical to that seen for untreated NTERA2. Moreover, cell morphology does 
not alter upon treatment with NTERA2.  
 
4.4.3. Acute exposure to CPT results in a limited loss of cell viability 
Having established that DMSO did not result in cell death, growth or proliferation arrest or 
differentiation of NTERA2 the response to an acute dose (3 hours) of CPT could be tested. A 
range of cell numbers were tested (cell numbers are given as the total number of cells per 2 
ml culture medium in a six well plates; cell numbers tested were 25,000, 50,000, 75,000 and 
1000,000 cells). Following addition of the CPT and 3 hours incubation the CPT-containing 
medium was removed and replaced with fresh pre-warmed medium which did not contain 
CPT. Figure 4.4. shows the data obtained for acute treatment of 75,000 cells with both 1 µM 
and 2 µM CPT, although a similar pattern was observed for all cell numbers tested (data not 
shown). As can be seen treatment with 2 µM resulted in an approximate 10-fold loss of 
viability during the exposure period, whereas as 1 µM did not generate this same viability 
loss. Following this, both sets of treated cells show a maximal reduction in cell counts of no 
greater than approximately 100-fold and appear to maintain a constant population of cells for 
up to 4 days post treatment. These data indicate that a significant population of NTERA2 
cells survive acute exposure to CPT.  
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4.4.4. NTERA2 is exquisitely sensitive to chronic exposure to CPT 
Having determined that a significant number of cells can survive acute exposure to CPT it 
was postulated that these survivors were not inherently resistant, but had not traversed an 
appropriate cell cycle period to take on significant CPT-dependent DNA damage. To test this 
NTERA2 cells were subjected to a more chronic exposure to CPT (24 hours). Cell cultures 
with different cell numbers (25,000, 50,000, 75,000 and 100,000 cells in 2 ml culture 
medium) were treated with 1 µM or 2 µM CPT for 24 hours, following which the medium 
was washed off and replaced with fresh pre-warmed medium. Figure 4.5 shows the data for 
the culture starting with 50,000 cells, although all cultures showed a similar pattern to chronic 
CPT exposure (data not shown). As can be seen chronic treatment (24 hours) results in a total 
loss of cell numbers and only cell debris could be observed following 24 hours exposure to 
CPT, where as the DMSO control shows cell numbers increasing, indicating the cells were 
continuing to proliferate in the absence of CPT (Figure 4.5.). Total loss of cell viability is 
seen immediately following (24 hours) of exposure and there was no measurable resistant 
population. An acute exposure (3 hours) was carried out alongside the chronic exposure (24 
hours) and the data for 50,000 cells can also be seen in Figure 4.5., again showing only a 
limited loss of cell number. 
Whilst mouse ES cells had been over 100 times more sensitive to CPT than the MEFs, this 
total loss of countable cells was not observed and there was a small population of survivors 
(Wakeman & McFarlane, unpublished data). It was noted that slightly higher numbers of 
cells had been used for the mouse ES population (approximately 140,000 cells in 2 ml 
medium). To determine whether this higher cell density could result in a reduced sensitivity 
(possibly due to fewer proliferating cells, although this was not directly tested), a cell number 
of 147,000 in 2 mls was tested for NTERA2 with both acute and chronic exposure to 1 μM 
and 2 µM CPT. As can be seen in Figure 4.6. a similar pattern was observed for this high cell 
number as had been observed for the lower cell numbers. This indicates that for NTERA2 
higher cell density does not result in a CPT resistant population following chronic CPT 
treatment. 
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Figure 4.4 Total number of NTERA2 cells following exposure to camptothecin. 75000 of 
NTERA2 cells were exposed to 1 µM and 2 µM of camptothecin in 6 well plates, 2 ml/ well 
for 3h and 24h, the total number of cells remaining at each time point determined by cell 
counting using haemocytometer. Error bars represent Standard Error of Mean and the p value 
is derived by one way ANOVA in all cases. 
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Figure 4.5.  Total number of NTERA2 cells following exposure to camptothecin. 50,000 
NTERA2 cells were exposed to 1 µM and 2 µM of camptothecin in 6 well plates, 2 ml/ well 
for 3h and 24h, the total number of cells remaining at each time point determined by cell 
counting using haemocytometer. 
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Figure 4.6. Total number of NTERA2 cells following exposure to camptothecin. 150,000 
NTERA2 cells were exposed to 1 µM and 2 µM of camptothecin in 6 well plates, 2 ml/ well 
for 3h and 24h, the total number of cells remaining at each time point determined by cell 
counting using haemocytometer. 
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4.5 Discussion 
4.5.1 NTERA2 cells treated with anticancer drugs such as camptothecin 
Chemotherapy for cancer treatment is extremely toxic, relatively nonspecific, and frequently 
fails to achieve long-term patient survival. Mortality can occur due to tumour relapse as an 
effect of chemotherapy-resistant CSCs. Therefore, it is vital to develop new therapeutic 
strategies that specifically target CSCs. Selective differentiation therapy specifically affecting 
CSC differentiation and with fewer toxic side effects could be used to treat tumours. 
Camptothecin is an anti-tumour agent with robust inhibitory effects against DNA 
topoisomerase I. Topoisomerase l is an enzyme that affects the topology of DNA by 
transiently breaking and resealing the phosphodiester acid backbone, and its expression is 
altered in human cancer cells (van der Zee et al. 1994, Boonsong et al. 2002, Gouveris et al. 
2007). Therefore, we selected CPT as the anti-cancer agent and used two different 
concentrations—l µM and 2 µM—as described previously in this chapter. 
 
Many investigations have established that camptothecin induces apoptotic cell death (Nelson 
& Kastan 1994, Piret & Piette 1996, Shao et al. 1999, Alexandre et al. 2000a, Davis et al. 
1998a, Morris & Geller 1996a). However, it is still unclear whether this is the primary anti-
tumour mode of action of camptothecin. Apoptotic cell death induced by camptothecin has 
been shown to occur solely at high concentrations of camptothecin (1 μM and 2 μM) 
(Alexandre et al. 2000b, Davis et al. 1998b, Morris & Geller 1996b). At lower 
concentrations, camptothecin leads to primarily S-phase cells and does not result in cells 
exhibiting all the features of apoptotic cell death (e.g. cell shrinkage and nucleosomal DNA 
laddering) (Morris, Geller 1996b, Davis et al. 1998c, Morris & Geller 1996c). The relevance 
of apoptotic cell death at clinical doses of camptothecin is debatable. The TOP1-mediated 
double-strand breaks could be responsible for apoptotic cell death induced by high 
concentrations of camptothecin. 
 
It has previously been suggested that increased proliferative kinetics, self-renewal ability, 
high tumorigenicity and invasiveness are the common features of CSCs (Jordan, Guzman & 
Noble 2006, Shackleton 2010, Fulda & Pervaiz 2010). We demonstrated that exposure of 
undifferentiated NTERA2 cells at different densities to different concentration of 
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camptothecin led to death of all the cells when exposed for long periods (24 hours), whereas 
some of the cells were not affected when they were exposed to camptothecin for shorter 
period (three hours). Our study on a small population of NTERA2 cells showed cell survival 
and cell resistance to camptothecin, and the NTERA2 cells were undifferentiated in most 
conditions but some cells underwent differentiation; therefore, we think that those cells are 
small populations of NTERA2 cells may have been resistant to camptothecin. Figure 4.8 
shows the three different culture conditions: super-confluent, sub-confluent and confluent 
cells. A small number of differentiated cells were present in all the three culture conditions. 
Immunostaining revealed Oct4 expression in more than 95% of cells.  
 
 
                                                
Figure 4.7 shows Oct4 expression in three different cultures of NTERA2 cells. 
 
Finally, further studies are required to identify the pathways implicated in the behaviour of 
drug-resistant CSCs that survived exposure to camptothecin for three hours. A better 
understanding of the molecular pathways that control CSC differentiation and identification 
of new differentiation-inducing agents that specifically target these CSCs may offer novel 
treatment options for cancer. We will describe some of these pathways in detail in the 
subsequent three chapters in this thesis.  
      Oct4             Pi               DIC            Merge 
NTERA2 
(Superconfluent) 
 
NTERA2 
(Confluent) 
 
NTERA2 
(Subconfluent) 
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Chapter 5       The effects of differentiation on DNA damage response pathways 
Introduction 
Despite the recent advances in the diagnostic, protective and therapeutic modalities for 
cancer, it remains a serious health concern worldwide. Over the last few years, studies have 
to improved knowledge of the genetic, molecular and cellular mechanisms involved in 
carcinogenesis, resulting in the development of various intervention procedures. This chapter 
deals with one such novel intervention procedure, namely, differentiation therapy. 
 
5.1 Differentiation the NTERA2 cells by hexamethylene bisacetamide 
NTERA2 was obtained after passage of TERA2 in an athymic (nu/nu) (nude) mouse wherein 
a xenograft tumour with obvious teratoma characteristics was created (Andrews et al. 1984b). 
TERA2 and NTERA2 xenografts included several types of cells, primarily glandular 
structures and neural elements. Single-cell clones of NTERA2 were isolated, and the 
NTERA2 D1 clone (commonly known as NT2/D1) is a well-known cell line that is 
extensively used. NTERA2 cells exhibit features similar to human embryonic carcinoma 
(EC) cells such as 2102Ep, namely, the presence of the markers TRA-1-60, SSEA4 and 
SSEA3 and high levels of alkaline phosphatase (ALP). Interestingly, unlike many other 
human EC lines, TERA2-derived lines do not express any placental-like ALP activity and 
indicate no confirmation of trophoblastic differentiation when cultured at low cell density. 
 
Differentiation of NTERA2 EC cells is identified not only by alterations in specific surface 
antigen but also by changes in predisposition to infection with certain viruses, especially 
human cytomegalovirus (HCMV) and human immunodeficiency virus (HIV). While 
NTERA2 stem cells are immune to HIV and HCMV infections, the differentiated cells permit 
the replication of both these viruses (Gonczol, Andrews & Plotkin 1984b, Hirka et al. 1991b). 
In the case of HCMV, the resistance occurs due to inactivity of the major immediate-early 
promoter of the virus in the EC cells (Lafemina, Hayward 1988b, Nelson, Groudine 1986b). 
Further, several other genes exhibit marked regulation during NTERA2 differentiation. For 
instance, Oct4, which is expressed by EC and ES cells, is downregulated following exposure 
of NTERA2 cells to retinoic acid (Alexander Przyborski, Smith & Wood 2003)(S.A. 
Przyborski & P.W. Andrews, 2001). Simultaneously, the expression of some of the genes is 
induced following retinoic acid exposure. One such gene is a member of the Wnt family—
Wnt13—which is not expressed by NTERA2 or different human EC cells, but is strongly 
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induced following retinoic acid exposure (Wakeman, Walsh & Andrews 1998b). Curiously, 
while Wnt1 is well known to be induced through differentiation of the mouse ECline P19 line 
(Papkoff 1994b), none of the other members of the Wnt family were expressed during 
NTERA2 differentiation. Members of the frizzled family of genes that encode putative 
receptors for Wnt are also expressed at different levels during NTERA2 differentiation, and a 
previous study hypothesised that Wnt signalling could play a potential role in regulating cells 
obtained through differentiation (Wakeman et al. 1998), which is a part of the Wnt signalling 
processes, is as well capable of inducing NTERA2 differentiation, and it has been 
hypothesised that this might show a possible route for EC cell differentiation to be modulated 
by Wnt signalling (Giesberts et al. 1999).  
 
NTERA2 EC cells are susceptible to induction not just through retinoic acid but also via 
several agents, particularly hexamethylene bisacetamide (HMBA) (Andrews et al. 1990) and 
members of the bone morphogenetic protein (BMP) family (Andrews et al. 1994). NTERA2 
cells induced with 3 mM HMBA can be distinguished from those induced with retinoic acid, 
as neural factors are usually not expressed, although NCAM is an obvious marker of 
differentiation in HMBA-induced cells. Some substances interfere in the nature of the cells 
induced by these agents. A previous study reported that smooth muscle actin induction occurs 
after exposure to BMP7 and, to a slightly lower extent, retinoic acid (Qualtrough 1998). Even 
if several of the markers typical of retinoic acid induction are not expressed shortly after 
HMBA treatment; eventually, the HMBA-induced cultures frequently express some of the 
markers typical of retinoic acid-treated cultures, and the presence of  neurons is sometimes 
observed. Therefore, although the process of differentiation induced by these two agents 
(retinoic acid and HMBA) is dissimilar, these agents appear to interfere with one another and 
the pathways are not reciprocally exclusive. However, the nature of the non-neural cells 
observed in the differentiating NTERA2 cultures, induced by retinoic acid or HMBA, and has 
not been wholly distinguished.  
 
5.1.1 Hexamethylene bisacetamide 
HMBA is a clinically employed agent (Andreeff et al. 1992a) that was initially developed as 
an anticancer drug, which could be involved in the reactivation of the dormant reservoirs. 
HMBA leads to the release of pTEFb from HEXIM1 and precipitates Cdk9 enrolment to the 
HIV-1 5′ LTR via an unforeseen interaction with the transcription element Sp1 (Choudhary, 
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Archin & Margolis 2008). HMBA has been demonstrated to induce gene expression in 
latently-infected T-lymphoid and monocytic cell lines, and to cause downregulation of the 
receptor CD4 but not of the coreceptors CXCR4/CCR5 at the surface of peripheral blood 
mononuclear cells (PBMCs) (Klichko et al. 2006). Pilot human clinical trials have proposed 
that HMBA or other parallel compounds may therapeutically function in cells latently 
infected with HIV-1. 
 
5.1.2 Action of HMBA 
HMBA can induce apoptosis in isolated human myeloma cells. All the cell lines exhibited 
downregulation of Bcl-2, which is a recognised inhibitor of apoptosis. Further, this finding 
established that Bcl-2 overexpression rendered myeloma cells immune to HMBA-induced 
cell death, thereby reinforcing the relationship between HMBA and apoptosis, suggesting the 
possible benefit of HMBA and related compounds in the medication of multiple myeloma 
(Siegel et al. 1998a). Ouyang et al. 2004 studied human hepatocellular carcinoma cells and 
demonstrated that at low concentrations, HMBA can arrest cell growth and at higher 
concentrations it can induce apoptosis by lowering the Bcl-2/Bax ratio, thereby proposing 
another possible use of HMBA in the treatment of liver cancer (Ouyang et al. 2004). Further 
studies implied the potential application of HMBA in T acute lymphoblastic leukaemia (T-
ALL), where it was shown to increase the predisposition of leukemic cells to apoptosis 
(Chiaramonte et al. 2008). The molecular mechanism of HMBA is yet to be elucidated; thus 
far, no studies have investigated the effects of HMBA in lung cancer. NFκB is a transcription 
factor that plays a central role in the control of inflammation, apoptosis and cell proliferation. 
The NFκB mechanism is constitutively switched on in most human cancers, and several 
studies have focussed on recognising the molecules that inhibit the NFκB mechanism 
(Gilmore, Herscovitch 2006, Greten et al. 2004, Aggarwal et al. 2006). The Akt pathway is 
important for cell survival and is an essential regulator of NFκB activation. (Gustin et al. 
2004, Madrid et al. 2000, Mayo et al. 2002, Ozes et al. 1999, Coffer, Jin & Woodgett 1998). 
The ERK/MAPK pathway is another significant mechanism implicated in cell survival (Dent 
et al. 1999, Tran et al. 2001, Xia et al. 1995a) and has been indicated to induce NFκB 
responses by stimulation of p90 Rsk. (Richards et al. 1999, Panta et al. 2004, Ryan et al. 
1993, Schouten et al. 1997). In an effort to identify the mechanism of HMBA, a study has 
investigated the influence of HMBA on the NFκB mechanism. It was found that HMBA-
mediated sensitisation to cell death could be attributed partly to its capability to downregulate 
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the NFκB mechanism (Dey et al. 2008a). Studies have reported that HMBA simultaneously 
targets the MAPK and Akt mechanisms, both of which are critical for cell survival. 
Downregulation of both these mechanisms consequently affects the NFκB mechanism; this 
could be the mechanism by which HMBA represses NFκB activation (Dey et al. 2008a). The 
same study also suggested the possibility of application of this HMBA mechanism in multi-
targeted therapy for controlling lung cancer and as therapy in combination with kinase 
inhibitors. They also supplied possible biomarkers to determine the tumour response to 
treatment with HMBA (Dey et al. 2008a).  
 
HMBA is a hybrid polar compound that has been deliberately used to induce terminal 
differentiation of transformed cells. It has been shown to control cell proliferation many 
cancers such as acute myelogenous leukaemia (AML), solid tumours (liver) and myelomas 
(Li, Du & Huang 1996, Rifkind, Richon & Marks 1996, Andreeff et al. 1992b, Siegel et al. 
1998b). Nevertheless, the mechanism of action of HMBA has not yet been clarified. Figure 
5.1 illustrates a suggested mechanism of action of HMBA. Studies have demonstrated that 
HMBA increases cell cytotoxicity and represses NFκB gene expression in response to TNFα 
and IL1. The same study also shows that HMBA simultaneously downregulates the Akt and 
MAPK pathways, both of which are necessary for cell survival and growth and feed into the 
NFκB pathway (Ghosh et al. 2006). Therefore, HMBA may repress the TNFα-induced 
activation of NFκB via both these pathways (Fig. 5.1). Moreover, a previous study indicates 
that HMBA decreases the IKK kinase activity, IκBα phosphorylation and p65 
phosphorylation at the essential Ser536 residue (Dey et al. 2008a). This study also suggested 
that some of the tumour response markers to HMBA in lung and breast cancer are 
downregulated in Akt and ERK phosphorylation. The Akt/PKB pathway is an essential 
survival pathway that plays a primary role in several cancers, including lung cancer 
(Vivanco, Sawyers 2002). The Akt/PKB pathway has been shown to be constitutively active 
in non-small cell lung cancer (NSCLC) cell lines, resulting in immunity to chemotherapy and 
radiation (Brognard et al. 2001). Consequently, improving the inducers that repress the Akt 
pathway would be of considerable benefit. Tissue microarray studies of tumour samples 
obtained from patients with NSCLC suggested p-Akt overexpression as an independent 
prognostic indicator, and patients with increased p-Akt had a significant survival 
disadvantage over patients with lower Akt phosphorylation, while p53 or Ki-67 expressions 
were not statistically significant prognostic indicators (David et al. 2004). A study by (Tang 
et al. 2006) compared immunohistochemical staining of normal and lung cancer samples and 
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reported that p-AKT overexpression and lack of PTEN expression in lung cancer cases is a 
poor prognostic indicator and is associated with poor differentiation and metastasis. Various 
agencies have illustrated how Akt activates the NFκB pathway. Sizemore et al. suggested that 
in response to IL1, Akt could activate NFκB by inducing p65 phosphorylation independent 
from its liberation from IκBα (Sizemore, Leung & Stark 1999). Madrid et al. suggested that 
Akt activates NFκB directly by utilising IKK or indirectly through IKK via p38 (Madrid et al. 
2001). Another study reported Akt-dependent activation of IKK following the interaction of 
mTOR and IKK, thereby providing fresh insights into these processes and their clinical 
relevance (Dan et al. 2008). Established data propose that HMBA represses NFκB by 
downregulating Akt phosphorylation, followed by repression of an IKK kinase process and 
following decrease in p65 phosphorylation at the Ser536 residue, which is essential for 
chromatin remodelling. The extracellular signal-regulated (ERK) or mitogen-activated 
protein kinase (MAPK) cascade is another significant pathway in cell survival and 
proliferation (MacKeigan, Collins & Ting 2000, Xia et al. 1995b). Its activation is mediated 
by MEK1, a necessary intersection in the pathway with ERK1 and ERK2 being its identified 
targets. (Vicent et al. 2004) carried out immunohistochemical investigations of samples 
obtained from patients with NSCLC, and observed increased phosphorylation of ERK1/2 in 
the patient population with histologically proven NSCLC, suggesting that ERK1/2 was 
stimulated. This ERK1/2 activation was found to be connected with metastases and advanced 
and aggressive NSCLC tumours. (Brognard, Dennis 2002) demonstrated the role of ERK1/2 
activation in promoting immuno to chemotherapy and apoptosis. HMBA represses TNFα-
induced phosphorylation of ERK1/2 in a time-dependent manner. If studied in detail, the Akt 
and ERK/MAPK cascade have great potential as prognostic indicators in lung cancer and 
further studies on inducers that inhibit both these processes, such as HMBA, have 
considerable potential in therapy. 
It is possible that HMBA affects a phosphatase or kinase linked to both the Akt and MAPK 
pathways, and efforts are ongoing aimed at further understanding its mechanism of action 
(Dey et al. 2008a). While inhibition of both these pathways are being extensively studied in 
the context of lung cancer, a recent study (Tang et al. 2006) indicated that p65 tissue nuclear 
expression was increased in both small cell and non-small cell lung cancers, suggesting the 
possible function of inflammation in the early pathogenesis of lung cancer. Therefore, 
inducers such as HMBA that repress the NFκB pathway and also inhibit TNFα-induced 
activation of NFκB target genes are implicated in anti-apoptosis (Bcl-xL and FLIP), 
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proliferation (Cox-2) and tumour invasion (ICAM-1). Apart from lung cancer, HMBA has 
been shown to repress TNFα-induced activation of NFκB target genes in breast cancer cells 
with various mutation classes; this is especially significant in obtaining a deeper 
understanding of the mechanism of action of HMBA. The ideal cancer treatment strategy 
would include a combination of drugs with the same target that synergistically affect different 
mechanisms. This is considered the optimal method to combat drug resistance and improve 
the efficacy of chemotherapy. An important problem in cancer drug progression is the 
discovery of biomarkers of response (Park et al. 2004).  
                                                      
Figure 5.1. Flowchart illustrating the mechanism of action of HMBA and its inhibition 
of the NFκB process. (A) TNFα-induced activation of the NFκB process. (B) HMBA 
represses both Akt and MAPK processes and also downregulates the NFκB process and its 
gene products (Dey et al. 2008b). 
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5.2.3 Oct4 as a master key for NTERA2 cells 
The strongest evidence suggesting that stem cells are the potential origin of the ―cancer‖ stem 
cells and that stem cells are targets for carcinogenesis was obtained when studies reported 
that the transcription factor Oct3/4 (later known as Oct4), required for maintaining 
―stemness,‖ was found in embryonic stem cells but not in normal tissues (Pesce, Schöler 2001). 
Later, Oct4 was detected in a few tumours. These authors concluded that Oct4 expression in 
tumour cells was ―restored‖ by the transformation process (Monk, Holding 2001b, Gidekel et 
al. 2003). In my experiment, I used this stimulus to determine whether the undifferentiated or 
differentiated NTERA2 cells were the targets where the cancer stem cell (CSC) process was 
initiated. Since NTERA2 cell lines were treated with HMBA were available in our 
laboratory, we evaluated the Oct4 expression in these cells in two ways (differentiated and 
undifferentiated cells) and all the test samples were treated with four anticancer drugs, 
namely, camptothecin, aphidicolin, phleomycin and hydroxyurea. The results indicated that 
Oct4 was expressed in all the CSCs (undifferentiated stage) but not in the differentiated cells. 
This can be seen in the undifferentiated cells. Our results suggested that 100% of the 
NTERA2 expressed Oct4. 
These findings are consistent with the notion that tumours contain cells with for stem cell 
biomarkers (Oct4), suggesting that they originate from the normal adult stem cells. 
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5.2  Results 
5.2.1  Analysis of NTERA2 HMBA induced differentiation 
NTERA2 offers a unique model system for studying human stem cell and cancer stem cell 
biology. NTERA2 cells can be differentiated using various agents to generate populations of 
proliferating cells which no longer have the markers of stem cells (as Oct4). Our aim in this 
chapter is to differentiate NTERA2 down a non-stem like lineage and determine whether the 
cellular response to DNA damage-inducing agents alters during the differentiation period. 
This provides an in vitro system with which to dissect the mechanisms of action of agents 
which might be applied to differentiation therapies. Use of NTERA2 has the added advantage 
that the stem-like and differentiated cell populations have an identical genetic lineage. 
 
Here HMBA is to be used of the induction of differentiation. Given this, it was essential to 
establish that differentiation of NTERA2 can be induced under the laboratory conditions used 
here. Moreover, it was essential to test that the differentiation potential of the NTERA2 
stocks used here has been maintained. For these reasons differentiation experiments were set 
up in which stem markers were followed, with an expectation that the key marker for 
stemness, Oct4, would be lost from the cell population upon differentiation.  
 
NTERA2 cell cultures were set up and monitored over eight days by western blotting and 
immune fluorescence to evaluate levels of Oct4 (with the expectation that they will be 
reduced). Four independent culture sets were established, one left untreated, one treated with 
3 mM HMBA and to others treated with 3 mM HMBA and 1 µl or 2 µl DMSO (as this is the 
solute for some of the genotoxic agents to be used, such as CPT). Different culture sets of 
four were established with distinct cell seeding densities (50,000, 75,000, 100,000 cells per 2 
ml culture). The data shown are for 75,000 seeded cells. Each experimental set (within the 
sets of four) was established with 8 different cell cultures, one for each day of the experiment. 
Each culture was set up on day 0 and every day one culture was taken for western blot 
analysis and immune fluorescence. All experiments were triplicate to permit statistical 
analysis of western blot data. Figure 5.2 shows western blot data for Oct4 levels for all four 
conditions (no HMBA; + HMBA; +HMBA/ 1 µl DMSO; +HMBA / 2 µl DMSO) over a 6 
day period (days 7 and 8 are not. The gels are shown use a tubulin loading/normalisation 
control. The values of Oct4 protein level are taken as a percentage of the untreated control 
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(no HMBA / no DMSO). Cultures were also immune stained for Oct4 and the proliferation 
marker Ki-67; Figure 5.3 shows examples of Oct4 stained and Ki-67 stained cells for days 0 
– 6 for following HMBA treatment. As can be seen from the figures (5.2 & 5.3), the cells 
treated with HMBA lose Oct4 protein (as measured by western blot), and Oct4 levels start to 
diminish on day 1 and are almost undetectable from about 4 days onward. The staining for 
Ki-67 demonstrates a relatively uniform staining in all cultures indicating that all cultures 
maintain proliferative potential and activity. These data indicate that the NTERA2 cultures 
have retained differentiation capability, can be induced to differentiate under the laboratory 
conditions used here and that proliferation is maintained during and following the 
differentiation process. 
 
5.2.2 Effect of HMBA on proliferation of NTERA2 
In conjunction with the analysis of differentiation (above), it was important to establish 
whether HMBA treated cells maintained a proliferative ability. The Ki-67 staining of the 
HMBA treated cells indicated the cells had indeed retained proliferative potential. To analyse 
this in more detail we measured cell proliferation of NTERA2 cells over a four day period 
without HMBA treatment and with HMBA (3 mM) treatment. 
 
Cells were treated with HMBA for a 24 hour period and then the HMBA containing medium 
was washed off and replaced with fresh pre-warmed medium. Seeding densities of 50,000 / 2 
ml, 75,000 / ml and 125,000/ 2 ml were used. A similar growth response was observed for all 
three seeding densities. Figure 5.4 shows the 50,000 cell seeding density (data for other 
cultures is not shown – a similar pattern was seen). As can be seen NTERA2 cells continue to 
proliferate following HMBA treatment, but the rate of proliferation is slightly less than 
untreated cells. This indicates that HMBA treatment reduces proliferation rates slightly, but 
still permits cells to divide, which is essential if the response of cells to DNA replication-
dependent DNA damage is to be assessed.  
 
5.2.3.   Preliminary assessment of CPT on differentiated NTERA2 cells 
Having established that NTERA2 cells differentiate and maintain proliferative capacity 
following HMBA treatment an initial assessment was carried out to determine the response of 
HMBA differentiated NTERA2 to CPT. Cultures were set up with and without HMBA (see 
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above) and permitted to proliferate for 8 days, when differentiation should have been 
completed (see above). At 8 days CPT was added (either 1 µM or 2 µM) and the cells were 
incubated for 3 hours prior to the medium being changed to fresh pre-warmed medium 
without CPT. Different cell seeding densities were used (50,000, 75,000 and 125,000) and the 
data shown in Figure 5.5 are for 75,000 cells per 2 ml well; all seeding densities gave similar 
patterns indicating that within this seeding range responses are similar. All cultures were 
carried out in triplicate and mean values presented. Figure 5.5 shows that whilst the HMBA 
treated cells proliferate more slowly, the percentage of cells killed by 3 hour treatment with 
CPT is less than that of cells not differentiated with HMBA. Cells untreated with HMBA 
have approximately 2% and 1.8% survival in response to 1 µM and 2 µM CPT respectively, 
whereas the HMBA differentiated NTERA2 exhibit approximately 12.5% and 10% survival 
following 1 µM and 2 µM CPT respectively. This small difference in survival might simply 
be due to the slightly slower proliferation rate of differentiated, HMBA treated cells (as CPT 
is only toxic for dividing cells) (see Discussion). When a more chronic CPT exposure time of 
24 hours was used both differentiated and undifferentiated cells showed 100% killing (data 
not shown), indicting there is no major difference in the response to CPT.   
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Figure 5.2 Differentiation status and Oct4 gene expression in NTERA2 with HMBA and 
without treatment. The expression of markers of pluripotency (Oct4) is shown. In each 
case, data represents changes in expression in the differentiate state during six days after 
exposure the cells to 3 mM HMBA and western blots were scanned by using (Sion Image 
program). In NTera2 cells, differentiation status is confirmed by decreases in expression of 
Oct4. Error bars represent Standard Error of Mean and the p value is derived by one way 
ANOVA in all cases. (A) Level of Oct4 after treatment the cells with HMBA for one day. (B) 
Level of Oct4 after treatment the cells with HMBA for two days. (C) Level of Oct4 after 
treatment the cells with HMBA for three days. (D) Level of Oct4 after treatment the cells 
with HMBA for four days. (E) Indicate to level of Oct4 after treatment the cells with HMBA 
for five days. (F) Level of Oct4 after treatment the cells with HMBA for six days. 
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Figure 5.3. Immunoflurescent staining shows decreased Oct4 expression in NTERA2 
cells during six days after treatment with HMBA indicating loss of self-renewal during 
six days.(A). It indicates of Oct4 expression . (B) It indicates phase contrast. (C) Indicates 
Ki-67. (D) Pi nucleus stain. (E) It indicates phase contrast. (F) It indicates to merge between 
Ki-67 and Pi stain. 
 
 
 
 
111 
 
                             
 
Figure 5.4. The effect HMBA as potential inducer on the proliferating of NTERA2 cells 
during four days. Untreated cells (red) were seeded at density of 50,000 cells/ well in 24-
wellplate in DMEM medium without treatment. HMBA treated cells were also seeded at 
dendity of 50,000 cells/ well were with DMEM medium containing with 3 mM HMBA. 
Mean cells numbers were generated from three independent experiments. Statistical 
significance in cellular response to HMBA was assessed by the two-way ANOVA with 
comparison test and Student‘s t test. NTERA2 cells were significantly reduction with HMBA 
comapsion without HMBA (p < 0.001) for all day 4. 
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5.2.4 NTERA2 response to DNA damaging agents during differentiation 
Following the preliminary analysis of differentiated and undifferentiated cells to CPT the 
analysis was extended by studying the response to DNA damaging agents during the 
differentiation processes. NTERA2 cultures were set up so that the sensitivity to the agents 
could be tested on every day of an 8 day differentiation period. At the start of each 
experimental set 8 cultures of undifferentiated NTERA2 cells were set up in duplicate (all 
experiments were also triplicate to obtain data which could be subjected to statistical 
analysis). All cultures were induced to differentiate using HMBA (see page 108). On each 
day, one duplicate pair of cultures was removed for analysis, one being exposed to a DNA 
damaging agent and one being left without DNA damage, both cultures were then incubated 
in the DNA damaging agent for a short period (3hours) and then incubated to 24 hours. Both 
cultures were then analysed by western blot for the presence of Oct4 and cell numbers were 
counted by haemocytometer. Using this method the cell survival levels were determined for 
each day of the 8 day differentiation period.  
 
5.2.4.i  Response to CPT 
1 µM and 2 µM CPT exposure was used and both concentrations resulted in similar 
sensitivities. Figure 5.6 shows the response to 2 µM CPT. As can be seen at day 0 (with no 
HMBA) the cells show a survival of about 2%, as had previously been shown (see above). 
During differentiation the percentage of the cells surviving increases slightly, peaking on day 
3. These data suggest a subtle resistance to CPT developing during the differentiation 
process; as indicated above, this might be due to the reduced proliferation rate following 
HMBA treatment (see Discussion). The western blot data are shown for the CPT treated cells 
(after 24 hours incubation); for days 0 to day 2 cellular survival levels were too low to obtain 
significant whole cell extract material, as measured by the loss of α-tubulin (control) signal 
(Figure 5.6 A). However, it is clear that from day 3 onwards there is no detectable Oct4 
present indicating that differentiation had occurred in the HMBA + CPT treated cells.  
 
5.2.4.ii Response to Aphidicolin  
Cell cultures were treated as above for CPT, but the CPT was replaced by 1 µM aphidacolin, 
a DNA polymerase inhibitor. As can be seen from Figure 5.7A, significant levels of Oct4 are 
no longer detected from about day 3 to day 4 onward, indicating that differentiation was 
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occurring in these cultures. A relatively uniform response to aphidicolin is observed. This 
indicates there is no measurable change in the response to DNA replication inhibition during 
NTERA2 differentiation in response to HMBA.  
 
5.2.4.iii Response to hydroxy urea 
Cell cultures were treated as above for CPT, but the CPT was replaced by 1 µM hydroxy urea 
(HU), a ribonuclease reductase inhibitor which reduces cellular levels of nucleotides and thus 
inhibiting DNA replication. As can be seen from Figure 5.8A, significant levels of Oct4 are 
no longer detected from day 3 onward, indicating that differentiation was occurring in these 
cultures. As for aphidicolin, as relatively uniform sensitivity is observed for HU, indicating 
there is no inherent difference in the response to this drug during differentiation.  
 
5.2.4.iv Response to phleomycin 
In addition to CPT two agents capable of inducing DNA damage were tested (Aphidicolin 
and HU; see above), both of which inhibit DNA replication. Both these agents differ to CPT 
in that they do not necessarily generate double-stranded DNA breaks (although they are 
capable of this). Given the fact that CPT seems to cause a subtle increased sensitivity to Oct4 
expressing NTERA2 cells than these two agents (see above) another agent was tested which 
is known to generate DSBs directly, phleomycin. Figure 5.9 shows the response to 
pheleomycin. As for the other experimental sets Oct4 signal is lost from approximately day 3 
onwards, indicating the differentiation programme is proceeded as in these cultures. As can 
be seen, there is a slight difference in the sensitivities to phleomycin, with day 0 and day 1 
showing slightly higher levels of sensitivity to this agent relative to the other days (days 2-8). 
The correlation between Oct4 levels and sensitivity are not exact, but there is a subtle pattern 
(i.e. high Oct4 correlates with increased phleomycin sensitivity).  
114 
 
       
 
Figure 5.5.  Two charts display the effect of two different concentrations 1µM and 2 µM 
camptothecin on undifferentiated and differentiated NTERA2 cells after day 7. (A) 
75,000 NTERA2 cells were seeded and treatment by anti-cancer drugs 1µM and 2 µM CPT 
after day 7. (B) 50,000 NTERA2 cells were seeded in medium containing 3 mM HMBA and 
treated by anti-cancer drug 1µM and 2 µM CPT after day 7. Cytotoxic responses to 
camptothecin were analyzed by cell accounting using haemocytometer. Columns were 
generated from three independent experiments. Statistical significance in cellular response to 
different concentrations of camptothecin was assessed by the two-way ANOVA with 
comparison test and Student‘s t test. NTERA2 cells were significantly hypersensitive from 
1µM and 2 µM CPT (p < 0.001) for all days and three stars were donated on the columns. 
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Figure 5.6. The effect camptothecin on differentiated NTERA2 cell after treatment with 
3 mM HMBA for eight days. (A) Western blot analysis for level of Oct4 during eight days 
and alph-tubulin was control. (B) Percentage of survival cells for eight days and cytotoxic 
responses to 2 µM CPT were analyzed by cell accounting using haemocytometer. Columns 
were generated from three independent experiments. Statistical significance in cellular 
response to 2 µM CPT was assessed by the two-way ANOVA with comparison test and 
Student‘s t test. NTERA2 cells were significantly sensitive to 2 µM CPT (p < 0.01) for all 
days comparing with control.  
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Figure 5.7. The effect aphidicolin on differentiated NTERA2 cell after treatment with 3 
mM HMBA for eight days. (A) Western blot analysis for level of Oct4 during eight days 
and alph-tubulin was control. (B) Percentage of survival cells for eight days and cytotoxic 
responses to aphidicolin were analyzed by cell accounting using haemocytometer. Columns 
were generated from three independent experiments. Statistical significance in cellular 
response to aphidicolin was assessed by the two-way ANOVA with comparison test and 
Student‘s t test. NTERA2 cells were significantly sensitive to aphidicolin (p < 0.01) for all 
days comparing with control.  
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Figure 5.8. The effect 1 µM hudroxyurea on differentiated NTERA2 cell after treatment 
with 3 mM HMBA for eight days. (A) Western blot analysis for level of Oct4 during eight 
days and alph-tubulin was control. (B) Percentage of survival cells for eight days and 
cytotoxic responses to 1 µM hudroxyurea were analyzed by cell accounting using 
haemocytometer. Columns were generated from three independent experiments. Statistical 
significance in cellular response to 1 µM hudroxyurea was assessed by the two-way ANOVA 
with comparison test and Student‘s t test. NTERA2 cells were significantly sensitive to 1 µM 
hudroxyurea (p < 0.01) for all days comparing with control.  
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Figure 5.9. The effect 100 mg phleomycin on differentiated NTERA2 cell after 
treatment with 3 mM HMBA for eight days. (A) Western blot analysis for level of Oct4 
during eight days and alph-tubulin was control. (B) Percentage of survival cells for eight days 
and cytotoxic responses to 100 mg phleomycin were analyzed by cell accounting using 
haemocytometer. Columns were generated from three independent experiments. Statistical 
significance in cellular response to phleomycin was assessed by the two-way ANOVA with 
comparison test and Student‘s t test. NTERA2 cells were significantly sensitive to 
phleomycin (p < 0.01) for all days comparing with control.  
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5.4.  Discussion 
In the previous chapter we demonstrated that NTERA2 exhibited sensitivity to the 
topoisomerase inhibitor CPT. NTERA2 was employed in this study as is shares many 
characteristics with human embryoic stem cells (Pal, Ravindran 2006) and extensive gene 
expression analysis and profiling of NTERA2 has shown that a strong correlation to validated 
human ES cells (Schwartz et al. 2005, Sperger et al. 2003). Indeed, the pluripotency 
regulating transcription factor Oct4 is present in NTERA2 and is required for pluripotency in 
this cell line (Pal, Ravindran 2006).  
 
The study of NTERA2 was triggered by the preliminary observation that a mouse ES cell line 
and non-isogenic mouse embryonic fibroblast cells exhibited different sensitivities to CPT 
(Wakeman and McFarlane, unpublished, personal communication). This implied that ES cells 
might have distinct mechanisms for regulating their genome stability. Indeed this observation 
is supported by a variety of other observations which indicates ES and ES-like cells have 
unique pathways to regulate their genomic integrity (Momčilović, Navara & Schatten 2011). 
Indeed, recent work has directly linked transcription of Oct4 via the nucleotide excision 
repair pathway complex XPC suggesting a unique genome stability monitoring process in 
stem cells, perhaps also including NTERA2 (Fong et al. 2011). 
 
In this study it was observed that NTERA2 cells in the undifferentiated state (no HMBA / 
expressing Oct4) appeared to be slightly more sensitive to the DNA damaging agent CPT 
than cells which had been induced to differentiate using HMBA (see page 115). CPT works 
by inhibiting topoisomerase I. Topoisomerase I normally functions to regulate DNA super 
coiling and it does so by forming breaking the sugar-phosphate back bone of DNA by 
forming a transient covalent phosphotyrosyl intermediate between the broken strand and a 
tyrosine residue on the topoisomerase (Lorence, Nessler 2004, Keck, Berger 1999, Rasheed, 
Rubin 2003, Pommier 2006, Rothenberg 1997b). CPT acts by stabilising the transient 
covalent complex between the protein and the DNA resulting in a prolonged unsealed nick in 
the duplex (Hsiang et al. 1985). These relatively stable nicks can be converted to DNA DSBs 
during DNA replication when the replisome encounters them, making a one sided DSB which 
will require recombinogenic repair mediated by homologous recombination factors. This 
dependence upon DNA replication to generate DSB damage might provide an explanation for 
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why undifferentiated (no HMBA) NTERA2 cells show more sensitivity to CPT than the 
differentiated. This work has demonstrated that HMBA treated, differentiating / differentiated 
cells proliferate (they express the proliferation marker Ki-67; Figure 5.3) and the cell number 
continues to increase (Figure 5.4). However, their rate of proliferation appears to be lest than 
undifferentiated NTERA2. This reduced proliferation rate might simply indicate that the 
levels of DNA damage generated by CPT may be less in cell populations which divide more 
slowly (HMBA treated NTERA2), or alternatively these cells have more time to recover from 
the damage acquired (or a combination of both). This possibility cannot be dismissed by 
studying these data, but it remains possible that there is a subtle distinction in the  
mechanistic pathways governing the response to CPT (possibly DSBs) between differentiated 
and undifferentiated NTERA2 (see below).  
 
Following this two DNA replication inhibitors were employed to determine whether or not 
NTERA2 responded differently to this agent during differentiation. These agents should 
result in failures in DNA replication, which have the potential to generate failed DNA 
replication forks without causing DSBs (McFarlane, Al-Zeer & Dalgaard 2011 ), although it 
can result in DSBs (Liu, Kuo & Melendy 2003). Aphidicolin was shown to repress growth of 
human cultured cells over 30 years ago (Pedrali-Noy, Spadari 1979, Bucknall et al. 1973c) 
and it has been shown to be an inhibitor of polyα-like DNA polymerases which generates 
regions of un-replicated DNA (Brox, Hunting & Belch 1984, Wang et al. 1999, Hellman et 
al. 2000, Hellman et al. 2000). HU inhibits ribonucleotide reductase and thus exhausts 
nucleotide pools resulting in failures in DNA replication progression (Mirkin, Mirkin 2007a, 
Feng et al. 2006, Bianchi, Pontis & Reichard 1986, Matsumoto, Rey & Cory 1990, Koç et al. 2004).  
 
Treatment of differentiated and undifferentiated NTERA2 with these two agents resulted in a 
relatively uniform sensitivity. This is clearly distinct from the response shown to CPT and the 
subtle increased sensitivity observed in undifferentiated NTERA2 to CPT was not reflected 
upon treatment with these two agents. This observation challenges the postulate that the 
subtle difference in sensitivities observed in response to CPT was due to cell proliferation, as 
one might have anticipated a similar response in the case of these two agents if this was 
correct. The uniformity of sensitivity to aphidicolin and HU suggests that the distinction 
between differentiated and undifferentiated NTERA2 in response to CPT might indeed reflect 
an inherent difference in the way these cells deal with genomic insult, most likely DSBs. It is 
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possible that CPT generates DSBs, whereas the levels of aphidicolin and HU employed here 
might not be sufficient to induce DSBs, rather they generate failed forks which do not get 
processed to DSBs and forks are reactivated effectively without a DSB intermediate.  
 
The data obtained for phleomycin go some way to supporting this latter proposal. Phleomycin 
is a copper-containing protein acquired form Streptomyces verticillus (Maeda et al., 1956) 
and has been used for many years and an anti-tumour agent (Bradner, Pindell 1962a). Whilst 
the exact mechanism of action for phleomycin has not been elucidated carefully, it is widely 
accepted to be an agent that directly generates DSBs given the similarity of action to the DSB 
inducer bleomycin (Saito, Andoh 1973). Phleomycin treatment also resulted in a slightly 
elevated sensitivity of the undifferentiated (no HMBA) NTERA2 relative to cells which were 
differentiating (reduced Oct4) or differentiated (no Oct4). This observation supports the 
possibility that there is an inherent difference in the mechanism of action between stem-like 
cells (undifferentiated NTERA2) and differentiated cells in the way they process and respond 
to significant levels of DSBs, but not failures in DNA replication which result in fork 
collapse with no increased associated DSB formation.  
 
Previous studies have demonstrated that there are distinctions between multipotent 
haematopoietic stem cells and proliferating myeloid cells (Francis, Richardson 2007) and that 
mouse stem cells have distinct homologous recombination regulatory systems relative to 
isogenic mouse embryonic fibroblast (MEF) cells (Cervantes et al. 2002). The preliminary 
observations of McFarlane and Wakeman, which showed that mouse ES cells and non-
isogenic MEFs responded distinctly to CPT also pointed to a difference in DSB repair 
pathways between ES cells and differentiated cells. The data obtained here do not point to a 
clear distinction between ES-like human embryonal carcinoma (EC) cells and their 
differentiated counter parts, but there is a suggestive hint from these data that there is a subtle 
distinction to the response to DSBs. Recent findings have demonstrated that there are 
differences between mouse and human ES cells in their response to ionizing radiation-
induced DSBs (Banuelos et al. 2008a) and it might be the case that the data generated here 
indicate that the pathways in humans are not heavily altered between the undifferentiated and 
differentiated state. However, there are many other factors which have not been least of 
which is the nature of the model system we have used. NTERA2 does not have a normal 
human karyotype and the changes generated over the many passages these cells have 
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undergone might have resulted in NTERA2 developing genome repair mechanisms which are 
distinct from human ES cells or the NTERA2 progenitor cells.   
 
Despite the lack of a large margin differences in response to DNA damaging agents, the 
subtle difference observed in NTERA2 might provide a platform for the study of genome 
stability in human ES like cells. Induced pluripotent human stem cells might also present a 
model system, but they too appear to have draw backs (Blasco, Serrano & Fernandez-
Capetillo 2011). Given the potential clinical importance of human stem cells and the 
exponentially growing interest in these cells, it is interesting to note that cultured human ES 
cells take on genomic rearrangements in culture for examples, see (Draper et al. 2003, Spits 
et al. 2008). To safely employ these cells clinically it is essential we gain a full insight into 
the mechanisms governing their genomes and comparisons of NTERA2 to other ES and ES-
like systems and other differentiation pathways will provide a characterisation of genome 
stability pathways for clinically important biological cells.  
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Chapter 6 Analysis of the effect of HMBA on a non-stem cancer cell line 
 
6.1.  Introduction 
p53 and p21 are stimulated in cells after DNA damage. This transiently arrests cells at the G1 
and G2 checkpoints of the cell cycle (Bartek, Lukas 2001, Taylor, Stark 2001, Colman, 
Afshari & Barrett 2000). These occurrences give the cells enough time to maintain and repair 
damaged DNA, thus stopping harmful mutations in the cells that would otherwise be 
eventually transferred to daughter cells (Lane 1992, Levine 1997). DNA damage is sensed by 
the ataxia-telangiectasia mutated protein, which is a member of the phosphoinositol-3 lipid 
kinase families (Jeggo, Carr & Lehmann 1998, F. Lavin, Kum Kum Khanna, M. 1999). P53 
is one of the key targets that are subjected to activation by ataxia-telangiectasia mutated 
catalyzed phosphorylation (F. Lavin, Kum Kum Khanna, M. 1999). Activated p53 induces 
the expression of several proteins involving p21, which is a general inhibitor of the cyclin-
dependent kinases (Cdks)1 (Xiong et al. 1991), and is needed to arrest cells at the G1 and G2 
checkpoints of the cell cycle following DNA damage (Deng et al. 1995, Bunz et al. 1998, 
Waldman, Kinzler & Vogelstein 1995). 
DNA damaging agents, including γ-irradiation and inhibitors of the nuclear topoisomerases I 
and II (Top1 and Top2), are extensively incorporated in treatments for cancer patients. The 
progression of numerous kinds of human cancers (50%) is connected with the loss of p53 or 
mutations in p53. Hence, the connection between p53 level and the sensitivity of cancer cells 
to kinds of drugs, specifically DNA damaging agents, has been extensively inspected (Lowe 
1995, Morgan, Kastan 1997, Brown, Wouters 1999a).  
We used an adherent epithelial cell line, HCT-116, originating from a colorectal carcinoma 
that has a mutator phenotype. The apoptotic influence of DNA damaging agents on the 
HCT116 human colon cancer cells was displayed to be obstructed by p21, which was 
expressed by a p53-dependent process (Waldman et al. 1996, Bunz et al. 1999). The results 
acquired from a clonogenicity assay indicated that the long-period survival of HCT116 cells 
following DNA damage was independent of both p53 and p21 (Brown, Wouters 1999b). 
Hence, these studies show that the necessity for p53 in the mechanism of apoptosis depends 
on whether the cells are of rodent or human origin. Furthermore, opposite conclusions can be 
drawn regarding the connection between p53 and drug sensitivity because of variability in the 
experimental conditions addressed to study the influence of DNA damaging agents (Brown, 
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Wouters 1999b). Thus, it is probable that the loss of clonogenicity of cancer cells following 
DNA damage can cause an irreversible arrest of the cell cycle rather than the loss of viability. 
Apposite is the demonstration that p53 and p21 have significant functions in the senescence 
progression of normal human cells (Noda et al. 1994, Wynford‐Thomas 1996, Brown, Wei & 
Sedivy 1997, Itahana, Dimri & Campisi 2001). Therefore, it is possible that p53 and p21 are 
needed for the senescence development of human cancer cells following DNA damage. 
Regarding this relationship, we examined the long-term effect of four DNA damage agents 
that were treated with and without HCT116 cells in existing HMBA.  
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6.2 Result 
6.2. 1 HCT116 response to DNA damaging agents during differentiation 
Following the preliminary analysis of the response of differentiated and undifferentiated cells 
to four poisons with HMBA and RA in the previous chapter, the analysis was extended by 
studying the response to DNA damaging agents during the differentiation processes by using 
HCT116 cells, which do not have the properties of cancer stem cells.  
 
6.2.1.1 Response to CPT 
To induce Top1-mediated DNA damage, HCT116 cells were treated with CPT. The cells 
were exposed to high (1 µM and 2 µM) concentrations of CPT, and the effects on cell 
proliferation and survival were monitored. Treatment of the HCT116 cells with either 
concentration of CPT (1 µM and 2 µM) for 24 h was sufficient to induce cell cycle arrest. 
Treatment with 1 µM and 2 µM resulted in apoptosis of HCT116 cells (Figure 7.1). 
 
1 µM and 2 µM CPT exposure was used, and both concentrations resulted in similar 
sensitivities. Figure 7.1 shows the response to 2 µM CPT. As shown (with no HMBA), the 
cells show a survival of about 5%, as was previously shown (see above). During 
differentiation, the percentage of the cells that survived remained at a similar level. These 
data suggest that a subtle resistance to CPT develops during the differentiation process, which 
might be due to the reduced proliferation rate following HMBA treatment (see Discussion). 
The western blot data are shown for the CPT treated cells (after 24 hours incubation). For all 
days, cellular survival levels were too low to obtain significant whole cell extract material, as 
measured by the loss of α-tubulin (control) signal (Figure 7.1 A). However, it is clear that for 
all days, there is no detectable Oct4 present, which indicates that HCT116 cells had occurred 
in the HMBA + 1 µM or CPT 2 µM treated cells. Thus, HCT116 was not an expression of 
Oct4. 
 
Our results showed that HCT116 cells did not lose viability; however, they lost 
clonogenicity. These outcomes suggested that p53 and p21 were needed to block apoptosis of 
HCT116 cells treated with either 1 µM CPT or 2 µM CPT. The loss of clonogenicity of 
HCT116 cells treated with 1 µM CPT or 2 µM CPT was not because of the loss of long-term 
viability; rather, it was the effect of senescence development. 
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6.2.1.2   Response to Aphidicolin  
Cell cultures were treated as above for CPT, but the CPT was replaced by 1 µM aphidicolin 
and 2 µM aphidacolin (for data of 2 µM aphidicolin see the Appendix), a DNA polymerase 
inhibitor. As Figure 7.2 A shows, significant levels of Oct4 are not detected on all days, 
indicating that differentiation occurred in these cultures. A relatively uniform response to 1 
µM aphidicolin is observed, which indicates that there is no measurable change in the 
response to DNA replication inhibition during HCT116 differentiation in response to HMBA.  
 
6.2.1.3 Response to hydroxyurea 
Cell cultures were treated as above for CPT, but the CPT was replaced by 1 µM hydroxyurea 
(HU), a ribonuclease reductase inhibitor that reduces cellular levels of nucleotides and thus 
inhibits DNA replication. As Figure 7.3 A shows, significant levels of Oct4 are not detected 
from day 0 onward, indicating that differentiation occurred in these cultures without the 
effect of HMBA. With regard to aphidicolin, relatively uniform sensitivity is observed for 
HU, indicating that there is no inherent difference in the response to this drug during HCT116 
cells with HMBA.  
 
6.2.1.4 Response to phleomycin 
In addition to CPT, two agents capable of inducing DNA damage were tested (Aphidicolin 
and HU; see above), both of which inhibit DNA replication. Both agents differ from CPT in 
that they do not necessarily generate double-stranded DNA breaks (although they are capable 
of this). Given the fact that CPT does not cause a subtle increased sensitivity to Oct4 
expressing HCT116 cells more than these two agents (see above), another agent, phleomycin, 
was tested, which is known to generate DSBs directly. Figure 7.4 shows the response to 
pheleomycin. With regard to the other experimental sets, the Oct4 signal is lost from all days 
onwards, indicating that the differentiation programme proceeds as in these cultures. As 
shown, there is a slight difference in the sensitivities to phleomycin; days without HMBA 
show slightly higher levels of sensitivity to this agent relative to the other days (days 0-8). 
There is no correlation between Oct4 levels, and the sensitivities are not exact because 
HCT116 is not an expression of Oct4 protein. 
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Figure 6.1. The effect of camptothecin on differentiated HCT116 cells after treatment 
with 3 mM HMBA for eight days. (A) Western blot analysis for level of Oct4 during eight 
days; alph-tubulin was the control. (B) Percentage of survival cells for eight days; cytotoxic 
responses to 1 µM CPT were analyzed by cell accounting using haemocytometer. Columns 
were generated from three independent experiments. Statistical significance in cellular 
response to 1 µM CPT was assessed by the two-way ANOVA with a comparison test and 
Student‘s t test. HCT116 cells were significantly sensitive to 1 µM CPT (p < 0.01) for all 
days compared with the control. (C) Immunoflurescent staining shows decreased Oct4 
expression in HCT116 cells during seven days after treatment with HMBA, indicating loss of 
self-renewal during seven days. (Green) indicates Oct4 expression. (Black) indicates phase 
contrast. (Red) indicates Pi nucleus stain. (Merge) indicates the merging of Oct4 and Pi stain.      
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Figure 6.2. The effect of aphidicolin on differentiated HCT116 cells after treatment with 
3 mM HMBA for eight days. (A) Western blot analysis for level of Oct4 during eight days; 
alph-tubulin was the control. (B) Percentage of survival cells for eight days; cytotoxic 
responses to aphidicolin were analyzed by cell accounting using haemocytometer. Columns 
were generated from three independent experiments. Statistical significance in the cellular 
response to aphidicolin was assessed by the two-way ANOVA with a comparison test and 
Student‘s t test. HCT116 cells were significantly sensitive to aphidicolin (p < 0.01) for all 
days compared with the control. (C) Immunoflurescent staining shows decreased Oct4 
expression in HCT116 cells during seven days after treatment with HMBA, indicating loss of 
self-renewal during seven days. (Green) indicates Oct4 expression. (Black) indicates phase 
contrast. (Red) indicates Pi nucleus stain. (Merge) indicates the merging of Oct4 and Pi stain.        
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Figure 6.3.The effect 1 µM hudroxyurea on differentiated HCT116 cells after treatment 
with 3 mM HMBA for eight days. (A) Western blot analysis for level of Oct4 during eight 
days; alph-tubulin was the control. (B) Percentage of survival cells for eight days; cytotoxic 
responses to 1 µM hudroxyurea were analyzed by cell accounting using a haemocytometer. 
Columns were generated from three independent experiments. Statistical significance in the 
cellular response to 1 µM hudroxyurea was assessed by the two-way ANOVA with a 
comparison test and Student‘s t test. HCT116 cells were significantly sensitive to 1 µM 
hudroxyurea (p < 0.05) for day 6, day 0, and (p < 0.01) for other days compared with the 
control. (C) Immunoflurescent staining shows decreased Oct4 expression in HCT116 cells 
during seven days after treatment with HMBA, indicating loss of self-renewal during seven 
days. (Green) indicates Oct4 expression. (Black) indicates phase contrast. (Red) indicates Pi 
nucleus stain. (Merge) indicates the merging of Oct4 and Pi stain. 
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Figure 6.4. The effect of 100 mg phleomycin on differentiated HCT116 cells after 
treatment with 3 mM HMBA for eight days. (A) Western blot analysis for level of Oct4 
during eight days; alph-tubulin was the control. (B) Percentage of survival cells for eight 
days; cytotoxic responses to 100 mg were analyzed by cell accounting using a 
haemocytometer. Columns were generated from three independent experiments. Statistical 
significance in the cellular response to phleomycin was assessed by the two-way ANOVA 
with a comparison test and Student‘s t test. HCT116 cells were significantly sensitive to 
phleomycin (p < 0.01) for all days compared with the control. (C) Immunoflurescent staining 
shows decreased Oct4 expression in HCT116 cells during seven days after treatment with 
HMBA, indicating loss of self-renewal during seven days. (Green) indicates Oct4 expression. 
(Black) indicates phase contrast. (Red) indicates Pi nucleus stain. (Merge) indicates the 
merging of Oct4 and Pi stain. 
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6.3 Discussion 
TOP1 mutations that confer resistance to camptothecin and derivatives have been known in 
both mammalian cells and yeast (Chrencik et al. 2004, Arakawa et al. 2006, van der Merwe, 
Bjornsti 2008, Losasso et al. 2008).  
 
This chapter determined the connection between HCT116 cell differentiation and its relative 
sensitivity to four poisons, as described above. HCT116 cells were used as a controllable 
model of colon cancer. We found that the sensitivity of HCT116 cells to four poisons during 
cell differentiation + or - HMBA was minimal and did not significantly change with culture 
time. Proliferating HCT116 cells were significantly more sensitive to the four poisons; 
however, HCT116 cells appeared to become more resistant to camptothecin treatment as they 
differentiated with HMBA. This was illustrated by a 2- to 4-fold increase in the growth 
inhibition induced by the four poisons in differentiated cells compared with proliferating cells 
without HMBA. It is important to note that in the differentiated cells, CPT still displayed a 
strong topo I complex signal. A CPT cleavable complex was usually very weak and did not 
change appreciably through the differentiation of these cells (see Figures 7.1, 7.2, 7.3 and 
7.4). In addition, CPT-induced cytotoxicity did not change significantly throughout the 
differentiation system.  
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Chapter 7   Analysis of NTERA2 retinoic acid induced differentiation 
 7.1. Introduction 
Cancer relapse is the primary cause for the failure of cancer treatments. Cancer stem cells 
play a prominent role in the growth, relapse, and metastasis of cancers. These cells are 
analogous to normal stem cells, and possess features of self-renewal and differentiation. 
Unlike normal cells, cancer stem cells may result in two or more cancer stem cells as well as 
non-tumourigenic cancer cells, resulting in a perpetual increase in the total number of cancer 
cells, leading to neoplastic relapse (Hadnagy et al. 2006). Breast cancer stem cells with the 
CD44+/CD24− phenotype exhibit a strong ability for tumour induction. Cells with this 
phenotype were found to create fresh tumours even when present in small numbers, while 
large number of non-stem cells with additional phenotypes were required to elicit tumour 
formation in SCID mice (Ponti et al. 2005). 
However, cancer stem cells are normally quiescent, while cancer chemotherapy normally 
targets only those cells that are dividing. Therefore, cancer stem cells survive chemotherapy 
and then recreate the tumour, resulting in a relapse (Woodward et al. 2005, Marx 2003). 
Therefore, while chemotherapy may be able to destroy the majority of non-cancer stem cells, 
they do not affect cancer stem cells (Huff et al. 2006). Since the cancer stem cells that remain 
after chemotherapy may lead to possible relapse, it is necessary to improve the approach for 
eliminating cancer stem cells by a non-apoptotic or non-necrotic process. Inducing division 
of cancer stem cells (Soltysova, Altanerova & Altaner 2005) via chemotherapy may provide 
an opportunity to overcome the resistance of cancer stem cells to cytotoxic agents. 
In this chapter, we explored the hypothesis that all-trans retinoic acid (ATRA) could 
differentiate cancer stem cells using NTERA2 as a model. We investigated this hypothesis by 
using ATRA concomitantly with a cytotoxic agent for eliminating cancer stem cells, thus 
preventing relapse. 
If the tumour cells are cancer stem cells (Sell & Pierce 1994, Reya et al. 2001, Pardal, Clarke 
& Morrison 2003, Bonnet & Dick 1997, Singh et al. 2003), then the cancer may be treated by 
inducing differentiation of the stem cells, i.e. differentiation therapy (Pierce 1983). Tumour 
stem cells of teratocarcinomas can be affected by the conditions of the growing embryo to 
differentiate into normal adult tissues. If malignant cells can be constrained to differentiate 
and to break off proliferation, then their malignant ability will be restrained and controlled. 
Although many agents have been investigated in the past (Spira & Carducci 2003), most 
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studies have comprehensively examined and clinically studied retinoic acid (RA, Vitamin A), 
particularly ATRA, as a differentiating agent.  
After exposure of NTERA2 EC cells to retinoic acid, which results in cell differentiation, 
neural markers are manifested and neurons expressing neurofilament proteins and a 
characteristically neuronal morphology appear, most of which usually appear during the 
second week after the first exposure to retinoic acid (Andrews 1984a, Lee & Andrews 1986). 
Neurons derived from NTERA2 following retinoic acid treatment probably comprise only 2–
5% of all differentiated cells; however, they are the most evident and prominent cells among 
all cell populations. These neurons express tetrodotoxin-sensitive sodium channels (Rendt, 
Erulkar & Andrews 1989). The neurons may be purified from the cultures by using 
techniques involving differential trypsinisation and treatment with mitotic inhibitors 
(Pleasure, Page & Lee 1992). Recently, it has been suggested that these NTERA2-derived 
neurons could be implanted into the central nervous system to correct neural deficits resulting 
from various diseases. Thus, such neurons have been reported to survive and integrate 
functionally to correct partial defects resulting from experimentally induced stroke in rats 
(Borlongan et al. 1998, Hurlbert et al. 1999, Muir et al. 1999, Philips et al. 1999). 
The differentiation of NTERA2 cells into neurons occurs in several ways to summarise the 
stages through embryonic progression of the nervous system (Przyborski et al. 2000). For 
instance, nestin, a gene that encodes an intermediate neurofilament protein distinctive of 
proliferating neuroprogenitors, is quickly upregulated shortly after NTERA2 EC cells are 
exposed to retinoic acid.  
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7.2 Result 
7.2.1 Analysis of NTERA2 retinoic acid induced differentiation 
Thus far, all-trans-retinoic acid (ATRA) is the most widely used agent to induce EC cell 
differentiation. NTERA2 EC cells vary from other types of human EC cells due to their 
sensitivity to differentiation induced by retinoic acid (Andrews 1984b) and to distinct 
inducing agents such as hexamethylene bisacetamide (HMBA) (Andrews et al. 1986, 
Andrews et al. 1990) and bone morphogenetic proteins (Andrews et al. 1994). These agents 
induce differentiation in disting ways; however, researchers have thoroughly studied retinoic 
acid-induced differentiation, which resulting the formation of neurons and other cell types 
(Andrews, 1984). However, several other human EC cells do not respond to retinoic acid 
(Matthaei, Andrews & Bronson 1983). 
Here, RA was used for induction of differentiation. A stock solution (10–2 M) was prepared 
by dissolving RA in dimethyldioxirane (DMDO) at 3 mg/ml. A solution containing 0.1% 
DMSO was obtained at the highest commonly used RA concentration (10–5 M). While 
DMSO at this concentration is acceptable, at higher concentrations, DMSO itself may induce 
differentiation, depending upon the cell line used. Therefore, a control culture was made (see 
Chapter 4). The control was essential to establish that NTERA2 differentiation can be 
induced under the laboratory conditions used here. Moreover, it was essential to test that the 
differentiation potential of the NTERA2 stocks used in this experiment had been maintained. 
To this end, we set up differentiation experiments in which stem markers were followed, with 
the expectation that the key marker for stemness, Oct4, would be lost from the cell population 
upon differentiation.  
NTERA2 cell cultures were set up and monitored over eight days by western blotting and 
immunofluorescence to evaluate Oct4 levels (expecting a reduction in the Oct4 levels 
following differentiation). Four independent culture sets were established: one set was 
untreated and the other, treated with 3 mM HMBA. Figure 6.1 shows western blot data for 
Oct4 levels every day over a 7-day period. The gels shown in the figure contain tubulin as the 
control. The Oct4 protein levels of the untreated sample (without RA) were used for 
comparison. Cultures were immunohistochemically stained for Oct4 and the nuclear marker 
Pi. 
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7.2.2 Response of NTERA2 to DNA-damaging agents during differentiation 
Following the analysis of the sensitivity of differentiated and undifferentiated cells to four 
poisons with HMBA in a previous chapter, the analysis was extended by studying the 
response of cells to DNA-damaging agents during the differentiation processes initiated by 
exposure to RA. Treatment with RA results in loss of Oct4 signal (Figure 7.1).   
7.2.2.i. Response to CPT 
Differentiating cells were exposed to both 1 and 2 µM camptothecin (CPT), and the cells 
exhibited similar sensitivity to both concentrations of CPT. Figure 7.2 shows the response of 
the cells to 2 µM CPT. As shown in the figure, the cells show no survival on day 0 (with no 
RA), as shown previously . During differentiation, the percentage of surviving cells increases 
slightly, peaking on day 6. These data suggest a resistance to CPT developing during the 
differentiation process. This might be due to the reduced proliferation rate following RA 
treatment (see Discussion). The western blot data for the CPT-treated cells (after 24 h 
incubation); for days 0–2, show that survival levels were too low to obtain significant whole 
cell extract material, as measured by the loss of the α-tubulin (control) signal (Figure 7.2 A). 
However, it is clear that from day 3, there is no detectable Oct4 present, indicating that 
differentiation had occurred in the RA + 1 or 2 µM CPT-treated cells.  
7.2.2.ii. Response to Aphidicolin  
Cell cultures were treated with aphidicolin in the same manner as described for CPT, but the 
CPT was replaced by the DNA polymerase inhibitor aphidacolin at concentrations of 1 and 2 
µM (for data of 2 µM aphidacolin, see Appendix). As shown in Figure 7.3A, significant 
levels of Oct4 could no longer be detected from days 3–4, indicating that these cultures were 
undergoing differentiation. A relatively uniform response to 1 µM aphidicolin is observed, al 
after day 3 cells appear to become more resistance to aphidicolin. 
7.2.2.iii. Response to hydroxyurea 
Cell cultures were treated as above for CPT, but CPT was replaced by 1 µM of the 
ribonuclease reductase inhibitor hydroxyurea (HU), which reduces cellular levels of 
nucleotides, thus inhibiting DNA replication. As shown in Figure 7.4A, significant levels of 
Oct4 are no longer detected from day 3, indicating that these cultures were undergoing 
differentiation. Similar to that observed in response to aphidicolin, relatively uniform 
sensitivity was observed in response to HU, with an increased resistance correlating to loss of 
Oct4 level. 
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7.2.2.iv Response to phleomycin 
In addition to CPT, two agents capable of inducing DNA damage were tested (aphidicolin 
and HU), both of which inhibit DNA replication. Both these agents differ from CPT in that 
they do not necessarily generate double-stranded DNA breaks. Since CPT seems to cause a 
strong increased sensitivity in Oct4-expressing NTERA2 cells than these two agents (see 
above), we tested phleomycin, which is known to directly generate double-strand breaks 
(DSBs). Figure 7.5 shows the response of NTERA2 cells to phleomycin. As for the other 
experimental sets, the Oct4 signal disappears from approximately day 3 following exposure, 
indicating that the differentiation programme proceeds similarly in these cultures. There is a 
slight difference in the sensitivities of the culture to phleomycin: day 0 and day 1 culture 
showed slightly higher sensitivity to this agent as compared to the other days (days 2–8), 
when a decreased sensitivity is appearent. As for HU, resistance increases, peaking at day 5, 
to drop again at day 7. 
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Figure 7.1. Differentiation status and Oct4 gene expression in NTERA2 treated with 
retinoic acid (RA) and without treatment. The expression of the Oct4 marker is shown. 
The data represent changes in expression in the differentiate state during seven days after 
exposure the cells to 10
–2
 M RA and western blots were achieved. In NTERA2 cells, the 
differentiation status is confirmed by the decreased Oct4 expression. (A) Oct4 level after RA 
treatment for seven days. (B) Immunofluorescence staining shows decreased Oct4 expression 
in NTERA2 cells for seven days after RA treatment, indicating loss of self-renewal during 
this period. Green indicates Oct4 expression. Black represents phase contrast. Red represents 
Pi nucleus stain. Merge indicates a merged image of the Oct4 and Pi staining. 
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Figure 7.2. The effect of camptothecin on differentiated NTERA2 cells after treatment 
with 10
–2
 M RA for eight days. (A) Western blot analysis for Oct4 levels. α-Tubulin was 
used as the control. (B) Percentage of cells that survived for eight days and the cytotoxic 
responses to 1 µM CPT were analysed by cell counting in a haemocytometer. Columns were 
generated from three independent experiments. Statistical significance of the cellular 
response to 1 µM CPT was assessed by the two-way ANOVA with the comparison test and 
Student‘s t test. NTERA2 cells were significantly sensitive to 1 µM CPT (p < 0.01) for all 
days as compared to the control. 
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Figure 7.3. The effect of aphidicolin on differentiated NTERA2 cells after treatment 
with RA for eight days. (A) Western blot analysis for Oct4 levels. α-Tubulin served as the 
control. (B) Percentage of the cells surviving for eight days and the cytotoxic responses to 
aphidicolin were analysed by cell counting in a haemocytometer. Columns were generated 
from three independent experiments. Statistical significance of the cellular response to 
aphidicolin was assessed by the two-way ANOVA with the comparison test and Student‘s t 
test. NTERA2 cells untreated with RA were significantly sensitive to aphidicolin (p < 0.01) 
on day 1 as compared to the control on day 0 as compared with control (p < 0.05 in both 
cases).  
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Figure 7.4. The effect of 1 µM hudroxyurea on differentiated NTERA2 cells after 
treatment with 10–2 M RA for eight days. (A) Western blot analysis of Oct4 levels. α-
Tubulin served as the control. (B) The percentage of cells surviving for eight days and the 
cytotoxic responses to 1 µM hudroxyurea were analysed by cell counting in a 
haemocytometer. Columns were generated from three independent experiments. Statistical 
significance of the cellular response to 1 µM hudroxyurea was assessed by the two-way 
ANOVA with the comparison test and Student‘s t test. NTERA2 cells untreated with RA 
were significantly sensitive to 1 µM hudroxyurea (p < 0.05) on days 0 and 1 as compared to 
the control.  
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Figure 7.5. The effect of 100 mg phleomycin on differentiated NTERA2 cells following 
treatment with 10–2 M RA for eight days. (A) Western blot analysis of the Oct4 levels. α-
Tubulin served as the control. (B) The percentage of cells surviving for eight days and the 
cytotoxic responses to 2 µM CPT were analysed by cell counting in a haemocytometer. 
Columns were generated from three independent experiments. Statistical significance of the 
cellular response to phleomycin was assessed by the two-way ANOVA with the comparison 
test and Student‘s t test. NTERA2 cells without RA treatment were significantly sensitive to 
phleomycin (p < 0.01) on days 0 and 1 as compared to the control.  
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7.3.  Discussion 
A complicated and intricate process of signalling pathways decides if a cell will proliferate, 
differentiate, die, or survive. Since retinoids have a high impact on differentiative ability, 
they have been extensively used for both cancer prevention therapy and cancer induction 
(Sporn & Suh 2002). 
 
As described in the previous chapter, HMBA plays a role in the differentiation of NTERA2 
cells as cancer stem cells or stem cells. Further, we observed that undifferentiated NTERA2 
cells (no RA/expressing Oct4) appeared slightly more sensitive to CPT than cells that had 
been induced to differentiate using RA (see above). CPT works by inhibiting topoisomerase 
I. Topoisomerase I normally regulates DNA supercoiling by forming breaks in the sugar-
phosphate backbone of DNA and creating a transient covalent phosphotyrosyl intermediate 
between the broken strand and a tyrosine residue on the topoisomerase (Keck & Berger 1999, 
Lorence & Nessler 2004, Rothenberg 1997, Rasheed & Rubin 2003, Pommier 2006). CPT 
acts by stabilising the transient covalent complex between the protein and the DNA, resulting 
in a prolonged unsealed nick in the duplex (Hsiang et al. 1985). These relatively stable nicks 
can be converted to DNA DSBs during DNA replication when the replisome encounters 
them, making a one-sided DSB that requires recombinogenic repair mediated by homologous 
recombination factors.  
 
In this study we observed a more startling response of the cells to CPT following RA 
treatment, than had been observed for HMBA (see Chapter 5). As for the HMBA experiment 
we observed a relatively strong sensitivity of NTERA2 cells to CPT without treatment (down 
to about 2%). However, after day 3 cell survival increased to approximately 50% and was 
retained at this close to this level during the remained of the differentiation process. This is 
significantly different from what was observed for HMBA differentiation, when a subtle 
increase in survival levels was observed, not this larger increase. This increased resistance is 
concomitant with the timing of the loss of Oct4 (see Figure 6.2), suggesting that it is linked 
directly to the differentiation process. No significant reduction in cell proliferation levels 
were noted upon RA-induced differentiation relative to the HMBA-induced differentiation 
and cell numbers continued to increase during the RA-induced differentiation period. Given 
this, it seems unlikely that the increased resistance to CPT is due to decreased proliferation 
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levels. However, this scope of this study did not permit for a detailed analysis of the cell 
division cycle kinetics during the differentiation process and there may be differences in the 
cell division cycle which could account for this observation; for example, S-phase period 
might be altered.  
 
These data could suggest that there is a mechanistic distinction in how undifferentiated and 
differentiated cells deal with CPT damage. What this difference might be remains unclear, 
but these observation could provide the platform for further analyses; for example, studies 
into the levels of DSB formation during S-phase using histone δ-H2AX phosphorylation 
would determine whether the same levels of breakage occur during S-phase in differentiated 
cells as in undifferentiated cells. Determining this would enable us to distinguish between 
distinct levels/types of DNA damage being formed verses distinct mechanistic pathways 
dealing with similar levels of damage.  
 
Treatment with HMBA did appear to give a subtle mechanistic change, but this was not as 
pronounced as the difference previously seen when comparing the sensitivities of mouse ES 
cells with non-isogenic MEFs (McFarlane and Wakeman, personal communication). The 
results obtained with NTERA2 following RA-induced differentiation match the pattern seen 
previously with the mouse cells. This could indicate that there is a difference in cellular 
responses to CPT-induced DNA damage, but it is dependent upon the lineage down which 
cells are induced to follow. This possibility opens up the intriguing question of whether or not 
there are lineage-specific DNA repair pathways in complex metazoans. This would have 
considerable implications for how we view cancer development and how we might treat 
cancer-specific cancer stem cells.  
 
NTERA2 induced to differentiate with RA also showed changes in the patterns of sensitivity 
to the other DNA damaging agents used here. The changes were not as marked and the 
increased resistance was not maintained in the longer run (see phleomycin and HU result). 
However, these data indicate that there may be more global changes to the DNA damage 
response, although the CPT response is more pronounced, as was the case in the mouse study.  
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The data here have provided a human model for the further analysis of the mechanistic causes 
of increased sensitivity to CPT in cells with stem-like characteristics (Oct4 positive). They 
cast some questions over the dogma that differentiation therapy has a place in cancer therapy, 
as we find that the differentiated cells become more resistant to the therapeutic agent CPT 
relative to stem-like cells. Further work is needed to elucidate the molecular basis of these 
findings and the relevance to chemotherapeutic strategies. 
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Chapter 8    Preliminary analysis of mouse stem cells. 
 
8.1. Introduction  
Mouse embryonic stem cells (mESCs) are obtained from the inner cell mass of pre-
implantation blastocysts (Evans, Kaufman 1981b, Martin 1981b). The defining characteristic 
of mESCs is their capability to accompany multiple differentiation mechanisms, both in vitro 
and in vivo (Smith 2001a). mESCs have been widely used for forming mutant mice as  
a dominant reverse-genetics access to recognise in vivo biological events of genes of interest 
(Smith 2001b, Evans, Kaufman 1981a, Martin 1981a, Kaufman et al. 1983, Rossant 2001). 
mESCs can also be used to comprehend molecular processes that control primitive 
organogenesis using in vitro analysis procedures (Smith 2001c). mESCs are known for their 
inability to arrest in the G1 phase after DNA damage. Instead, mESCs with damaged DNA 
are preferentially eliminated through apoptosis (Aladjem et al. 1998). Furthermore, in 
addition to cell type-specific differences in the expression of repair elements, there are also 
species-specific dissimilarities. XRCC-4, for instance, is present in equivalent amounts in 
mESCs and MEFs, but in hESCs its expression is raised in contrast to differentiated cells 
(Momcilovic et al. 2010, Tichy et al. 2010). Furthermore, DNA ligase IV is present in higher 
amounts in hESCs compared to differentiated human cells (Momcilovic et al. 2010), but its 
expression is lower in mESCs contrasted to differentiated cells (Tichy et al. 2010). In 
comparison, DNA-PKCS exists in lower lots in mESCs contrasted to MEFs (Banuelos et al. 
2008b), while its expression is higher in hESCs in comparison to differentiated human cells 
(Momcilovic et al. 2010). Furthermore, expression of breast cancer 1 (BRCA-1), a tumour 
suppressor protein which is implicated in DNA repair regulation, transcription and cell cycle , 
is often lower in mESCs than in differentiated murine cells, but it exists in higher lots in 
hESCs than in differentiated human cells (Momcilovic et al. 2010). 
 
Studies show that mESCs are more resistant to oxidative stress and ionizing radiation (IR)-
induced DNA damage than differentiated mouse fibroblasts (Saretzki et al. 2004). However, 
mESCs are hypersensitive to several DNA damaging agents and readily undergo apoptosis 
(Park, Gerson 2005, Roos et al. 2007, Van Sloun et al. 1999). Furthermore, the efficiency of 
repair of UV-induced DNA damage is decreased when mouse embryocarcinoma stem cells 
are induced to differentiate (Rasko et al. 1993).  
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In this part, we address the issue of whether mESCs switch on the DNA damage response 
mechanism following exposure to four poisons compared with cancer stem cells (such as 
NTERA2) and cancer cells (such as HCT116). 
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8.2. Results 
8.2.1.  mESCs exposure to different DNA damage 
In our previous chapters, we explained two models of cancer stem cells (NTERA2) and 
cancer cells (HCT116 as control) and treated them by two inducers (HMBA) and (ATRA) 
and exposed them to four poisons: camptothecin, aphidicolin, phleomycin and hydroxyurea. 
We know that the most common response of cells to DNA damage is perturbation of 
progression through the cell cycle. In this part we examine the response of mouse embryo 
exposed (E14) cells to those poisons during 24 hours. Four poisons were used for exposure 
and were seeded in the same densities and four poisons were added at the same time for 24 
hours. Figure 8.1, (A) shows the Oct4 signal expression in all samples; but the very low 
expression with 2 µM CPT indicates that cells were undifferentiated as well as E14 cells 
having resistance to all poisons in different proportions. The greatest poison effect was with 
CPT especially the 2 µM CPT. DMSO had no effect compared with the control. 
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Figure 8.1. Analysis of cell survival in response to four DNA damaging poisons: CPT, 
aphidicolin, phleomycin and hydroxyurea. (A) Western blot analysis for level of Oct4 
during 24 hours with four DNA damaging poisons and alpha-tubulin as control. (B) Total 
number of mESc cells following exposure to camptothecin. E14 cells were exposed to four 
DNA damaging poisons separately in 6 well plates, 2 ml/ well for 24h. The total number of 
cells remaining at each time point was determined by cell counting using a haemocytometer. 
Statistical significance in cellular response to four DNA damaging poisons was assessed by a 
two-way ANOVA with comparison test and Student‘s t test. E14 cells were significantly 
sensitive to all poisons (p < 0.01) but DMSO was not sensitive (p < 0.05) compared with the 
control. 
 
 
 
B 
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8.3 Discussion 
We described the effect of the four poisons on two types of cells, (1) Cells that have the 
property of stem cells, which are called NTERA2, as cancer stem cells and showed the effect 
the four poisons had on these cells in two ways: undifferentiated and differentiated. (2) Cells 
that do not have the property of stem cells, which are originally differentiated. Then we found 
there are different responses in those cells to different types of DNA damage. In this part, 
using E14 cells in the same way experimentally, it was shown that E14 cells have low 
resistance similar to undifferentiated NTERA2 cells and it was indicated that they appeared 
to be slightly more sensitive to the DNA damaging agents. This inspection supports the 
probability that there is a similarity in the process of activity between cancer stem-like cells 
NTERA2 and mESCs cells in the way they process and respond to significant levels of DSBs. 
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Chapter 9 Final Discussion 
 
Genomic instability is a threat to the normal proliferation and homeostasis of cells, and it can 
cause cancer as well as many kinds of degenerative and ageing effects. DNA receives large 
amounts of damage from the endogenous metabolites of cells as well as from exterior factors, 
such as UV radiation and chemicals. In order to prevent malignant transformation and the 
transmission of damaged genomic material, cells have evolved a DNA damage response 
(DDR). This response includes an assembly of mechanisms that 1) sense and identify the 
damage, 2) promote cell cycle arrest, and 3) permit the repair of the damaged DNA or 
stimulate apoptosis if the damage is extreme (Jackson et al. 2009). In malignant cells, this 
response is frequently modified, and many anti-cancer drugs that take advantage of this to 
specifically target cancer cells.   
 
9.1. Does the DDR change as cell undergo differentiation?  
The bulk of the work in this thesis is aimed at addressing this key question, with an aim of 
gaining insight into the behaviour of human cells. There is a developing body of literature 
which indicates there are differences in DDRs between differentiated and undifferentiated 
cells; for example, the changes in levels of some DDR proteins when comparing 
differentiated and undifferentiated cells (for example, see Momcilovic et al., 2010 and 
Chapter 8). Moreover, there is a growing interest in experimentally exploring this question in 
more detail. The work in this current programme is set against this backdrop of increased 
studies in this area and the increase in interest in human embryonic stem cells and induced 
pluripotent stem cells.  
 
The initial observation which triggered this work was from a preliminary study from 
Wakeman and McFarlane (personal communication). As previously mentioned in the thesis, 
they studied the cellular survival levels of mouse ES cells with MEF, albeit MEFs from a 
non-isogenic source. They found that in most cases mES cells exhibited similar sensitivities 
to drugs which induced DNA damage, mostly through inhibition of DNA replication or in a 
DNA replication-dependent fashion; however, the response to CPT was markedly different in 
that the mES cells were significantly more sensitive relative to the terminally differentiated 
MEFs. Given these findings, in conjunction with the evidence that there are DDR distinctions 
between differentiated and undifferentiated cells, much of which has been revealed during the 
time frame of the work presented here, we set out to chose an appropriate model for studying 
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DDR responses during human differentiation. Obtaining and differentiating human ES cells is 
both difficult and contentious; indeed, there is current controversy as to whether bona fide 
human ES which are equivalent to the well characterised mES cells have actually been 
isolated, or whether current so called hES cells actually represent cells from a later 
developmental period (for example, see Nichols and Smith, 2011). Given this, we chose to 
use the well characterised teratocarcinoma cell line NTERA2, which can form teratomas and 
can be induced to differentiate upon treatment with distinct molecular differentiating agents, 
including HMBA and RA. Upon treatment with HMBA we found that at best there is a subtle 
change in the cellular DDR during the differentiation process. This does not offer substantive 
evidence to indicate that there is a major change in the molecular programme underpinning 
the DDR during differentiation of a more naive human cell (Oct4 positive) and a 
differentiated state (Oct4 negative). However, when NTERA2 cells were differentiated with 
RA a much greater difference was observed between the sensitivity of the cells in the 
undifferentiated state relative to the differentiated state. This difference was only seen for 
CPT treatment and was not as apparent for the other damaging agents. Taken at face value, 
this observation appears to indicate that there are changes to the DDR upon differentiation, 
but that these depend upon which specific differentiation pathway is followed (in this case 
RA or HMBA-induced). If correct, this observation could have implications for the 
development of tissue-specific DDR pathways. Taking this further, one could speculate that 
this reflects distinct oncogeninc / tumour suppressor pathways in distinct tissues.  
 
The data presented here also appear to indicate a damage-specific change which appears to 
relate to CPT-induced DNA damage. CPT has been reported to have a highly specific mode 
of action in inhibiting the topoisomerase I reaction, which is thought to result in 
chromosomal breakages as topoisomerase I-induced nicks are converted to DSBs upon being 
encountered by the replication machinery (Hsiang and Liu, 1988). Given this, the data here 
might indicate that there is a distinct change to the pathway(s) related to DNA replication-
associated DSBs. However, prior to making too strong a set of conclusions the fact that no 
detailed cell cycle analysis was carried out on RA-induced NTERA2 should be taken into 
account. Whilst cells appeared to continue to divide and proliferate, this was not studied in 
enough depth to fully exclude the possibility that the change in sensitivity in response to CPT 
upon RA-induction was due to differentiation being paralleled by a significant reduction in 
proliferation. If this were the case then the loss of sensitivity might simply reflect the fact that 
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CPT-induced damage, which is dependent upon DNA replication, might be reduced. Further 
detailed analysis of cell division (e.g., Ki-67 analysis) would be required.  
 
9.2.   Are human and mouse ES cells / ES-like cells different? 
If the data for HMBA-induced NTERA2 are compared to the preliminary data from 
Wakeman and McFarlane, where mouse ES cells are more sensitive to CPT than non-
isogenic MEF, but NTERA2 show only a slight decrease in CPT sensitivity in response to 
HMBA induction, then it could be argued that mouse cells behave in a different fashion. 
There are examples in the literature where there are differences in the components of the 
DRR in mouse and humans; for example, XRCC-4 is present in equal amounts in mES cells 
and MEFs, whereas human ES cells have higher measurable levels than observed in 
differentiated cells (Momcilovic et al., 2010, Tichy et al., 2010). However, in the case of CPT 
response this has undergone little in the way of detailed investigation. One route to address 
this might be to examine directly the levels of DSBs induced in differentiated and 
undifferentiated NTERA2 vs. mES cells and MEFs. This might provide insight into whether 
these differences arise due to distinct levels of DNA damage being generated or the way in 
which they are processed. This however does not address the fundamental question of 
whether there are inherent differences between mouse and human systems. In addition to this, 
the fact that the response to RA-induced differentiation appears to indicate commonalities, 
i.e. sensitivity in the undifferentiated state and reduced sensitivity upon induction, implies 
that this is not a question which can be resolved with a simple study of this nature. This study 
reveals the possibility of different differentiation pathways (see above) behaving in distinct 
ways. To try and then make inter species comparisons using these data is potentially flawed 
and future independent studies should focus the questions relating to how distinct 
differentiation pathways result in distinct DDRs.  
 
With this in mind, what can we take from this work? If there are distinct DDR pathways 
dependent upon which differentiation inducing agent one uses, then this could indicate there 
is a complex network of DDR programmes for distinct lineages. However, there is one 
common feature of both RA- and HMBA-induced pathways for differentiation of NTERA2 
and that is that both pathways result in Oct4 being lost from the cells. This indicates that what 
ever factors govern the distinct DDR mechanisms following differentiation induction, the role 
of Oct4 is not the differentiator (as it is lost in both cases). This is an important observation as 
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recent work has demonstrated a role for the nucleotide excision repair (NER) XPC complex 
in Oct4-mediated gene transcription activation (Fong et al., 2011). This work has linked the 
association of XPC with Oct4 to a novel genome stability control mechanism which proposes 
that DNA damage which requires XPC repair (NER) will sequester XPC to sites of damage 
and prevent the Oct4-mediated transcription of genes needed for stem cell maintenance (e.g. 
Nanog) thereby triggering differentiation or apoptosis in response to DNA damage. This 
suggestion implicates Oct4 directly in control of at least one DDR programme. Here we have 
provided evidence that distinct DDR mechanisms which might occur in response to distinct 
differentiation pathways (HMBA- or RA-induced) are independent of direct Oct4 control.  
 
9.3 Closing remarks 
In this work the link between genome stability maintenance mechanisms and developmental 
programmes have been investigated, with particular focus on DNA replicative stress 
scenarios. Firstly, the question of whether meiotic recombination hotspots can be activated in 
situations where the DNA replication machinery is compromised or the cell is under a given 
stress condition. A model system, the fission yeast, was employed, as studies of this nature in 
humans are only now becoming possible as human meiotic recombination hotspots become 
identified, which was not the case at the onset of this work. Intriguingly, we did not find any 
conditions in which the S. pombe developmentally related hotspot could be activated in 
mitotically proliferating cells. This leaves open the question of whether this can occur. This 
might reflect the fact that the developmental programme of meiosis requires many novel 
genes to be expressed for hotspot activation, such as the meiosis-specific nuclease Spo11 
(Rec12). It might be the case that a tight transcriptional and post transcriptional regulation of 
the activation of meiotic factors is central to preventing meiotic recombination hotspot 
becoming the sites of genomic rearrangements in mitotically dividing cells. Interestingly in 
human cancer many testis-specific genes do become deregulated, and may provide a 
sufficient platform for human recombination hotspots to be more readily activated to drive 
oncogenic changes.  
 
Finally, this work has taken a preliminary view of how human cells with pluripotent potential 
respond to DNA damage before, after and during the differentiation process, with a particular 
focus on DNA damage associated with DNA replication. One key observation comes from 
this work, one which might indicate that the response to DNA damage can differ significantly 
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between the differentiated and undifferentiated state, but that this is dependent upon which 
pathway of differentiation is followed. If this observation should hold up upon further more 
extensive scrutiny (for example, more extensive cell cycle analysis of RA-induced 
NTERA2), then it has extensive implications which could ultimately impinge upon how we 
view distinct tissue specific cancers and distinct tissue-specific regenerative clinical 
approaches using stem cells.  
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